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  CHAPTER 1 
INTRODUCTION 
 
1.1 Macrophage Activation and Function 
Macrophages are a dynamic and highly plastic subset of innate immune cells1-4. Derived from 
myeloid progenitor cells in the bone marrow, macrophages have the capacity to take on a broad range 
of roles within many different contexts1-4. Macrophages can become highly specialized resident 
macrophages within various tissues, such as alveolar macrophages in the lung, osteoclasts with bone, 
microglial cells in the central nervous system, and Kupffer cells within the liver3. Macrophages are also 
highly efficient, professional phagocytes, which is an essential role in both embryogenesis and in the 
maintenance of blood and tissue homeostasis2,3. Moreover, macrophages are highly adapted for 
immune surveillance, antigen presentation, and pathogen clearance2,3. The fate of a macrophage is 
highly dependent on the cytokine milieu and other environmental cues within the niche a macrophage 
occupies2-5. The role of macrophages in the context of immune response to pathogens and 
tumorigenesis will be the focus of this dissertation.  
An essential step in macrophage function is macrophage activation, sometimes referred to as 
macrophage polarization2,3,6, which is outlined in Figure 1. Classically activated M1 macrophages are 
highly pro-inflammatory and anti-microbial2-4,6. M1 macrophages are activated in response to pathogen 
associated molecular patterns, and cytokines that include interferon (IFN)-γ, and tumor necrosis factor 
(TNF)-α1-3. Common markers of M1 macrophages are nitric oxide synthase 2 (NOS2), interleukin (IL)-
1β, TNF-α, IL-6, and IL-122-4,6. M1 macrophages are essential for the clearance of bacterial pathogens 
and for the initiation of adaptive immune responses1,4. M1 macrophages are associated with Th1 and 
Th17 responses because they produce IL-1β, IL-6, IL-12, and IL-23, cytokines known to induce said T 
cell subsets3,6. M1 macrophages have traditionally been associated with anti-tumorigenic responses, as 
well4,6,7. However, recent studies have called this into question, citing the potential for DNA damage 
caused by high levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced 
by activated macrophages8-10. 
1
Figure 1. Molecular pathways of macrophage activation. M1 stimuli such as lipopolysaccharide 
(LPS) and interferon (IFN)-γ signal through the toll-like receptor (TLR) 4, IFN-α, or IFN-β receptor 
(IFNAR) and IFN-γ receptor (IFNGR) pathways, inducing activation of the transcription factors nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB; p65 and p50), activator protein 1 (AP-1), 
interferon regulatory factor (IRF) 3 and signal transducer and activator of transcription (STAT) 1, which 
leads to the transcription of M1 genes (red lettering indicates molecules encoded). In contrast, M2 
stimuli such as interleukin (IL)-4 and IL-13 signal through IL-4 receptor alpha (IL-4Rα) to activate 
STAT6, which regulates the expression of M2 genes (green lettering indicates molecules encoded). 
The regulation of these genes also involves jumonji domain-containing protein 3 (JMJD3), IRF4, 
peroxisome proliferator-activated receptor (PPAR)-γ and p50. IL-10 and immune complexes, plus LPS 
and IL-1, trigger M2-like macrophage polarization. IL-10 signals through its receptor (IL-10R), activating 
STAT3. Immune complexes trigger Fcγ receptor (FcγR) signaling, leading to the expression of 
molecules such as A20, ABIN3, SOCS3, prostaglandin E2 and IL-10, which negatively regulate the 
TLR4 and IL-1R and interferon-signaling pathway. Activatory and inhibitory FcγR signaling is initiated 
by activation of Syk–phosphatidylinositol-3-OH kinase (PI(3)K) and tyrosine phosphatase SHP-1–
inositol phosphatase SHIP, respectively. Methylation of histone H3K27 is a post-translational 
modification linked to gene silencing. A20, deubiquitinating enzyme; ABIN3, A20-binding NF-κB 
inhibitor; IgG, immunoglobulin G; IκB, NF-κB inhibitor; IKKi, inducible IκB kinase; ITAM, intracellular 
tyrosine-based activatory motif; ITIM, intracellular tyrosine-based inhibitory motif; Jak, Janus kinase; 
TBK1, NF-κB activator; TRIF, adaptor protein. Adapted from Reference 6. 
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  M2 macrophages, also known as type 2 or alternatively activated macrophages, are commonly 
associated with wound healing and anti-fungal responses2,3,11. High levels of IL-4, IL-10, and IL-13 are 
responsible for M2 macrophage activation3,11. M2 macrophages produce low levels of pro-inflammatory 
cytokines and high levels of arginase 1 (ARG1), chitinase-like 3 (CHIL3), and resistin like A 
(RETNLA)2,3,11. M2 macrophages are also known as tumor-associated macrophages because of their 
pro-tumorigenic properties2,3,5,7,11-13. M2 macrophages promote cellular growth and proliferation, and 
angiogenesis, all of which are hallmarks of carcinogenesis2,3,5,7,11-13. 
While there is much disagreement within the field of macrophage research, some investigators 
posit that a third subset of macrophage exists – the regulatory macrophage (Mreg)3,14. The hallmark of 
Mreg activation is the production of extremely high levels of IL-103,14. Thus, Mreg macrophages serve 
as a counterbalance to M1 macrophages in that they limit tissue damage and the extent of 
inflammation3,14. Mreg macrophages are also associated with higher levels of regulatory T cell (Treg) 
activation in order to prevent autoimmunity3,14. Further studies are necessary to confirm the existence 
of Mreg macrophages. However, this paradigm adequately illustrates the highly plastic nature of 
macrophage activation, indicating a spectrum of activation rather than distinct subtypes2,3,6,14. 
Macrophage activation is a highly regulated process (Figure 1), marked by the involvement of 
many different signaling pathways6,12,15,16. The balance between M1 and M2 macrophage activation is 
determined by environmental cues recognized by macrophages5,17, leading to the activation of different 
programs of transcriptional regulation6,12,15,16,18. M1 macrophages are typically marked by nuclear factor 
kappa-light-chain enhancer of activated B cells (NF-κB) signaling and interferon regulatory factor (IRF) 
5 activation, while M2 macrophages are associated with increased signal transducer and activator of 
transcription (STAT) 3/6 signaling and IRF4 activation6,12,15,16,19.  However, many questions remain 
related to the initiation and regulation of macrophage activation.  
A recent study demonstrated that macrophages are essential to the pathogenesis of 
Helicobacter pylori, a highly prolific human pathogen20. As will be discussed in Section 1.2, H. pylori 
infection is the single greatest risk factor in the development of gastric cancer21,22. Thus, the H. pylori 
model allows for the study of macrophage activation and function within the context of both bacterial 
3
	  infection and carcinogenesis, which encompassed both goals of this dissertation. We also performed 
studies with Citrobacter rodentium, an additional gastrointestinal pathogen that causes colitis in mice, 
and with known macrophage stimuli, including IFN-γ, lipopolysaccharide (LPS), IL-4, and IL-10. 
However, H. pylori infection is the primary model utilized in the studies outlined in this dissertation.  
 
1.2 Helicobacter pylori  
H. pylori is a Gram-negative, microaerophilic bacterium that infects up to 50% of the global 
human population21-24. H. pylori selectively colonizes the human gastric mucosa and is directly 
responsible for gastroduodenal pathologies that include chronic gastritis, peptic ulcers, mucosa-
associated lymphoid tissue lymphoma, and gastric adenocarcinoma21-24. Because H. pylori confers an 
attributable risk of 75% for gastric carcinogenesis, the World Health Organization has classified this 
organism as a type I carcinogen25. As gastric cancer is the third leading cause of cancer death26, H. 
pylori infection remains a significant public health threat. 
  Risk factors for the development of gastric cancer include several bacterial factors. Cytotoxin 
associated gene A (CagA) is one of the most potent virulence factors expressed by H. pylori, with 
pleiotropic effects on both epithelial and immune cells within the stomach27. Individuals infected with 
strains of H. pylori that possess the cagA gene harbor an increased risk of developing gastric cancer 
(odds ratio = 1.9, 0.9-4.0 95% confidence interval) over persons infected with a cagA− strain27. CagA is 
translocated into host cells via a type IV secretion system (T4SS) that is encoded on the same 
pathogenicity island as the cagA gene. Once in the cell, host kinases phosphorylate CagA, which 
initiates a variety of CagA functions, including activation of mitogen activated protein kinases (MAPK), 
inhibition of apoptosis, disruption of cell growth, and dysregulation of cell motility28,29. Intriguingly, the 
mechanism by which CagA increases an individual’s risk for gastric cancer has not been fully 
elucidated.  
Another H. pylori virulence factor linked to gastric cancer is the vacuolating cytotoxin A (VacA). 
VacA enhances the ability of H. pylori to successfully and persistently colonize human gastric 
mucosa30. Moreover, strains harboring the vacA s1m1 allele are associated with increased severity of 
4
	  gastric inflammation and cancer risk30. VacA increases intracellular concentrations of ROS and 
augments oxidative stress in both epithelial and immune cells28,31,32. Additional risk factors for gastric 
cancer include the phylogeographic origin of the infecting strain33; several host genetic factors, 
including polymorphisms in genes encoding IL1B, IL8, IL10, TNFA and IFNG34; lifestyle choices9,35, 
such as smoking; the microbiome9,35; and other environmental factors9,35. Thus, both bacterial and host 
risk factors are important, but the ability to predict gastric cancer risk remains elusive.  
It is still unclear why only 1-3% of the H. pylori-infected population will progress to cancer. 
Despite this low rate of progression from H. pylori infection to cancer, the global incidence of gastric 
cancer is still incredibly high (Figure 2), with nearly one million new cases reported since 201236. Based 
on decades of research, gastric cancer in H. pylori-infected individuals is a result of synergism between 
host factors, bacterial factors, and environmental factors21,27,35,37-39. Thus, more research is necessary 
to better understand which factors that are most critical for progression from H. pylori infection to gastric 
cancer. In particular, more studies related to the relationship between H. pylori and the human immune 
system are necessary, especially considering the ability of the pathogen to evade nearly all immune 
responses. Thus, we chose to focus this dissertation on the relationship between H. pylori and the 
immune system – particularly macrophages – to better understand the role of inflammation in the 
promotion of gastric cancer. 
 
1.3 The Immune System and H. pylori: A Dynamic Relationship 
 
H. pylori is one of the more prolific and highly successful human pathogens. Its success is 
centered on the ability of the bacterium to establish a persistent infection, while resisting the chronic 
inflammatory responses designed to clear the infection9,40-42. The host immune system mounts a robust 
response that integrates innate and adaptive constituents (Figure 3), as well as the generation of a 
humoral response40,42.  
The innate immune response includes macrophage, neutrophil, and dendritic cell functions. 
Indeed, macrophages in particular are essential for H. pylori-induced gastritis in murine models of 
infection20. The oxidative burst from phagocytes – primarily neutrophils and macrophages – comprises 
a major component of the initial immune response to H. pylori43. As previously discussed, H. pylori is 
5
Figure 2. Global gastric cancer incidence rates among males. Gastric cancer is the third leading 
cause of cancer-related death. Nearly one million new cases of gastric cancer were diagnosed since 
2012. H. pylori infection is the leading risk factor for gastric carcinogenesis. As such, high infection 
rates and increased prevalence of highly virulent H. pylori strains in Latin America and Eastern Asia 
account for the high incidence rates in these regions. Adapted from Reference 36. 
6
	  capable of inducing oxidative bursts, which release significant amounts of oxyradicals into the infected 
microenvironment44,45. Unlike many other human pathogens, H. pylori has the ability to survive the 
oxidative burst. Neutrophil activating protein A (NapA), catalase, and superoxide dismutase (SOD) work 
in concert to alleviate the stress of this response44. Furthermore, H. pylori can survive oxidative damage 
by subverting phagolysome-mediated killing in a VacA-dependent manner, the details of which remain 
to be determined46. The ability of H. pylori to evade the innate immune response creates a cycle of 
consistent immunocyte infiltration, oxidative burst, and DNA damage that contributes to gastric 
carcinogenesis. 
Another key aspect of the insufficient immune response is incomplete polarization of 
macrophages to the antibacterial, classically activated, M1 phenotype. Our laboratory has reported that 
oral administration of α-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine 
decarboxylase (ODC), reduces H. pylori colonization in mice, and this was associated with increased 
NOS2 protein expression and nitric oxide (NO) production by gastric macrophages47. While ODC is not 
a prototypical marker of alternatively activated, M2 macrophages, it may function in much the same 
way by reducing antimicrobial NO production and thus an M1 response. Additionally, H. pylori subverts 
M1 macrophage activation through the induction of heme oxygenase 1 (HMOX1) via a CagA-
dependent mechanism48. And, the induction of HMOX1 in macrophages enhances anti-inflammatory, 
Mreg activation to promote H. pylori survival48. 
Moreover, we have found that gastric macrophages from H. pylori-infected mice can express IL-
10 and transforming growth factor (TGF)-β, which also can act to impair M1 response.  By failing to 
eradicate the bacteria, the innate immune system continually mounts a response to H. pylori, further 
contributing to the malicious cycle of immune cell ROS production, oxidative stress, and DNA damage.  
Dendritic cell activation by H. pylori has also been demonstrated in a number of studies40,49. 
Intriguingly, it appears that as in the intestine, dendritic cells send dendrites into the gastric lumen to 
sample lumen antigens50. It is established that signaling through dendritic cells can have potent effects 
on activating Th1 and Th17 responses50. However, in the case of H. pylori infection, dendritic cells can 
also contribute to the bacterial persistence by inducing immune tolerance. Despite such a vigorous 
7
Figure 3. Schematic summary of the interactions between H. pylori and innate and adaptive 
immune cells in the stomach. H. pylori infection leads to Interleukin (IL)-8 production, which may be 
dependent on cytotoxin gene A (CagA) translocation. IL-8 is a chemoattractant that recruits neutrophils. 
H. pylori neutrophil activating protein A (NapA) and urease cause neutrophils to undergo an oxidative 
burst, exuding substantial amounts of reactive oxygen species (ROS) into the infected 
microenvironment. Moreover, NapA leads to increased H. pylori survival in neutrophils, compounding 
their effects on oxidative stress. Macrophage inducible nitric oxide synthase (iNOS) is induced by 
urease during infection, leading to the production of nitric oxide (NO), a reactive nitrogen species 
(RNS). As yet, undetermined H. pylori (HP) factors induce arginase 2 (ARG2) activation in 
macrophages, resulting in apoptosis. Ornithine decarboxylase (ODC) is also induced in macrophages 
during infection. This leads to downstream H2O2 production by spermine oxidase (SMOX) and 
apoptosis. Moreover, H. pylori infection alters the cytokine milieu produced by dendritic cells in favor of 
an increased Treg response and a decreased Th1/Th17 response. Such alterations promote immune 
tolerance and persistence of the pathogen. Image adapted from Reference 35. 	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  response, eradication of this pathogen is rarely achieved in the absence of antibiotics, leading to 
sustained inflammation over the lifetime of the infected host. Chronic inflammation leads to tissue 
injury, oxidative stress, and DNA damage9,35,40,42.  
The adaptive branch of the immune system, specifically T helper cells, has also been implicated 
as contributory to H. pylori-induced chronic inflammation51. Th1 and Th17 T cell subsets primarily 
mediate chronic gastritis52,53. Th1 cells secrete high levels of pro-inflammatory IFN-γ, and IL-17 
produced by Th17 cells has been shown to enhance the production of the chemokine, IL-851-53. These 
pro-inflammatory cytokines enhance recruitment of immunocytes to the site of infection and perpetuate 
the chronic inflammatory state of an infected host. Moreover, the influx of Th1 and Th17 cells into the 
gastric mucosa has been associated with increased epithelial damage, increased epithelial proliferation 
and metaplastic responses54.   
Numerous studies have also found that Tregs are present within the gastric mucosa during 
infection50,55-57. H. pylori, acting through dendritic cells, can preferentially induce a Treg response 
instead of Th1/Th17 responses50,58. This is in marked contrast to findings in models of colitis, where 
dendritic cells and macrophages are linked to activation of Th1/Th17 responses. Moreover, IL-10 
produced by Tregs results in decreased IL-8 production57.  This facilitates bacterial persistence within 
the host and promotes immune tolerance. 
 Taken together, these data demonstrate a dynamic and prolonged interaction between H. pylori 
and the host immune system. The inability of the immune system to clear H. pylori infection results in a 
vicious cycle of inflammatory events, which result in tissue and DNA damage. This promotes gastric 
carcinogenesis. A better understanding of the immune response to H. pylori is necessary to identify 
therapeutic targets for intervention in H. pylori-mediated carcinogenesis. Additionally, the findings made 
within the H. pylori model can be applied to other disease states marked by chronic inflammation. 
 The macrophage response to H. pylori infection, as well as macrophage responses during 
carcinogenesis, is the central theme of this dissertation. The studies presented herein aimed to better 
understand macrophage activation, specifically focusing on two pathways that are essential for life and 
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  have ubiquitous roles in cellular function – epidermal growth factor receptor (EGFR) signaling and 
ODC-mediated polyamine metabolism. 
 
1.4 Epidermal Growth Factor Receptor: An Overview 
 EGFR (also known as ERBB1) is a 170 kilodalton (kD) receptor tyrosine kinase59-61. EGFR 
contains multiple domains, including an extracellular ligand binding domain, a transmembrane domain, 
a kinase domain, and a regulatory domain59-61. There are at least seven ligands that can activate EGFR 
signaling. The canonical ligand is epidermal growth factor (EGF) and non-canonical ligands include 
amphiregulin (AREG), TGF-α, betacellulin (BTC), epiregulin (EPR), epigen (EPGN), and macrophage-
produced heparin-binding EGF (HB-EGF)60-63. Upon ligand binding, EGFR can form a homodimer or a 
heterodimer with any member of the avian erythroblastosis oncogene B (ERB)/human epidermal 
growth factor receptor (HER) family of proteins59-61,64. In the event of heterodimerization, EGFR most 
often forms a dimer with ERBB260. Canonically, dimerization as a result of ligand binding upregulates 
the kinase activity of EGFR, such that autophosphorylation occurs at one of a least six known tyrosine 
residues (Figure 4), the most common of which is tyrosine (Y) 106859-61. It should be noted, however, 
that non-canonical phosphorylation can occur at serines and threonines in the intracellular domain, and 
that non-canonical phosphorylation can be ligand independent65-67 (Figure 4). 
 Following phosphorylation, EGFR transactivation leads to downstream signaling. EGFR 
signaling is one of the most important and ubiquitous signaling pathways in mammalian cells (Figure 4), 
as EGFR has been shown to interact with at least 219 downstream modulators68. Common EGFR 
signaling targets include protein kinase B (PKB, also known as AKT), MAPK proteins, Janus kinase 
(JAK)/STAT proteins, and protein kinase C (PKC)59,60,68.  As such, EGFR signaling has broad effects on 
cellular proliferation, growth, differentiation, transcriptional regulation, angiogenesis, and survival59,60,68.  
 EGFR signaling has been associated with several diseases, including Alzheimer’s disease, 
polycystic kidney disease, and inflammatory bowel disease61. However, EGFR signaling has received 
the most attention in carcinogenesis69-73. EGFR mutations, leading to aberrant signaling, has been 
linked to increased risk for lung, breast, liver, colorectal, and gastric cancers69. In fact, high levels of 
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Figure 4. An overview of epidermal growth factor receptor (EGFR) signaling. EGFR signaling can 
be induced in a ligand-dependent manner. Known EGFR ligands include epidermal growth factor 
(EGF), transforming growth factor (TGF)-α, betacellulin (BTC), epigen (EPGN), heparin-binding-EGF 
(HB-EGF), epiregulin (EPR), and amphiregulin (AREG). Ligands bind to the extracellular ligand binding 
domain. Upon binding, EGFR forms a homodimer or a heterodimer with (ERBB) 2 (not depicted here). 
Dimerization increases the kinase activity of the intracellular kinase domain that then 
autophosphorylates the autophosphorylation domain at the listed tyrosines (Y). Ligand-independent 
activation can occur through tumor necrosis factor (TNF)-α binding to TNF receptor (TNFR), which then 
leads to transforming growth factor beta-activated kinase 1 (TAK1)-mediated phosphorylation at serine 
(S) 1046/47. Phosphorylation of a tyrosine leads to the activation of many downstream pathways, 
including i) phospholipase C (PLC) and protein kinase C (PKC) signaling, ii) Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) signaling, iii) v-src avian sarcoma (Schmidt-Ruppin A-
2) viral oncogene homolog (SRC) signaling, iv) mitogen-activated protein kinase (MAPK) signaling 
[Constituents: son of sevenless (SOS), rat sarcoma viral oncogene homolog (RAS), rapidly accelerated 
fibrosarcoma (RAF), mitogen-activated protein kinase kinase (MEK), and extracellular signal-regulated 
kinase (ERK)], v) phosphatidylinositol-3-kinases (PI3K) and protein kinase B (PKB; also known as AKT) 
signaling, and vi) nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling. 
EGFR signaling has pleiotropic effects on a multitude of cellular processes.  
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  EGFR overexpression have been linked to decreased survival in both gastric and colorectal cancers69, 
which are of particular relevance in this dissertation. The exact nature of the role of EGFR signaling in 
the aforementioned diseases remains unclear8,73 and further studies are needed to identify additional 
points of therapeutic intervention within this pathway. 
 
EGFR and Macrophages: A Limited History 
 To date, the role of EGFR signaling has primarily been studied in epithelial cells60,67,71,74-77 and 
there is a lack of literature related to the role of EGFR signaling in macrophages. Tyrosine kinase 
phosphorylation in the regulation of macrophage activation is not a novel concept78. The receptor 
tyrosine kinases, macrophage stimulating protein receptor 1 (MSTR1; known as stem cell-derived 
tyrosine kinase receptor (STK) in mice) and tyrosine-protein kinase receptor 3 (TYRO3), have been 
shown to extensively modulate macrophage activation78. MSTR1 and TYRO3 recruit downstream 
mediators, such as growth factor receptor bound protein 2 (GRB2) and phosphatidylinositol 3 kinase 
(PI3K), in order to alter gene expression toward either M1 or M2 macrophage activation78. GRB2 and 
PI3K are also known downstream mediators of EGFR signaling, setting a precedent for the study of 
EGFR signaling in macrophages61. 
 Indeed, previous studies have begun to assess the presence and role of EGFR in 
macrophages. EGFR was first identified in macrophages in cases of uveal melanoma79. Further studies 
revealed that monocytes, macrophage precursors located in blood, also express EGFR and that the 
expression of EGFR was necessary for human cytomegalovirus entry80. EGFR signaling was shown to 
be indirectly activated in macrophages during meprin-α-mediated oxidized low-density lipoprotein 
release in models of atherosclerosis in the heart81. Importantly, this study revealed a function for EGFR 
signaling – the regulation of ROS production81.  
 Prior to the studies outlined in Chapters 2-4, only two studies had established relevance for 
EGFR signaling in macrophages in human disease. EGFR signaling in Kupffer cells (resident liver 
macrophages) was shown to promote liver tumorigenesis through enhanced IL-6 expression82. IL-6 is 
an M1-associated cytokine with known roles in epithelial cell proliferation82. Additionally, EGFR 
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signaling in macrophages was shown to regulate cytokine production during experimental colitis in 
mice83. However, there are no studies assessing the role of EGFR signaling in macrophages 
specifically during either bacterial infection or colon carcinogenesis, providing impetus for the studies 
outlined in Chapters 2-4. 
 
1.5 Ornithine Decarboxylase and Polyamines: An Overview 
 Polyamine metabolism is responsible for the synthesis of the three main polyamines – 
putrescine, spermidine, and spermine84,85. The semi-essential amino acid, L-arginine, is transported 
into cells by either solute carrier family 7, member 1 (SLC7A1) or solute carrier family 7, member 1 
(SLC7A2)86-88. Once in cells, L-arginine is converted into L-ornithine and urea by ARG1 or arginase 2 
(ARG2)86,87. It should be noted that L-arginine is also the substrate for NOS2, and competition for L-
arginine is important in macrophage activation89. L-ornithine is the substrate for ODC, which is the rate-
limiting enzyme in polyamine metabolism84,86,87. The enzymatic activity of ODC results in the 
decarboxylation of L-ornithine to produce putrescine84,86,87. Putrescine is then converted into spermidine 
by spermidine synthase (SRM) and spermine by spermine synthase (SMS)86,87. Polyamines are 
constantly in flux such that spermine can be converted into spermidine by spermine oxidase (SMOX) 
and spermidine can be converted into putrescine by the combined activity of spermidine/spermine N-1 
acetyl transferase (SAT1) and polyamine oxidase (PAOX)86,87. As ODC is the rate-limiting enzyme in 
this process, Chapter 5 will focus on ODC. Polyamine metabolism is outlined in Figure 5. 
 ODC is essential for life and is intensively regulated from transcription to post-translational 
modifications to direct inhibition by ODC modifying enzymes, like antizyme87. ODC has been implicated 
as having a role in many different cancers because of the global control exerted by polyamines on 
cellular survival, growth and proliferation, DNA synthesis, transcription, and translation84,85,87,90-93. As 
such, ODC is a common target for therapeutic intervention87,91,94, and one such inhibitor, DFMO, is 
routinely used as a chemotherapeutic in various cancers87,91,94. 
 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Polyamine metabolism. L-arginine is transported into cells via solute carrier transport 
protein, family 7, member 1 (SLC7A1) or SLC7A2. Once in cells, L-arginine is converted into L-ornithine 
by arginase 1 (ARG1) or ARG2, producing urea as a by-product. L-ornithine is converted into 
putrescine by ornithine decarboxylase (ODC), producing carbon dioxide (CO2) as a by-product. 
Putrescine is converted into spermidine by spermidine synthase (SRM) and into spermine by spermine 
synthase (SMS). Spermine is converted back into spermidine by spermine oxidase (SMOX), producing 
hydrogen peroxide (H2O2) as a by-product. Spermidine is converted into putrescine by polyamine 
oxidase 1 (PAOX) and spermidine/spermine N-1 acetyl transferase (SAT1). Putrescine, spermidine, 
and spermine affect many cellular processes. 
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  ODC, Macrophages, and H. pylori 
The Wilson laboratory has been particularly interested in the role of ODC in macrophages 
during H. pylori infection for many years. Previous studies from the Wilson laboratory have made 
several key advances in our understanding of the role of ODC in macrophages during infection. 
Firstly, ODC is induced in both murine95,96 and human47 macrophages during H. pylori infection 
in vitro and in vivo. This was the first direct evidence that ODC may have a role in macrophage function 
during H. pylori infection. Induction of ODC expression in macrophages is dependent upon the activity 
of C-v-myc avian myelocytomatosis viral oncogene homolog (C-MYC) as a transcriptional enhancer95. 
Moreover, MAPK1/3 (also known as extracellular signal-regulated kinase [ERK1/2]) signaling in 
macrophages is critical for ODC expression and activity during H. pylori infection97. MAPK1/3 signaling 
is also downstream of EGFR signaling, representing a potential link between EGFR and ODC in 
macrophages. 
From a functional perspective, ODC appears to play a role in the regulation of inflammation 
during H. pylori infection. The induction of ODC has been linked to increased macrophage apoptosis 
during H. pylori infection95,96. Moreover, knockout or inhibition of ODC in macrophages increases NOS2 
expression and NO production during H. pylori infection47,96. The increase in NO production was seen in 
both the macrophage cell line, RAW 246.7, and in isolated gastric macrophages (Gmacs) following 
acute H. pylori infection47,96. Treatment of Mongolian gerbils with DFMO attenuated H. pylori-mediated 
gastric cancer in gerbils, in part, by decreasing inflammation37. While the gerbil model allows for the 
study of H. pylori-mediated gastric carcinogenesis, no experiments can be performed on macrophages 
specifically, due to lack of available reagents for gerbil studies, leaving lingering questions about the 
role of ODC in macrophage function in vivo. 
As such, to date, we have no mechanism by which ODC in macrophages regulates the 
response to H. pylori infection. The study outlined in Chapter 5 was designed to specifically address the 
role of ODC in macrophages in the regulation of macrophage activation and in the modulation of the 
pathogenesis of gastrointestinal pathogens in vivo. The cell-specific knockout mouse model is a critical 
tool that has allowed for the studies in Chapter 5 to take place. 
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  1.6 Thesis Aims and Significance 
The overarching goal of this dissertation is to identify proteins that significantly modulate 
macrophage activation and function during bacterial infection and carcinogenesis. Macrophage 
activation along the M1 to M2 paradigm is not a new concept, and much is known about the regulation 
of macrophage activation. However, what is known about macrophage activation is mostly limited to 
reductionist experiments performed in vitro with known stimuli; relatively fewer studies have focused on 
macrophage activation and function in disease models in vivo, especially in bacterial infection models. 
The studies outlined in this dissertation have identified two proteins – EGFR and ODC – as regulators 
of macrophage activation during bacterial infection and carcinogenesis.  
Prior to this dissertation, relatively little was known about the function of either EGFR or ODC in 
regulating macrophage activation and function. The concept of EGFR signaling occurring in 
macrophages had been minimally addressed prior to this work, and no mechanisms by which EGFR 
may regulate macrophage function had been determined. Similarly, the Wilson laboratory had studied 
the role of ODC in macrophages for several years, but only within the context of macrophage 
apoptosis. No studies had been performed to determine the role of ODC in the regulation of 
macrophage activation along the M1 to M2 paradigm. This dissertation provides the first 
comprehensive studies related to the roles of EGFR and ODC in macrophage activation by addressing 
four specific aims. The aims of this dissertation are outlined in Figure 6. 
EGFR signaling robustly occurs in macrophages, but the function of EGFR signaling in 
macrophages remains poorly understood. Chapters 2-4 address three aims designed to determine the 
role of EGFR signaling in macrophages during both H. pylori and C. rodentium infection and during 
carcinogenesis. Chapter 2 focuses on the role of EGFR signaling in macrophages during bacterial 
infection. The presence of EGFR in macrophages was confirmed in both murine and macrophage cells 
lines. Moreover, since there is a notably higher gastric cancer incidence in Latin America (Figure 2), we 
obtained samples from H. pylori-infected individuals and determined that EGFR signaling also occurs in 
humans during active H. pylori infection. In addition to human samples, we assessed the levels of 
EGFR signaling in macrophages using a human tissue microarray (TMA). This TMA contains samples 
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Figure 6. Outline of the aims of this dissertation. The overarching theme of this dissertation is to 
determine mechanisms by which macrophage activation is regulated. Chapters 2-4 will determine the 
role of epidermal growth factor receptor (EGFR) signaling in the regulation of macrophage activation 
and function during bacterial infection and carcinogenesis. Chapter 5 will assess the role of ornithine 
decarboxylase (ODC) in the regulation of macrophage activation and function during bacterial 
infections. 
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  that spanned the entire Correa Cascade of gastric carcinogenesis – normal tissue to gastritis and 
metaplasia to gastric adenocarcinoma. Importantly, we demonstrated that EGFR signaling is detectable 
from gastritis to gastric adenocarcinoma, and the level of signaling increases in cancer. This is the first 
time that active EGFR signaling in macrophages was demonstrated in human cancer cases and is 
indicative of the potential importance of macrophage-specific EGFR signaling in carcinogenesis, 
providing the impetus for the studies outlined in Chapter 3. 
Moreover, by leveraging a myeloid-specific EGFR knockout mouse model and primary bone 
marrow-derived macrophages (BMmacs), we were able to examine H. pylori and C. rodentium 
pathogenesis in vivo and macrophage activation in vitro in Chapter 2. This chapter outlines the central 
role that EGFR signaling has in regulating M1, M2, and Mreg activation across a variety of stimuli. 
EGFR deficiency in macrophages had a marked effect on the adaptive immune response, as it resulted 
in a diminished Th17 and enhanced Treg response to chronic H. pylori infection, leading to decreased 
histologic gastritis and increased bacterial persistence. Similarly, myeloid-specific deletion of EGFR 
also attenuated the immune response to C. rodentium infection in the colon. Thus, these data indicate 
that EGFR signaling promotes M1 macrophage activation and is pro-inflammatory during enteric 
bacterial infections. The findings in Chapter 2 represent a critical advancement in our understanding of 
EGFR signaling in the regulation of macrophage function during bacterial infection. 
Building upon the findings in Chapter 2, the aim of Chapter 3 is to explore the role of EGFR 
signaling in macrophages during colon carcinogenesis. Obviously, H. pylori is the leading risk factor for 
gastric cancer, but a mouse model necessary for studying the role of EGFR signaling in macrophages 
during gastric cancer is not yet available. However, the azoxymethane (AOM)-dextran sodium sulfate 
(DSS) model of colon carcinogenesis can be readily utilized in our myeloid-specific EGFR knockout 
mouse model. Chapter 3 demonstrates that EGFR signaling in macrophages – not epithelial cells – is a 
key factor in colitis-associated carcinogenesis (CAC). These results of these studies were surprising in 
that i) macrophage EGFR, and not epithelial EGFR, was pro-tumorigenic, and ii) both pro-tumorigenic 
M2 activation and M1 activation, typically thought to be anti-tumorigenic, were necessary for CAC. The 
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  studies in Chapter 3 provide the impetus for further studies related to the role of EGFR signaling in 
macrophages during colon carcinogenesis, given that these were the first observations of their kind. 
EGFR signaling in macrophages is an extremely understudied subject. Within the context of 
epithelial cells, the downstream targets of EGFR signaling are well understood59,60, but it does not 
necessarily follow that the pathways that are downstream of EGFR in epithelial cells must be the same 
pathways that are downstream of EGFR in macrophages. Thus, the aim of Chapter 4 is to utilize 
unbiased proteomic techniques to elucidate pathways that are downstream of EGFR in macrophages. 
Many pathways are known to be downstream targets of EGFR signaling (Figure 4), but pathways 
specific to EGFR signaling in macrophages remain unknown. Chapter 4 outlines the use of stable 
isotope labeling with amino acids in cell culture (SILAC), an unbiased technique, to identify phospho-
proteins that are modified by EGFR signaling during H. pylori infection in macrophages. While this aim 
is not yet fully developed, the goal is to identify factors specific to macrophages that may represent 
targets for chemotherapeutics. Indeed, SILAC analysis thus far has identified tripartite motif containing 
28 (TRIM28) as a potential downstream target of EGFR signaling in macrophages. Further studies are 
planned. 
Finally, Chapter 5 assesses a second protein, ODC, which is the rate-limiting enzyme in 
polyamine metabolism. Like EGFR, ODC is essential for life and its role in regulating polyamine 
metabolism has effects on many different cellular processes. Myeloid-specific ODC knockout mice had 
exacerbated histologic gastritis, coupled with decreased H. pylori burden following chronic infection. 
Similarly, in the C. rodentium infection model, the mice with myeloid-specific ODC knockout exhibited 
increased colitis. Moreover, M1 macrophage activation was significantly enhanced due to alterations in 
histone modifications that increased transcription of pro-inflammatory cytokines. While the studies 
outlined in Chapter 2 and Chapter 3 demonstrated that EGFR is a pro-inflammatory mediator, Chapter 
5 determined that ODC was an anti-inflammatory mediator.  
Overall, this dissertation is focused on the regulation of macrophage activation under various 
conditions. The studies outlined in the subsequent chapters reveal roles for EGFR and ODC, two 
proteins critical for life, in controlling macrophage responses during both bacterial infection and 
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  carcinogenesis. Taken together, the data underscore that while many studies have been performed, 
much remains to be learned about the proteins and pathways that regulate macrophage activation. 
Moreover, EGFR and ODC are classically studied in the context of epithelial cell function. The coming 
chapters demonstrate the importance of challenging existing norms, as such studies can reveal critical 
new information about biology. 
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CHAPTER 2 
EGFR SIGNALING IN MACROPHAGES DURING BACTERIAL INFECTION 
 
2.1 Introduction 
Macrophages represent a dynamic subset of innate immune cells, with functions in immune 
surveillance, immunity to pathogens, wound healing, antigen presentation, and cytokine/chemokine 
production1,3,4. A critical step in macrophage function is macrophage activation2. Classically-activated, 
M1 macrophages are generated in response to pathogens and pro-inflammatory cytokines1-3,98. M1 
macrophages mediate the anti-microbial response to pathogens1-3. Alternatively-activated, M2 
macrophages are generated in response to IL-4 and are associated with wound healing2,3,11,98 and 
promotion of tumorigenesis7,13. Thirdly, Mregs are anti-inflammatory, secreting high concentrations of 
IL-10 to counter-regulate the M1 response2,14. 
 Many studies have focused on signaling pathways that regulate macrophage activation, 
including JAK/STAT, NF-κB, IRF, and cAMP response element-binding protein (CREB)12,15,16,18,19,99. 
Recent evidence suggests that tyrosine kinase signaling also regulates macrophage activation78. 
Specifically, EGFR signaling has been implicated in macrophage function in mouse models of 
glaucoma, colitis, and cancer79,82,83,100. Mice lacking EGFR in resident liver macrophages (Kupffer cells) 
developed less hepatocellular carcinoma, as a direct result of decreased cytokine production by Kupffer 
cells82. However, the role of macrophage EGFR signaling in bacterial infections has not been studied.  
 To investigate this, we chose a highly prolific human pathogen, Helicobacter pylori21. H. pylori is 
a Gram-negative, microaerophilic bacterium that infects approximately 50% of the global 
population24,101. Infection with H. pylori is the single greatest risk factor for the development of gastric 
cancer, which is the third leading cause of cancer death worldwide22,24,102. The combination of H. pylori-
produced oncoproteins, such as CagA, and infection-induced chronic inflammation, which fails to 
eradicate the infection, creates a vicious cycle of tissue and DNA damage9,35,37,40,41. Importantly, 
macrophages play a critical role in H. pylori-mediated gastritis20,47,103. Thus, enhanced understanding of 
the  regulation  of  macrophage responses to H. pylori  could prove very  useful in devising  new strategies	  
	  for chemoprevention of gastric cancer, as antibiotic treatment is often ineffective in eradicating the 
pathogen, especially in high-risk regions9,23,35,40.  
 To gain further insights into the role of macrophage EGFR signaling in mucosal inflammation 
driven by bacterial infection, we also utilized the murine pathogen, Citrobacter rodentium, an attaching 
and effacing enteric bacterial pathogen that mimics enteropathogenic and enterohemorrhagic 
Escherichia coli104. C. rodentium infection leads to acute colon inflammation, marked by significant 
macrophage infiltration105,106 and has been used as a mouse model of inflammatory bowel disease. 
Here, we demonstrate that EGFR signaling i) is activated in macrophages in response to the bacterial 
pathogens H. pylori and C. rodentium, ii) plays a critical role in macrophage activation and function, and 
iii) is involved in human macrophages during H. pylori-induced disease progression. 
 
2.2 Results 
EGFR phosphorylation in macrophages occurs during human H. pylori infection  
 In previous studies, we determined that phosphorylated EGFR (pEGFR) in epithelial cells is 
correlated with early stages of gastric carcinogenesis in humans74. We also observed that mononuclear 
cells in the lamina propria of stomach tissues contained pEGFR (Appendix A, Figure 1). To determine if 
pEGFR localized to macrophages, we utilized human tissues from Colombia, a region with a high 
prevalence of gastric cancer33,37,107. These gastric biopsies were from patients with cagA+ H. pylori 
infection and chronic, active gastritis. Using CD68 as a macrophage marker, we found high levels of 
CD68+pEGFR+ macrophages in gastritis tissues, which were significantly increased versus uninfected, 
control patients (Figure 7A and 7B). These data indicate that pEGFR is upregulated in human gastric 
macrophages during H. pylori-induced inflammation. 
 To examine these findings in a larger number of cases, we utilized a human TMA74 from 
Vanderbilt University Medical Center that included gastric tissues from patients spanning the 
histological range from normal to gastric cancer. We stained the TMA for CD68 and pEGFR          (Figure 
7C) and utilized CellProfiler to quantify CD68+pEGFR+ cells. The percentage of CD68+pEGFR+ 
macrophages was significantly increased in gastritis and in intestinal metaplasia (Figure 7D). Further, 
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Figure 7. Increased pEGFR levels in human gastric macrophages in H. pylori-induced gastritis 
and precancerous intestinal metaplasia. (A) Representative immunofluorescence images of human 
gastric biopsies with normal histology and active, non-atrophic gastritis. CD68 = red, pEGFR Y1068 = 
green, Yellow = merge, Blue = DAPI. Scale bar = 50 µM. n = 4 normal samples and 5 gastritis samples. 
(B) Quantification of the percentage of CD68+pEGFR+ macrophages per the total number of CD68+ 
cells in 10 fields per slide from (A). Slides were analyzed in a blinded manner. ***P < 0.001. n = 4 
normal samples and 5 gastritis samples. Statistical significance was calculated by the Student’s t test. 
(C) Representative hematoxylin and eosin (H&E) images and immunofluorescence images of gastric 
tissues from the Vanderbilt University TMA. Red = CD68, Green = EGFR pY1068, Yellow = merge, 
Blue = DAPI. Scale bar = 100 µM. n = 12 normal samples, 41 gastritis samples, and 9 intestinal 
metaplasia samples.  (D) Quantification of the percentage of CD68+pEGFR+ cells per the total number 
of cells in each individual core in the TMA, as determined by CellProfiler. *P < 0.05. **P < 0.01. n = 12 
normal samples, 41 gastritis samples, and 9 intestinal metaplasia samples. Statistical significance was 
calculated by one-way ANOVA with the Kruskal-Wallis test, followed by the Mann-Whitney U test. 
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  the percentage of CD68+pEGFR+ macrophages was also increased in both intestinal-type and diffuse-
type gastric cancer (Appendix A, Figure 2A and 2B). Importantly, a significant percentage of the total 
CD68+ macrophages were pEGFR+ in intestinal metaplasia, and in intestinal-type and diffuse-type 
gastric cancer, indicating that EGFR signaling in macrophages has a critical role in gastric 
carcinogenesis (Appendix A, Figure 2C). The percentage of CD68–pEGFR+ cells, the majority of which 
are epithelial cells, decreased in both types of gastric cancer (Appendix A, Figure 3A). These data are 
consistent with our previous report in which we demonstrated diminished pEGFR levels in gastric 
epithelial cells by immunoperoxidase staining in cases of gastric cancer compared to earlier stages of 
disease74. While there was an overall positive correlation between the percentage of CD68+pEGFR+ 
and the percentage of CD68–pEGFR+ cells (Appendix A, Figure 3B), this was driven primarily by cases 
of active gastritis (Appendix A, Figure 3C), suggesting a potential interaction between macrophages 
and non-macrophages in induction of EGFR signaling during gastric inflammation. Importantly, the 
correlation between macrophage and non-macrophage/epithelial pEGFR levels was lost in intestinal-
type and diffuse-type gastric cancer (Appendix A, Figure 3C), indicating that macrophage EGFR 
signaling is independent of epithelial EGFR signaling at the end stages of the histologic cascade. 
These data demonstrate that EGFR signaling plays an important role in macrophage function during 
chronic inflammation and carcinogenesis in the human stomach. 
 
H. pylori infection induces EGFR phosphorylation in macrophages 
To extend these observations, we determined whether H. pylori infection is sufficient to induce 
EGFR phosphorylation in macrophages in vitro. In murine RAW 264.7 cells, pEGFR levels peaked at 
30 minutes post infection (p.i.) (Figure 8A). Phosphorylation was detectable at two residues, Y1068 and 
serine (S) 1046/7 (Figure 8A). Densitometric analysis confirmed the induction of EGFR phosphorylation 
at both residues, and determined that the induction at 30 min p.i. was significantly greater than the 
induction at 15 min p.i. at pY1068 and pS1046/7 (Figure 8B and 8C). Additionally, phosphorylation of 
differentiation into macrophages (Figure 8D). The clinically-available, EGFR-specific tyrosine kinase 
inhibitor, gefitinib, effectively diminished EGFR phosphorylation (Figure 8E). Similarly, in primary 
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Figure 8. EGFR signaling in macrophages is induced by H. pylori infection in murine and human 
macrophages. (A) Representative western blot of EGFR pY1068 and pS1046/7 in RAW 264.7 cells at 
various time points post-infection (p.i.) with H. pylori PMSS1 or stimulation with EGF (5 ng/mL). n = 3 
biological replicates. (B) Densitometric analysis of the levels of pY1068 compared to levels of tEGFR at 
15 and 30 min p.i. *** P < 0.001. n = 3 biological replicates. (C) Densitometric analysis of the levels of 
pS1046/7 compared to levels of tEGFR at 15 and 30 min p.i. * P < 0.05, ** P < 0.01, *** P < 0.001. n = 
3 biological replicates. Statistical significance in (B) and (C) was calculated by one-way ANOVA with 
Newman-Keuls post-test. (D) Representative western blot of EGFR at pY1068 and pS1046/7 in THP-1 
cells at 15 min p.i. with H. pylori PMSS1. Monocytes [− phorbol-12-myristate-13-acetate (PMA)] and 
macrophages (+ PMA) are represented in this blot. n = 3 biological replicates. (E) Representative 
western blot of EGFR at pY1068 and pS1046/7 in RAW 264.7 cells at 15 min p.i. with H. pylori PMSS1 
± 10 µM gefitinib. n = 3 biological replicates. (F) Representative immunofluorescence images of WT 
BMmacs infected with H. pylori PMSS1 ± 10 µM gefitinib at times indicated. Green = EGFR pY1068, 
Blue = DAPI. Scale bar = 50 mM. n = 5 biological replicates. (G) Representative immunofluorescence 
images of WT BMmacs infected with H. pylori PMSS1 ± 10 ng/mL anti-TNF-α or ± 25 ng/mL anti-HB-
EGF at 30 min p.i. Green = pEGFR Y1068, Blue = DAPI. Scale bar = 50 µM. n = 3 biological replicates. 
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  BMmacs from naive C57BL/6 wild-type mice, H. pylori infection was sufficient to induce EGFR 
phosphorylation, which was attenuated by gefitinib (Figure 8F). Thus, EGFR transactivation is 
upregulated in macrophages in response to a bacterial pathogen, and it is a conserved feature of 
macrophage immune responses, as it is present in both mouse and human systems. 
EGFR activation can occur in either a ligand-dependent or ligand-independent manner66,108. 
Previous studies in epithelial cells have revealed that pY1068 is a marker of ligand-dependent 
activation and pS1046/47 is a marker of ligand-independent activation66,108. Since our data indicate that 
H. pylori infection leads to the phosphorylation of both residues, we investigated activation mechanisms 
in macrophages. HB-EGF is primarily produced by macrophages and is an EGFR ligand63. TNF-α is a 
known inducer of ligand-independent EGFR activation66,67. Treatment of wildtype (WT) BMmacs with an 
anti-HB-EGF neutralizing antibody resulted in a modest inhibition of H. pylori-induced EGFR 
phosphorylation (Figure 8G). However, treatment of macrophages with anti-TNF-α neutralizing 
antibody ablated EGFR activation at pY1068 and pS1046/47 (Figure 8G and Appendix A, Figure 4). 
Moreover, treatment with recombinant TNF-α also stimulated phosphorylation at S1046/47 (Appendix 
A, Figure 4). These data suggest that EGFR can be activated in a ligand-independent, TNF-α-
dependent mechanism in macrophages during H. pylori infection.  
 
Macrophage EGFR signaling is critical for controlling bacterial burden and mounting an 
adequate immune response to infection 
 To determine the role of EGFR signaling in macrophages in vivo, we obtained Egfrfl/fl mice 
crossed to LysMcre/cre mice, creating the Egfr∆mye mouse83. The LysM driver leads to the excision of the 
Egfr alleles that are flanked by loxp sites in myeloid cells83,109.  
We determined knockdown of EGFR in several ways. Firstly, Egfrfl/fl and Egfr∆mye BMmacs were 
isolated and infected with H. pylori PMSS1 for 24 hours (h); DNA was isolated and excision of the Egfr 
gene was detected (Appendix A, Figure 5A). Secondly, significant knockdown of total EGFR (tEGFR) 
protein levels was demonstrated in Egfr∆mye versus Egfrfl/fl BMmacs, both before and after infection with 
H. pylori (Appendix A, Figure 5B and 5C).  
26
	  	   27 
Thirdly, previous studies have demonstrated that the peak of macrophage infiltration is 48 h p.i. 
with H. pylori97,110. Using flow cytometry, and F4/80 and CD11b as macrophage markers, the number of 
tEGFR+ Gmacs was significantly decreased in Egfr∆mye versus Egfrfl/fl mice at this timepoint (Appendix 
A, Figure 5D). Further, the number of infiltrating Gmacs was not different between genotypes (Appendix 
A, Figure 5E). The number of pan-cytokeratin+tEGFR+ gastric epithelial cells was also not different 
(Appendix A, Figure 5F), indicating the specificity of the LysM-Cre driver. The use of an isotype control 
antibody verified the specificity of the tEGFR staining (Appendix A, Figure 5G). 
Lastly, we determined expression levels of lysozyme 2 (Lyz2), the gene on which the Cre 
recombinase was placed, and of Cre itself. Gastric tissues at 4  months (mo) p.i. and BMmacs infected 
with H. pylori demonstrated that while the Egfrfl/fl mice expressed Lyz2, the Egfr∆mye mice had no Lyz2 
expression (Appendix A, Figure 6), verifying the durability of the Lyz2 knockout. Further, there were 
very high levels of Cre mRNA both before and after chronic infection, confirming that there was no loss 
of Cre expression during our experiments  (Appendix A, Figure 6).  
Having established that EGFR is effectively deleted only in macrophages before and after 
infection, we utilized our established model of chronic infection with H. pylori Sydney Strain 1 (SS1) for 
4 mo47,96,103. Egfr∆mye mice demonstrated significantly decreased histologic gastritis after four-month H. 
pylori SS1 infection (Figure 9A and 9B), and decreased acute gastritis after one-month H. pylori pre-
mouse Sydney Strain 1 (PMSS1) infection (Appendix A, Figure 7A). Previous reports have indicated 
that gastric inflammation, as a marker of immune response, is associated with control of H. pylori load 
in mouse models111,112. As such, there was increased H. pylori colonization in Egfr∆mye mice, compared 
to Egfrfl/fl or LysMcre/cre mice (Figure 9C). Increased colonization in Egfr∆mye mice was also observed in 
the one-month model of infection with H. pylori PMSS1 (Appendix A, Figure 7B).  
CD68+ Gmacs from infected gastric tissues in Egfrfl/fl and LysMcre/cre mice demonstrated a high 
level of co-localization with pEGFR in situ, indicating that H. pylori infection induces EGFR signaling in 
macrophages (Figure 9D). CD68+ Gmacs in infected Egfr∆mye gastric tissues did not have any 
detectable pEGFR (Figure 9D). Moreover, CD68+ Gmacs in infected Egfr∆mye gastric tissues did not 
have any demonstrable tEGFR, while CD68+ Gmacs from Egfrfl/fl and LysMcre/cre mice had high levels of	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Egfr∆mye mice have significantly increased H. pylori burden, but significantly decreased 
gastritis after chronic infection. (A) Gastritis scores were assessed 4 mo p.i in by a gastrointestinal 
pathologist in a blinded manner according to the updated Sydney System. *P < 0.05. ***P < 0.001. (B) 
Representative H&E images from infected mice in (A). Scale bars = 100 µM. (C) Colonization of H. 
pylori SS1 was assessed by serial dilution and culture 4 mo post infection (p.i.). ***P < 0.01. In (A) and 
(C), n = 5-10 uninfected and 11-30 H. pylori SS1 mice per genotype. Statistical significance in (A) and 
(C) was calculated by one-way ANOVA with Newman-Keuls post-test. (D) Representative 
immunofluorescence images of pEGFR from infected mice in (A) and (B). Green = EGFR pY068, Red = 
CD68, Yellow = merge, Blue = DAPI. Closed arrows indicate CD68+pEGFR+ macrophages. Open 
arrows indicate CD68+pEGFR— macrophages. Scale bars = 50 µM. (E) Immunofluorescence images of 
tEGFR from infected mice in (A) and (B). Green = tEGFR, Red = CD68, Yellow = merge, Blue = DAPI. 
Closed arrows indicate CD68+tEGFR+ macrophages. Open arrows indicate CD68+tEGFR— 
macrophages. Scale bars = 50 µM. In (D) and (E), n = ≥ 3 mice per genotype. 
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  tEGFR (Figure 9E). These data indicate that the deletion of EGFR is maintained throughout chronic H. 
pylori infection. 
To determine if our findings were generalizable to another enteric bacterial infection, Egfrfl/fl and 
Egfr∆mye mice were inoculated with C. rodentium for 14 days, a model of colitis113. Egfr∆mye mice 
exhibited increased C. rodentium bacterial burden in colonic tissue (Appendix A, Figure 8A). When 
compared to Egfrfl/fl mice, Egfr∆mye mice were protected from weight loss, indicative of decreased clinical 
disease severity (Appendix A, Figure 8B). Decreased disease severity, combined with increased 
colonization, in the C. rodentium model is concordant with the findings in the H. pylori model above. 
CD68+ macrophages from infected colonic tissues in Egfrfl/fl mice demonstrated a high level of co-
localization with pEGFR, indicating that C. rodentium infection also induces EGFR signaling in 
macrophages (Appendix A, Figure 8C). CD68+pEGFR+ colonic macrophages were not present in 
infected Egfr∆mye colonic tissues, again confirming effective Egfr excision in these mice (Appendix A, 
Figure 8C). These data further indicate that EGFR signaling in macrophages is important in the host 
response to enteric infections. 
 
EGFR signaling is critical for pro-inflammatory chemokine production in vivo 
 Based on our in vivo findings, we hypothesized that the loss of Egfr in myeloid cells diminished 
the innate immune responses to bacterial pathogens. To assess host immune responses, we utilized a 
Luminex Multiplex Array to assess 32 chemokines/cytokines. Six analytes were significantly decreased 
in gastric tissues from H. pylori-infected Egfr∆mye mice versus Egfrfl/fl or LysMcre/cre mice (Figure 10). 
Moreover, all of these analytes, C-X-C motif ligand (CXCL) 1 (GRO-α, KC), CXCL9 (MIG), CXCL10 (IP-
10), C-C motif ligand, CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES), were altered    at  both the 
mRNA and protein levels (Figure 10), indicating that loss of EGFR in myeloid cells leads to a significant 
ablation of the innate immune response at the transcriptional level. Alterations in chemokine responses 
further indicate that macrophage EGFR signaling is necessary for the gastric inflammatory response to 
H. pylori. Cytokines that were either not significantly different between genotypes, not increased by H. 
pylori infection, or not detected are listed in Appendix A, Table 1. 
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Figure 10. Egfr∆mye mice have significantly decreased chemokine production in gastric tissue. 
mRNA and protein levels of cytokines/chemokines, (A) CXCL1 (KC), (B) CXCL10 (IP-10), (C) CXCL9 
(MIG), (D) CCL3 (MIP-1α), (E) CCL5 (RANTES), and (F) CCL4 (MIP-1β), were assessed by RT-PCR 
and Luminex Multiplex Array, respectively, from gastric tissue 4 mo p.i. with H. pylori SS1. *P < 0.05. 
**P < 0.01. Statistical significance was calculated by one-way ANOVA with the Kruskal-Wallis test, 
followed by the Mann-Whitney U test. In all panels, n = 2-5 uninfected and 6-11 infected mice per 
genotype. 	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  EGFR signaling is critical for pro-inflammatory cytokine production and Nos2 expression by 
macrophages in vivo  
Given the high degree of co-localization of pEGFR and CD68+ macrophages in both gastric and 
colonic tissues during infection and the fact that macrophages are known to be major drivers of H. 
pylori-induced inflammation20, we next examined genes typically expressed by macrophages. Markers 
of M1 macrophage activation –Nos2, Tnfa, and Il1b – were all decreased in gastric tissues from H. 
pylori-infected Egfr∆mye versus Egfrfl/fl mice (Figure 11A). Markers of Mreg activation – Il10, Tgfb, and 
tumor necrosis factor (ligand) superfamily member 14 (Tnfsf14; Light) – were also decreased in 
infected Egfr∆mye gastric tissues (Figure 11B). Markers of M2 activation – Arg1 and Chil3 – were not 
significantly altered in Egfr∆mye mice (Appendix A, Figure 9). IL-1β protein was also significantly 
decreased in H. pylori-infected Egfr∆mye gastric tissues (Figure 11C), supporting the mRNA data 
indicating a role for myeloid EGFR in regulating the M1 response to H. pylori. Furthermore, Gmacs from 
infected Egfr∆mye mice expressed less Nos2 mRNA (Figure 11D) and NOS2 protein (Figure 11E) 
compared to Gmacs from infected Egfrfl/fl mice. As there was no difference in macrophage infiltration 
(Appendix A, Figure 4E), these data indicate that the changes in NOS2 levels are specifically due to 
loss of EGFR rather than alterations in macrophage number.   
In the C. rodentium model, only M1 markers were significantly induced by infection in colon 
tissues from Egfrfl/fl mice; as in H. pylori infection, expression levels of Nos2 and Tnfa were significantly 
decreased in the Egfr∆mye mice, and Il1b showed a similar trend (Appendix A, Figure 10). Thus, 
macrophage EGFR signaling is an important mediator of pro-inflammatory and anti-inflammatory gene 
expression during gastrointestinal mucosal infection.  
 
EGFR signaling is a key component in macrophage activation and function  
 Because limited numbers of Gmacs can be obtained for experimentation, we utilized BMmacs 
for further studies addressing the role of EGFR in macrophages. We also utilized bone marrow-derived 
dendritic cells (BMDCs) to assess the role of EGFR signaling in the dendritic cell population. 
Differentiation of macrophages and dendritic cells is demonstrated in Appendix A, Figure 11. WT 
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Figure 11. Egfr∆mye mice have significantly decreased M1 and Mreg cytokine production in 
gastric tissue and gastric macrophages. (A) mRNA levels of pro-inflammatory cytokines, Nos2, 
Tnfa, and Il1b, were assessed by RT-PCR from gastric tissue 4 mo p.i. with H. pylori SS1. *P < 0.05. 
**P < 0.01. (B) mRNA levels of anti-inflammatory cytokines, Il10, Tgfb, and Tnfsf14 (Light), were 
assessed by RT-PCR from gastric tissue 4 mo p.i. with H. pylori SS1. *P < 0.05. **P < 0.01. Statistical 
significance in (A) and (B) calculated by one-way ANOVA with Kruskal-Wallis test, followed by Mann-
Whitney U test. In (A) and (B), n = 3 uninfected and 5 infected mice per genotype. (C) Measurement of 
IL-1β by ELISA in gastric tissues 4 mo p.i. with H. pylori SS1. ***P < 0.001. n = 4 uninfected and 10 
infected mice per genotype. (D) F4/80+ gastric macrophages (Gmacs) were magnetically selected from 
the lamina propria at 48 h p.i. with H. pylori SS1 and mRNA levels of Nos2 were assessed by RT-PCR. 
**P < 0.01. n = 6 uninfected and 9-10 infected mice per genotype. Statistical significance in (C) and (D) 
was calculated by one-way ANOVA with Newman-Keuls post-test. (E) Protein levels of NOS2 were 
assessed in F4/80+ Gmacs 48 h p.i. with H. pylori SS1. *P < 0.05. n = 4 uninfected and 6 infected mice 
per genotype. Statistical significance calculated by one-way ANOVA with Kruskal-Wallis test, followed 
by Mann-Whitney U test. 	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  BMmacs treated with gefitinib demonstrated significantly decreased M1 activation in response to H. 
pylori, as determined by decreased expression of Nos2, Tnfa, and Il1b (Figure 12A). BMmacs from 
Egfr∆mye mice also exhibited decreased expression of these M1 genes when compared to Egfrfl/fl 
BMmacs (Figure 12B). As in gastric tissues, Mreg activation with H. pylori infection, denoted by 
induction of Il10 and Tgfb, was decreased in both WT BMmacs treated with gefitinib and in Egfr∆mye 
BMmacs (Appendix A, Figure 12A and 12B). M2 gene expression was not induced by H. pylori infection 
in BMmacs (Appendix A, Figure 12C and 12D). Similarly, M1 and Mreg markers induced by C. 
rodentium infection were decreased by inhibition of EGFR signaling (Appendix A, Figure 13A and 13B). 
These BMmac data corroborate our in vivo findings and indicate that EGFR is a key regulator of 
macrophage activation during bacterial infection.  
To determine if EGFR has a global role in macrophage activation, we treated Egfrfl/fl and Egfr∆mye 
BMmacs with the prototypical stimuli for M1, M2, and Mreg activation and assessed activation by gene 
expression. Stimulation of BMmacs with IFN-γ and LPS induces an M1 response3. As with H. pylori or 
C. rodentium infection, an M1 stimulus induced significantly decreased expression of Nos2, Il1b, and 
Tnfa in Egfr∆mye BMmacs (Appendix A, Figure 14A). Neither H. pylori nor C. rodentium induce a 
significant M2 response (Appendix A, Figure 9; Appendix A, Figure 12D and C). However, Egfr∆mye 
BMmacs activated with IL-4, a classical M2 stimulus3, demonstrated significantly diminished mRNA 
expression of M2 genes, Arg1, Chil3, and Retnla (Relma) when compared with Egfrfl/fl BMmacs 
(Appendix A, Figure 14B). Moreover, Mreg activation, as evidenced by Il10 and Tgfb expression, was 
significantly diminished in Egfr∆mye BMmacs (Appendix A, Figure 14C). Thus, EGFR has the capacity to 
regulate all subsets of macrophage activation under various conditions. These data further demonstrate 
the central role that EGFR plays in regulating macrophage activation. 
H. pylori-stimulated NOS2 protein levels were also diminished in RAW 264.7 cells treated with 
gefitinib or AG1478, a second inhibitor of the EGFR tyrosine kinase domain (Figure 12C), or in WT 
BMmacs treated with gefitinib (Figure 12D). Both RAW 264.7 cells treated with EGFR inhibitors (Figure 
8E) or Egfr∆mye BMmacs (Figure 12F) produced decreased NO, an effector we have shown to have anti-
microbial effects47,114,115, in response to H. pylori. Thus, when RAW 264.7 cells were treated with 
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Figure 12. EGFR signaling is critical for macrophage activation and function. (A) mRNA levels of 
M1 activation markers, Nos2, Tnfa, and Il1b, were assessed by RT-PCR in WT BMmacs 24 p.i. with H. 
pylori PMSS1 ± 10 µM gefitinib. ***P < 0.001. n  = 3 biological replicates. (B) mRNA levels of M1 
activation markers Nos2, Tnfa, and Il1b, were assessed by RT-PCR in Egfrfl/fl and Egfr∆mye BMmacs 24 
p.i. with H. pylori PMSS1. ***P < 0.001. n = 3 mice per genotype. (C) Representative western blot of 
NOS2 in RAW 264.7 cells 24 h p.i. with H. pylori PMSS1 ± 150 nM AG1478 (AG) or 10 µM gefitinib 
(Gef). UT = untreated. n = 3 biological replicates. (D) Representative western blot of NOS2 in WT 
BMmacs 24 h p.i. with H. pylori PMSS1, SS1 or 7.13 ± 10 µM gefitinib. n = 3 biological replicates. (E) 
Measurement of NO2— from RAW 264.7 cell supernatants 24 h p.i. with H. pylori PMSS1, SS1  or 7.13 
± 150 nM AG1478 or 300 nM PD153035. †P < 0.05 vs. PMSS1 only. *P < 0.05, **P < 0.01 vs. SS1 
only. §P < 0.05 vs. 7.13 only. n = 5 biological replicates. (F) Measurement of NO2— from Egfrfl/fl and 
Egfr∆mye BMmac supernatants 24 h p.i. with H. pylori PMSS1. **P < 0.01. n = 3 mice per genotype. (G) 
Measurement of IL-1β in Egfrfl/fl and Egfr∆mye BMmacs supernatants 24 h p.i. with H. pylori PMSS1. **P 
< 0.01. n = 3 mice per genotype. Statistical significance in all panels was calculated by one-way 
ANOVA with Newman-Keuls post-test. 
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  gefitinib there was significantly increased H. pylori survival when bacteria were separated from 
macrophages by a Transwell filter support, a model that prevents phagocytosis and allows for direct 
measurement of the ability of macrophages to kill extracellular H. pylori (Appendix A, Figure 15). These 
data are consistent with the increased bacterial survival in both the H. pylori and C. rodentium mouse 
models of infection with myeloid-specific deletion of Egfr. Moreover, H. pylori-stimulated IL-1β protein 
secretion was attenuated in Egfr∆mye versus Egfrfl/fl BMmacs (Figure 12G). There was no H. pylori strain 
specificity for inducing EGFR-mediated macrophage immune responses, as infection with multiple H. 
pylori strains resulted in similar findings.  
Macrophages are also professional phagocytes. Therefore, we assessed the effect of EGFR 
signaling on macrophage phagocytosis of H. pylori, using a gentamicin protection assay48 and siRNA to 
ensure effective loss of EGFR (Appendix A, Figure 16A). There was no difference in phagocytosis 
between Egfr knockdown cells and cells transfected with a non-targeting siRNA pool (Appendix A, 
Figure 16B). Additionally, there was no difference in phagocytosis between untreated and gefitinib- 
treated cells, confirming the findings with Egfr siRNA (Appendix A, Figure 16C). We verified that 200 
µg/mL gentamicin effectively killed extracellular H. pylori, while 10 µM gefitinib and 0.1% saponin had 
no effect on H. pylori viability (Appendix A, Figure 16C). These findings confirmed the efficacy of this 
assay. Thus, EGFR signaling does not appear to play a role in bacterial phagocytosis. 
 EGFR is associated with resistance to apoptosis in epithelial cells74, raising the possibility that 
the phenotypic effects observed in macrophages lacking EGFR are due to diminished cell survival. 
However, there was no difference in H. pylori-induced apoptosis in RAW 264.7 cells with Egfr 
knockdown (Appendix A, Figure 17A and 17B) or treated with gefitinib (Appendix A, Figure 17C). 
Additionally, neither WT BMmacs with our without gefitinib, nor Egfr∆mye versus Egfrfl/fl BMmacs had any 
differences in H. pylori-induced apoptosis (Appendix A, Figure 17D and 17E). Similarly, we detected no 
differences in Annexin-V/7AAD levels in F4/80+CD11b+ Gmacs from H. pylori-infected Egfrfl/fl and 
Egfr∆mye mice (Appendix A, Figure 17F). Importantly, there were no differences in the number of Gmacs 
between genotypes, further indicating that the cells are viable with or without EGFR (Appendix A, 
Figure 17G). Moreover, no differences in cleaved caspase 3 levels were detected in CD68+ Gmacs in 
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  tissues from Egfrfl/fl and Egfr∆mye mice 4 mo p.i., when assessed by immunofluorescence (Appendix A, 
Figure 17H). Taken together, these data indicate that EGFR does not regulate cell viability in 
macrophages and further confirm that the effects on macrophage phenotype of Egfr deletion are due 
solely to the loss of EGFR.  
 As our mouse model is a myeloid-specific knockout of EGFR, we also examined expression of 
dendritic cell cytokines under conditions where EGFR signaling is inhibited. WT BMDCs treated with 
gefitinib exhibited no differences in H. pylori-induced mRNA expression of relevant cytokines, Tnfa, Il6, 
Il12b, and Il10 (Appendix A, Figure 18A). Similarly, Egfr∆mye BMDCs demonstrated no difference in H. 
pylori-stimulated expression of these same cytokines, when compared to Egfrfl/fl BMDCs (Appendix A, 
Figure 18B). Moreover, Egfr∆mye BMDCs expressed the same level of surface major histocompatibility 
complex II during H. pylori infection as the Egfrfl/fl BMDCs (Appendix A, Figure 18C, and 18D). Taken 
together, these data indicate that EGFR signaling does not regulate dendritic cell cytokine production or 
antigen presentation. 
 
EGFR signaling and NF-κB signaling form an important link in macrophages that is necessary 
for cytokine production 
To further address downstream effects of EGFR in macrophages, we examined the NF-κB 
signaling pathway, a key mediator of cytokine production and innate immune responses to pathogens. 
H. pylori infection leads to NF-κB signaling, directly resulting in the production of cytokines and 
chemokines116,117. Because we are studying bacterial pathogens, we examined the classical NF-κB 
signaling pathway that includes myeloid differentiation primary response 88 (MyD88), inhibitor of kappa 
light polypeptide gene enhancer in B cells, kinase (IKBK, IKK), and inhibitor of kappa light polypeptide 
gene enhancer in B cells, inhibitor a (NFKBIA, IκBα). 
Based on our findings that H. pylori-induced phosphorylation of EGFR was present at 15 min 
p.i. and abundant at 30 min p.i., downstream NF-κB-related signaling was assessed beginning at the 
latter timepoint. H. pylori-infected Egfr∆mye BMmacs demonstrated decreased MyD88 protein levels 30 
min p.i., as compared to Egfrfl/fl BMmacs (Figure 13A). A similar decrease was observed in WT 
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Figure 13. EGFR and NF-κB form a critical link in macrophages in response to H. pylori. (A) 
Representative western blot of MyD88 protein levels in Egfrfl/fl and Egfr∆mye BMmacs 30 min p.i. with H. 
pylori PMSS1. n = 3 biological replicates. (B) Representative western blots of pIKBK (pIKK) and 
pNFKBIA (pIkBa) protein levels in Egfrfl/fl and Egfr∆mye BMmacs 30 min and 45 min p.i. with H. pylori 
PMSS1. n = 3 biological replicates. (C) Representative western blot of cytoplasmic and nuclear 
fractions of tRELA (p65) in Egfrfl/fl and Egfr∆mye BMmacs 60 min p.i. with H. pylori PMSS1. n = 3 
biological replicates. (D) Densitometric analysis of cytoplasmic and nuclear tRELA. n = 3 biological 
replicates. **P < 0.01. n = 3 biological replicates. Statistical significance was calculated by Student’s t 
test. (E) Western blot of cytoplasmic and nuclear fractions of phospho-RELA (pp65) in Egfrfl/fl and 
Egfr∆mye BMmacs 60 min p.i. with H. pylori PMSS1. (F) Measurement of luminescence from NF-κB 
luciferase reporter in immortalized, bone marrow-derived macrophages (NGL cells), at indicated time 
points p.i. with H. pylori PMSS1 or SS1 ± 10 µM gefitinib. *P < 0.05 vs. PMSS1 only. §P < 0.05 vs. SS1 
only. n = 4 biological replicates. Statistical significance was calculated by one-way ANOVA with 
Newman-Keuls post-test. 
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  BMmacs treated with gefitinib (Appendix A, Figure 19A). Moreover, Egfr∆mye BMmacs exhibited 
significantly decreased phospho-IKBK (pIKBK) and phospho-NFKBIA (pNFKBIA) levels at 30 and 45 
min p.i., versus Egfrfl/fl BMmacs (Figure 13B). H. pylori-infected WT BMmacs treated with gefitinib also 
had decreased pIKBK and pNFKBIA, as compared to untreated BMmacs (Appendix A, Figure 19B and 
19C).  
Consistent with the MyD88, pIKBK, and pNFKBIA data, there was significantly less v-rel avian 
reticuloendotheliosis viral oncogene homolog A (RELA; p65) translocation to the nucleus 60 min after 
H. pylori infection in Egfr∆mye BMmacs (Figure 13C). Densitometric analysis confirmed the significant 
decrease in nuclear RELA levels, with no change in the cytoplasmic levels of RELA (Figure 13D). A 
similar reduction in nuclear translocation of RELA was observed in WT BMmacs treated with gefitinib 
(Appendix A, Figure 19D, 19E, and 19F). Nuclear levels of phospho-RELA were also decreased in 
Egfr∆mye BMmacs 60 min p.i., as compared to Egfrfl/fl BMmacs (Figure 13E).  Moreover, BMmacs 
expressing an NF-κB luciferase reporter (NGL cells118,119) demonstrated decreased H. pylori-stimulated 
NF-κB activity when treated with gefitinib (Figure 13F). Taken together, these data indicate that pEGFR 
is a key enhancer of macrophage NF-κB signaling in response to H. pylori infection, potentiating 
production of inflammatory mediators, including cytokines and NO. 
 
ERK signaling is also linked to EGFR signaling and contributes to macrophage activation 
 EGFR signaling is known to interact with many signaling pathways, including MAPK 
signaling120,121. Components of the MAPK signaling pathway include MAPK1 and MAPK3 (hereafter 
referred to as MAPK1/3)120,121. We have previously demonstrated that MAPK1/3 signaling has a role in 
regulating macrophage function in response to H. pylori, and that H. pylori infection induces 
phosphorylation of MAPK1/397. 
 EGFR inhibition (Figure 14A) or deletion (Figure 14B) resulted in decreased phospho-MAPK1/3 
(pMAPK1/3) levels in BMmacs stimulated with H. pylori (Figure 14A and 14B). These data suggest that 
EGFR activation is upstream of MAPK1/3, and that MAPK1/3 signaling is closely linked to EGFR 
signaling. To determine the role of MAPK1/3 signaling in macrophage activation, we utilized the 
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Figure 14. EGFR signaling and MAPK1/3 signaling are linked in regulating macrophage 
activation in response to H. pylori. (A) Representative western blot of pMAPK1/3 levels in WT 
BMmacs ± 10 µM gefitinib or ± 50 µM ERKi at 15 and 30 min p.i. with H. pylori PMSS1. n = 3 biological 
replicates. (B) Representative western blot of pMAPK1/3 levels in Egfrfl/fl and Egfr∆mye BMmacs at 15 
and 30 min p.i. with H. pylori PMSS1. n = 3 biological replicates. (C) mRNA levels of M1 activation 
markers Nos2 and Il1b, were assessed by RT-PCR in WT BMmacs ± 10 µM gefitinib and/or ± 50 µM 
ERKi 24 p.i. with H. pylori PMSS1. ***P < 0.001. n = 5 mice. (D) mRNA levels of Mreg activation 
markers Il10 and Tgfb, were assessed by RT-PCR in WT BMmacs ± 10 µM gefitinib and/or ± 50 µM 
ERKi 24 p.i. with H. pylori PMSS1. ***P < 0.001. n = 5 mice. (E) mRNA levels of M1 activation markers 
Nos2 and Il1b, were assessed by RT-PCR in Egfrfl/fl and Egfr∆mye BMmacs ± 50 µM ERKi 24 p.i. with H. 
pylori PMSS1. **P < 0.01, ***P < 0.001. n = 3 mice per genotype. (F) mRNA levels of Mreg activation 
markers Il10 and Tgfb, were assessed by RT-PCR in Egfrfl/fl and Egfr∆mye BMmacs ± 50 µM ERKi 24 p.i. 
with H. pylori PMSS1. ***P < 0.001. n = 3 mice per genotype. Statistical significance in (C)-(F) was 
calculated by one-way ANOVA with Newman-Keuls post-test. 	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  MAPK1/3 inhibitor, ERKi, to prevent MAPK1/3 phosphorylation (Figure 14A). WT BMmacs were treated 
with gefitinib, ERKi, or both inhibitors in combination prior to infection with H. pylori. Gefitinib and ERKi 
each led to markedly decreased Nos2 and Il1b expression, markers of M1 activation (Figure 14C), and 
decreased Il10 and Tgfb expression, markers of Mreg activation (Figure 14D). Notably, the combination 
of gefitinib and ERKi did not further decrease M1 and Mreg gene expression (Figure 14C and 14D). 
Together, these data suggest that EGFR and MAPK1/3 are in the same pathway, and that EGFR is 
upstream of MAPK1/3. 
 Consistent with the data obtained using gefitinib and ERKi, H. pylori-infected Egfrfl/fl BMmacs 
treated with ERKi demonstrated a similar level of reduction of Nos2, Il1b, Il10, and Tgfb mRNA 
expression as the Egfr∆mye BMmacs not treated with ERKi (Figure 14E and 14F). As with the 
combination of gefitinib and ERKi, Egfr∆mye BMmacs treated with ERKi did not have any further 
decrease in M1 and Mreg gene expression (Figure 14E and 14F). These data further support the 
concept that EGFR and MAPK1/3 are in the same pathway(s), and exert potent effects on macrophage 
activation in response to H. pylori infection.  
 
Macrophage EGFR is necessary for regulating both Th17 and Treg T cell responses during H. 
pylori infection   
 As macrophages are antigen-presenting cells and play a role in initiating the adaptive immune 
response during H. pylori infection, we sought to determine the nature of the interaction between 
Egfr∆mye macrophages and T cells. Because we detected attenuated chronic inflammation at 4 mo p.i. in 
Egfr∆mye mice, we   focused on this timepoint for detailed  analysis of the adaptive immune response. We 
utilized two sources of T cells for these studies – magnetically selected CD4+ T cells from the lamina 
propria of the mouse stomach that were then analyzed by real-time (RT)-PCR and T cells from the 
perigastric lymph nodes (GLN) that were assayed by flow cytometry. 
 The Th1 response was detectable, but it was not particularly robust, and there were no 
significant differences in Ifng expression in gastric tissues from infected Egfrfl/fl, Egfr∆mye, and LysMcre/cre 
mice (Appendix A, Figure 20A). There was a modest, but not statistically significant induction of the 
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  CD4+IFN-γ+ population in the GLNs from infected Egfrfl/fl mice (Appendix A, Figure 20B). However, the 
CD4+IFN-γ+ population was significantly decreased in Egfr∆mye GLNs (Appendix A, Figure 20B). The 
lamina propria T cells exhibited a significant increase in both T box 21 (Tbx21, Tbet), a transcription 
factor regulating Th1 differentiation, and Ifng expression in Egfrfl/fl mice, but only Tbx21 expression was 
significantly decreased in Egfr∆mye mice (Appendix A, Figure 20C).  
 Th17 responses were more robust and more dependent upon macrophage EGFR signaling at 4 
mo p.i. Il17a mRNA levels were significantly increased in infected Egfrfl/fl and LysMcre/cre gastric tissues, 
and decreased in infected Egfr∆mye gastric tissues (Figure 15A). Similarly, IL-17 protein levels were 
increased in infected Egfrfl/fl gastric tissues, and significantly decreased in Egfr∆mye tissues (Figure 15B). 
Consistent with these data, the CD4+IL-17+ population in the Egfrfl/fl GLNs was significantly increased 
with infection, and the CD4+IL-17+ population in the Egfr∆mye GLNs was significantly decreased (Figure 
15C). Both RAR-related orphan receptor C (Rorc, Rorγt), encoding for a transcription factor that 
mediates Th17 differentiation, and Il17a mRNA levels were very highly induced in CD4+ T cells from the 
lamina propria of Egfrfl/fl mice (Figure 15D). Notably, Egfr∆mye mice had significantly less Rorc and Il17a 
expression in CD4+ T cells from the lamina propria (Figure 15D).  
IL-23, composed of IL-12p19 (IL-23A) and IL-12p40 (IL-12B), and TGF-β are necessary for 
Th17 differentiation122. IL-12B protein (Appendix A, Table 1) and Tgfb mRNA levels (Figure 11B) were 
significantly decreased in Egfr∆mye gastric tissue. Moreover, macrophage-derived Il23a (Appendix A, 
Figure 21) and Tgfb (Appendix A, Figure 12B) mRNA levels were significantly reduced in Egfr∆mye 
BMmacs. Taken together, these data indicate a diminished potential for Th17 differentiation. These 
data also indicate that EGFR signaling in macrophages is important for the Th17 response to H. pylori 
infection. The decreased Th17 response in Egfr∆mye mice likely contributes to the decreased histologic 
gastritis. 
 In contrast to the diminished Th17 response in Egfr∆mye mice, the Treg response was 
significantly increased. mRNA expression of forkhead box P3 (Foxp3), a transcription factor specific to 
Tregs, was not induced in infected Egfrfl/fl gastric tissues, but was significantly upregulated in Egfr∆mye 
tissues (Figure 16A). Similarly, the CD4+CD25+FOXP3+ population in the Egfr∆mye GLNs was 
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Figure 15. EGFR deficiency in macrophages leads to a diminished Th17 response to H. pylori. 
(A) mRNA levels of Il17a were assessed by RT-PCR in gastric tissues from Egfrfl/fl, Egfr∆mye, and 
LysMcre/cre mice 4 mo p.i. with H. pylori SS1. *P < 0.05, **P < 0.01. n = 3 uninfected and 6 infected mice 
per genotype. (B) IL-17 protein levels were assessed by ELISA in gastric tissues from Egfrfl/fl and 
Egfr∆mye mice 4 mo p.i. with H. pylori SS1. **P < 0.01, ***P < 0.001. n = 4 uninfected and 10 infected 
mice per genotype. (C) Assessment of CD4+IL-17+ T cells from perigastric lymph nodes (GLN) of Egfrfl/fl 
and Egfr∆mye mice 4 mo p.i. with H. pylori SS1 by flow cytometry. Isolated T cells were cultured in 96-
well plates containing 5 µg/mL anti-CD3 and 1 µg/mL anti-CD28. Cells were then stimulated with 20 
ng/mL PMA and 1 µg/mL ionomycin for 4 h. *P < 0.05, **P < 0.01. n = 3 uninfected and 7 infected mice 
per genotype. (D) mRNA levels of Th17 markers, Rorc (Rorγt) and Il17a, were assessed by RT-PCR 
from magnetically selected CD4+ T cells from the gastric lamina propria of Egfrfl/fl and Egfr∆mye mice 4 
mo p.i. with H. pylori SS1. **P < 0.01, ***P < 0.001. n = 3 uninfected and 6-7 infected mice per 
genotype. Statistical significance in all panels was calculated by one-way ANOVA with Newman-Keuls 
post-test. 	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Figure 16. EGFR deficiency in macrophages leads to an enhanced Treg response during H. 
pylori infection. (A) mRNA levels of Foxp3 were assessed by RT-PCR in gastric tissues from Egfrfl/fl 
and Egfr∆mye mice 4 mo p.i. with H. pylori SS1. **P < 0.01. n = 3 uninfected and 6 infected mice per 
genotype. (B) Assessment of CD4+CD25+FOXP3+ T cells from perigastric lymph nodes (GLN) of Egfrfl/fl 
and Egfr∆mye mice 4 mo p.i. with H. pylori SS1 by flow cytometry. Isolated T cells were not cultured or 
stimulated as in Figure 9C. *P < 0.05, **P < 0.01. n = 3 uninfected and 6-7 infected mice per genotype. 
(C) mRNA levels of Treg markers, Foxp3, Il10, and Tgfb, were assessed by RT-PCR from magnetically 
selected CD4+ T cells from the gastric lamina propria of Egfrfl/fl and Egfr∆mye mice 4 mo p.i. with H. pylori 
SS1. *P < 0.05, **P < 0.01. n = 3 uninfected and 6-7 infected mice per genotype. Statistical significance 
in all panels was calculated by one-way ANOVA with Newman-Keuls post-test. 	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  significantly larger than in Egfrfl/fl GLNs (Figure 16B). Significantly enhanced Foxp3, Il10, and Tgfb 
expression in CD4+ T cells from the lamina propria of Egfr∆mye mice further confirmed the enhancement 
of the Treg population during infection (Figure 16C). These data implicate a potential role for 
macrophage EGFR signaling in the Treg response during H. pylori infection.  
 We also assessed the role of macrophage EGFR in the initiation of the adaptive immune 
response to H. pylori. We examined the Th1, Th17, and Treg populations at 2 mo p.i. (Appendix A, 
Figure 22). In contrast to the 4 mo p.i. timepoint, there was no increase in Th1, Th17, or Treg 
populations with H. pylori infection in the Egfrfl/fl or Egfr∆mye GLNs when assessed by flow cytometry 
(Appendix A, Figure 22A, 22C, and 22E). There were, however, modest increases in the expression of 
the Th1- and Th17-related genes in the infected Egfrfl/fl mice that were decreased in the Egfr∆mye mice 
(Appendix A, Figure 22B and 22D). Together, these data suggest that the gastric T cell response is still 
developing at the 2 mo p.i. timepoint, and that the macrophage-T cell interaction is best assessed at 4 
mo p.i. in the H. pylori model.  
 
2.3 Discussion 
  EGFR regulates many epithelial cell functions, in addition to playing a pro-carcinogenic role in 
many cancers, including gastric cancer59,69,74-76. While EGFR signaling in macrophages has been 
demonstrated within the context of inflammation and cancer82,83, our work reveals the central role that 
EGFR has in regulating macrophage activation and function in response to bacterial pathogens (Figure 
17). Gastric carcinogenesis derives from deleterious, H. pylori-induced chronic inflammation that is 
substantially driven by macrophages9,20,41,48,103,123. We now show that EGFR signaling in macrophages 
has a causal role in gastric inflammation and is associated with H. pylori-induced gastric 
carcinogenesis. Specifically, human gastric macrophages have abundant levels of pEGFR, in the 
setting of both gastritis and intestinal metaplasia, and this continues in gastric carcinoma. As such, 
macrophage EGFR is a potential therapeutic target for this and other inflammation-mediated diseases 
and cancers. 
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Figure 17. Summary of findings related to EGFR signaling in macrophages during H. pylori 
infection. EGFR signaling is activated by either an unknown ligand-dependent stimulus at tyrosine (Y) 
1068 or by a ligand-independent mechanism at serine (S) 1046/47. TNF-α binds to TNF receptor 
(TNFR), leading to EGFR phosphorylation at S1046/47 via transforming growth factor beta-activated 
kinase 1 (TAK1). Once activated, EGFR signaling leads to NF-κB signaling by phosphorylation of IKBK 
(IKK), which phosphorylates NFKBKIA (IκBα) in order to release phosphorylated RELA (p65) for 
nuclear translocation. EGFR signaling also leads to phosphorylation of MAPK1/3 (ERK1/2). These 
signaling events lead to M1, M2, and Mreg gene expression. M1 activation, specifically, leads to the 
production of NOS2 and NO, causing reactive nitrogen species (RNS)-mediated DNA damage. 
Moreover, M1 activation leads to IL-23 production, along with other pro-inflammatory proteins, initiating 
a Th1/Th17 response. This leads to chronic gastritis, which when combined with RNS-mediated DNA 
damage, contributes to gastric carcinogenesis. 
	   Myeloid-specific deletion of EGFR in mice significantly attenuated gastritis, with a 
commensurate increase in H. pylori burden. This decrease in gastric damage was marked by 
significantly decreased pro-inflammatory cytokine and chemokine levels. Similarly, the diminished 
clinical severity of infectious colitis in Egfr∆mye mice, despite increased C. rodentium burden, further 
implicates the importance of EGFR signaling in macrophages in the deleterious inflammatory response 
to bacterial infections. This concept was also supported by the decreased pro-inflammatory cytokine 
expression in colon tissues from infected Egfr∆mye mice.  
 Either inhibition of signaling or genetic knockout of EGFR led to decreased M1 and Mreg 
activation during bacterial infection in vitro and in vivo. Canonical stimuli for M1, M2, and Mreg 
activation also resulted in decreased gene expression of subset specific markers. Macrophage 
activation is critical for defining function, and our studies have established that EGFR assumes a 
central role in regulating this key step in macrophage biology. Importantly, we have utilized the term 
“activation,” instead of “polarization”, because this study is focused on gene expression patterns related 
specifically to macrophage activation. It should be noted, however, that we have assessed expression 
of Arg2 and Odc, which encode for important enzymes involved in polyamine biosynthesis that we have 
previously shown to be upregulated in H. pylori-infected macrophages95,103. In BMmacs with either 
chemical inhibition or knockout of EGFR, there was no affect on H. pylori-induced expression of Arg2 or 
Odc (data not shown), suggesting that EGFR signaling does not have global effects on all macrophage 
genes induced by H. pylori.   
As M1 activation is responsible for pro-inflammatory, anti-microbial responses to bacterial 
pathogens, loss of M1 activation in Egfr∆mye mice is likely driving the decreased disease severity and 
increased bacterial load in the models utilized herein. Additionally, EGFR signaling in macrophages has 
marked effects on adaptive immunity, as it was required for Th17 responses, which have been 
implicated in clearance of H. pylori124 and C. rodentium125 infection.  
The link between EGFR and NF-κB provides a mechanism for the decreased cytokine 
production by macrophages. Inhibition or deletion of EGFR led to significantly decreased NF-κB 
pathway signaling, including the upstream components MyD88, pIKBK, and pNFKBIA, as well as RELA 
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  nuclear translocation and NF-κB activity. It should be noted that it has been reported that MyD88–/– 
mice exhibit attenuated gastritis and increased bacterial burden with H. pylori infection126, consistent 
with our data herein with myeloid-specific deletion of Egfr. Thus MyD88 may provide a link between 
EGFR signaling and NF-κB in macrophages.  
We have also implicated MAPK1/3 signaling as an additional target of EGFR signaling, which 
appears to be important in modulating macrophage activation in response to H. pylori. Since many 
potential pathways may be influenced by EGFR signaling, determining additional downstream targets of 
EGFR activation in macrophages is currently being investigated in our laboratory through proteomic 
approaches. These studies will enhance our understanding of mechanisms controlling macrophage 
responses.  
Furthermore, phosphorylation of EGFR was detectable at S1046/47, as well as the canonical 
Y1068, indicating that initiation of EGFR signaling in macrophages can be ligand-independent66,108. We 
have implicated a potential role for TNF-α in such a ligand-independent mechanism. Future studies to 
determine the mechanism by which EGFR signaling is initiated in macrophages in response to bacterial 
infections are warranted. These studies could provide useful targets for therapeutic intervention in 
preventing EGFR activation in macrophages during chronic inflammation.  
 In sum, our work outlines a new role for EGFR signaling in regulating the macrophage-mediated 
host responses to bacterial infections. We have implicated EGFR as a central element in macrophage 
activation, with broad effects on immunopathogenesis (Figure 17). In the particular case of H. pylori 
infection, specific inhibition of pathways that activate macrophage EGFR signaling could prove a useful 
chemopreventive strategy in high risk subjects, since antibiotic treatment of H. pylori once 
precancerous lesions of atrophic gastritis and intestinal metaplasia have occurred does not reduce 
gastric cancer risk39,127. Further, this work provides an impetus for further studies regarding the role of 
EGFR in macrophages, especially as it relates to the treatment and prevention of other inflammatory 
diseases and associated carcinogenesis. 
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  2.4 Materials and Methods 
 
Reagents 
All reagents used for cell culture are from Invitrogen (Carlsbad, CA, USA). Reagents for RNA extraction 
are from Qiagen (Valencia, CA, USA) Reagents for cDNA synthesis and quantitative real-time PCR 
were purchased from Bio-Rad (Hercules, CA, USA). Gefitinib (N-(3-Chloro-4-fluorophenyl)-7-methoxy-
6-(3-morpholinopropoxy)quinazolin-4-amine) was obtained from Selleck Chemicals (Houston, TX, 
USA). AG1478 (N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine) was obtained from Cayman 
Chemical (Ann Arbor, MI, USA). PD153035 (N-(3-bromophenyl)-6,7-dimethoxyquinazoline) was 
obtained from EMD Millipore (Billerica, MA, USA). The following compounds were obtained from EMD 
Millipore (Billerica, MA, USA): PD153035 (N-(3-bromophenyl)-6,7-dimethoxyquinazoline), and ERKi (3-
(2-Aminoethyl)-5-((4-Ethoxyphenyl)Methylene)-2,4-Thiazolidinedione, HCl). Cytocholasin D, an inhibitor 
of actin polymerization was obtained from EMD Millipore (Billerica, MA, USA). ON-TARGETplus siRNA 
against Egfr, and scrambled targets were purchased from Dharmacon (Lafayette, CO, USA).  
 
Antibodies 
See Appendix A, Table 3 for information regarding all antibodies utilized for this study. 
 
Bacteria, Cells, Culture Conditions and Infections 
H. pylori PMSS1, SS1, and 7.13 were grown and used as previously described47,96,103. C. rodentium 
was cultured as previously described106.  
 
The murine macrophage cell line, RAW 264.7, was maintained in complete Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/mL penicillin, 100 µg/mL streptomycin, 50 µg/mL gentamicin, 25 mM HEPES, and 10 mM sodium 
pyruvate. The human monocytic cell line, THP-1, was maintained in complete DMEM, supplemented 
with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 50 µg/mL 
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gentamicin. THP-1 cells were differentiated into adherent macrophages with 10 ng/mL phorbol-12-
myristate-13-acetate (PMA) for 24 hours. Cells were then washed and incubated in complete DMEM 
without PMA for 24 h prior to experimentation. RAW 264.7 cells and THP-1 cells were acquired from 
American Type Culture Collection (ATCC; Manassas, VA, USA). ATCC authenticates all cell lines 
before distribution. ATCC also tests for and confirms that all cell lines are free of Mycoplasma 
contamination. The murine, immortalized bone-marrow derived macrophage, NF-κB luciferase reporter 
cell line, NGL, were provided by Timothy Blackwell (Vanderbilt University Medical Center; Nashville, 
TN)118,119, and were maintained in complete DMEM, supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/mL penicillin, 100 µg/mL streptomycin, and 50 µg/mL gentamicin. None of the cell lines utilized in 
this study are found in the database of commonly misidentified cell lines maintained by International 
Cell Line Authentication Committee. 
 
BMmacs were isolated from all mouse genotypes utilized in this paper as previously described128, with 
the following exceptions. Red blood cells were lysed with ammonium-chloride-potassium lysing buffer 
for 4 min prior to plating bone marrow cells. Recombinant macrophage colony stimulating factor (M-
CSF) was used at a concentration of 20 ng/mL for seven days. Bone marrow-derived dendritic cells 
were isolated from all mouse genotypes as previously described129. Recombinant granulocyte-
monocyte colony stimulating factor was used at a concentration of 40 ng/mL for nine days. M-CSF and 
granulocyte-macrophage colony stimulating factor (GM-CSF) were purchased from PeproTech (Rocky 
Hill, NJ, USA). 
 
All cells were incubated in serum-free media for 14–16 h prior to infection for assays measuring 
pEGFR. All pharmacological inhibitors were added 1 h before infection. Cells were infected at a 
multiplicity of infection (MOI) of 100 for H. pylori experiments. Cells were infected at an MOI of 10 for all 
experiments with C. rodentium. Media without antibiotics were used for all experiments with live 
bacteria. 	  
	  Animal Studies 
Egfr∆mye and Egfrfl/fl x Villincre/+ were provided by Fang Yan (Vanderbilt University Medical Center; 
Nashville, TN). Egfrfl/fl mice were generated by backcrossing Egfrfl/fl; Villincre/+ mice to WT mice to 
remove the cre allele. LysMcre/cre mice were purchased from Jackson Laboratories (Bar Harbor, ME). 
Excision of the Egfr alleles was confirmed by PCR (See Appendix A, Table 2 for primer information). 
Male mice between the ages of six to twelve weeks were exclusively utilized for these studies, 
regardless of genotype and mice were not removed from the cages into which they were weaned. Male 
mice were selected for this study because female mice have been shown to be protected from gastric 
damage in experimental H. pylori infection130. Sample sizes were based on previous studies from our 
laboratory47,48,103 and mice were randomly selected for control and experimental groups, provided they 
met the sex and age requirements. Mice were infected orogastrically with 5 x 108 colony forming units 
(CFUs) with H. pylori SS1 or PMSS1. Inoculations occurred once for Gmac studies and three times, 
every other day, for all other H. pylori studies. Animals were sacrificed 48 h p.i. for Gmacs and 1 mo, 2 
mo, or 4 mo p.i. for all other H. pylori studies. Colonization was assessed by serial dilution and culture. 
Histology was assessed in a completely blinded manner by a gastrointestinal pathologist, M. Blanca 
Piazuelo, using the updated Sydney System48. 
 
For the colitis studies, the same sex and age requirements utilized for H. pylori experiments were 
applied to the mice. Moreover, samples sizes were based on previous studies in our laboratory106,113,131. 
Mice were infected orogastrically with 5 x 108 CFUs once for all studies with C. rodentium. Animals 
were weighed daily and sacrificed 14 days post-infection. Colonization was assessed by serial dilution 
and culture. Histology was assessed in a completely blinded manner by M. Blanca Piazuelo, as 
previously described113,131. 
 
Human Tissues 
Human gastric tissue samples were obtained as previously described74,107. Both a Vanderbilt University 
Medical Center TMA74 and samples from Colombia107 were utilized for this study. 
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  Real-Time PCR 
RNA was isolated from cells and tissues using RNeasy kits. cDNA was prepared from each sample 
using 1 mg of RNA and the iScript cDNA synthesis kit. PCR was performed as previously described48. 
Primers are listed in Appendix A, Table 2. 
 
Western Blot Analysis 
Cells were lysed in CellLytic MT Reagent (Sigma-Aldrich, St. Louis, MO, USA) or using the NE-PER 
Protein Extraction Kit (Pierce Biotechnology, Rockford, IL, USA). All lysis buffers were supplemented 
with the Protease Inhibitor Cocktail (Set III; Calbiochem, Darmstadt, Germany) and the Phosphatase 
Inhibitor Cocktail (Set I; Calbiochem, Darmstadt, Germany). Protein concentration was determined 
using the BCA protein assay (Pierce Biotechnology, Rockford, IL, USA). Primary and secondary 
antibodies are listed in Appendix A, Table 3. Densitometry was performed using ImageStudio (LI-COR, 
Version 4.0.21, Lincoln, NE, USA). 
 
Transfections 
RAW 264.7 cells in Opti-MEM I Reduced Serum Media were transfected using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA) with 100 nM ON-TARGETplus siRNAs directed against Egfr, and 
scrambled targets. After 6 h, the cells were washed and then maintained for 36 h in serum-containing, 
antibiotic-free DMEM. Cells were then stimulated as described in the “Bacteria, Cells, Culture 
Conditions, and Infections” section of the Methods. 
 
Measurement of Nitric Oxide 
The concentration of the oxidized metabolite of NO, nitrite (NO2—) was assessed by the Griess reaction 
as previously described47. 
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  Measurement of NO-mediated Bacterial Killing 
RAW 264.7 cells were plated in complete DMEM in 24 well plates and allowed to adhere. Cells were 
then washed and placed in complete DMEM, without antibiotics. Transwell filter supports were placed 
over the cells. H. pylori PMSS1 (MOI = 100) were then placed in the Transwell filter supports above the 
cells for 24 h. After 24 h, bacteria in the Transwells were quantified by serial dilution and culture. NO 
was measured by the Griess Reaction, described in the Methods, from the supernatants below the 
Transwell filter supports. 
 
Measurement of Phagocytosis 
Phagocytosis was measured by gentamicin protection assay as previously published48. 
 
NF-κB Reporter Assay 
The NF-κB reporter assay was performed as previously published118,119. In brief, NGL cells were pre-
treated with 10 µM gefitinib for 1 h and then infected with H. pylori PMSS1 and SS1 at MOI = 100 for 2, 
3 and 4 h. Luciferase activity was assessed using the Luciferase Assay System kit (Promega, Madison, 
WI, USA). 
 
Luminex Assay 
A 32-plex assay (EMD Millipore, Cat. MCYTMAG-70K-PX32, Billerica, MA, USA) was performed on 
gastric tissues from uninfected and infected Egfrfl/fl, Egfr∆mye and LysMcre/cre mice. Protein isolation, 
quantification and Luminex assay were performed as previously described132.  
 
Immunofluorescence Staining for CD68, pEGFR, tEGFR, and cleaved caspase 3 
Immunofluorescence staining was performed on BMmacs after H. pylori infection, on murine gastric 
tissues from mice 4 months after infection with H. pylori SS1, and on human gastric tissues from 
Colombia and the Vanderbilt University TMA, as previously published48,74. Antigen retrieval was 
performed as previously described74. (See Appendix A, Table 3 for antibody information). Slides were 
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  imaged using a SPOT RT slider camera system (Diagnostic Instruments, Inc., Sterling Heights, MI, 
USA) on a Nikon E800 microscope (Nikon, Inc. Melville, NY, USA). Images were all modestly adjusted 
in ImageJ with the brightness and contrast tool. 
 
Quantification of Human TMA Immunofluorescence  
The TMA was analyzed using CellProfiler (http://www.cellprofiler.org) software. Analysis was performed 
on images from the Ariol SL-50 platform (Leica Biosystems, Buffalo Grove, IL, USA). A CellProfiler 
pipeline was created that identified nuclei, CD68+ cells and pEGFR+ cells based on size and staining 
intensity. CD68+pEGFR+ cells were determined by the overlap of the CD68 and pEGFR staining, 
measured in pixels. All cells were required to have a nucleus to be counted in the analysis, thus 
eliminating red blood cells and non-specific staining. A serial section of the TMA was concurrently 
stained with hematoxylin and eosin (H&E) and histologic diagnosis was confirmed in order to ensure 
that only high quality cores were included in the analysis described in this section.  Samples were 
excluded from this analysis if histologic diagnosis could not be made due to sample degradation. 
 
Immunohistochemistry 
Immunohistochemistry was performed on gastric biopsies from the Vanderbilt University TMA. Paraffin-
embedded tissues were deparaffinized, antigen retrieval was performed, and tissues were stained for 
pEGFR as previously described74. See Appendix A, Table 3 for antibody information. 
 
Apoptosis 
Apoptosis was assayed using Annexin-V/7-AAD as previously published103. 
 
Purification of Gastric Macrophages 
Gastric macrophages were purified as previously described103. 
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  T Cell Studies 
Single-cell suspensions from GLNs of uninfected and H. pylori SS1 infected Egfrfl/fl and Egfr∆mye mice 
were cultured in Roswell Park Memorial Institute medium (RPMI) with 10% FBS, 10 mM HEPES, 100 
U/mL penicillin, 100 µg/mL streptomycin, and 10 µg/mL gentamicin in 96-well plates coated with 5 
µg/mL anti-CD3 and 1 µg/mL anti-CD28. Cells were stimulated with 20 ng/mL PMA and 1 µg/mL 
ionomycin for 4 h. Cells were then stained and assayed by flow cytometry, as described below. Cells 
from GLN utilized for assessing Treg populations were not cultured, and were stained directly upon 
isolation. 
 
CD4+ cells from the gastric lamina propria were purified utilizing the protocol for isolation and 
purification of Gmacs. Lamina propria cells were incubated in the presence of a 1:100 dilution of anti-
CD4, biotin tagged antibody (BD Biosciences, San Diego, CA) for 1 h, followed by incubation with 100 
mL streptavidin-conjugated iMag beads (BD Biosciences, San Diego, CA) for 1 h. CD4+ cells were then 
magnetically selected and RNA isolated utilizing the 5 PRIME PerfectPure 96 CS Cell RNA kit (5 
PRIME, Gaithersburg, MD) and cDNA synthesized as described above. Th1, Th17, and Treg genes 
were then assessed by RT-PCR. See Appendix A, Table 2 for primer information. 
 
Flow Cytometry 
Flow cytometry was performed a previously described103. Lamina propria cells were isolated from the 
stomach at 48 h p.i. with H. pylori SS1, as described103. Upon isolation, the cells were fixed and 
permeabilized with CytoFix/CytoPerm (BD Biosciences, Cat. No. 554714) for 20 min on ice. Following 
fixation and permeabilization, cells were washed 3 times with BD CytoFix/CytoPerm and then stained 
with a polyclonal rabbit anti-total EGFR antibody at 1:50, or a general rabbit IgG isotype control at 1:50, 
for 1 h on ice in BD CytoFix/CytoPerm. Cells were washed 3 times with BD CytoFix/CytoPerm and then 
stained for F4/80-PE, CD11b-PE-Cy7, and anti-rabbit-Alexa488 for 20 min on ice in flow cytometry 
staining buffer solution (eBiosciences, Cat. 04-4222-26). Upon completion of staining, cells were 
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  washed 3 times in flow cytometry staining buffer solution and subsequently analyzed utilizing flow 
cytometry. See Appendix A, Table 3 for all antibody information.  
 
Statistical Analysis 
All the data shown represent the mean ± standard error of the mean (S.E.M.) At least three biological 
replicates were performed for all studies utilizing cell culture. Where data was normally distributed, two-
tailed Student’s t test was used to determine significance in experiments with only two groups, and one-
way ANOVA with the Newman-Keuls test was used to determine significant differences between 
multiple test groups. In cases where data were not normally distributed, a one-way ANOVA with 
Kruskal-Wallis test, followed by a Mann-Whitney U test, was performed. All statistics were performed in 
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). A P value of < 0.05 was considered 
to be significant.  
 
Study Approval 
Animals were used under protocol M/10/155, approved by the Institutional Animal Care and Use 
Committee (IACUC) at Vanderbilt University. WT C57BL/6 mice were also bred and maintained under 
IACUC protocol V/13/230. Human tissues were obtained from a Vanderbilt University Medical Center 
repository and non-human exemptions were granted by the Vanderbilt University Institutional Review 
Board, as all information was completely de-identified. 
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CHAPTER 3 
EGFR SIGNALING IN MACROPHAGES DURING COLON CARCINOGENESIS 
 
3.1 Introduction 
Colorectal cancer is the third most common cancer globally26 and accounts for approximately 
10% of new cancer diagnoses annually26. The risk for colon carcinogenesis is linked to chronic 
inflammatory states, such as inflammatory bowel disease (IBD)8,133,134. Colitis-associated 
carcinogenesis (CAC) occurs in 20% of patients diagnosed with IBD, and mortality rates are over 50% 
in these patients8,133,134. While mechanisms by which chronic inflammation promotes colonic 
carcinogenesis are being investigated8,133,134, unanswered questions remain. 
 The tumor microenvironment contains various immune cell types, including macrophages8,133,134. 
Macrophages represent a heterogeneous subset of innate immune cells with roles in tissue 
homeostasis, pro-inflammatory and anti-microbial responses, and wound repair2,3,98, and are of 
particular interest given their highly plastic phenotypes that can both promote and inhibit 
tumorigenesis135,136. Macrophages can alter their function based on the activation program utilized – 
either M1 or M2 patterns2,3,11,98. M1 macrophages are pro-inflammatory, anti-microbial, and thought to 
be anti-tumorigenic, although this remains the subject of debate2,3,98. M2 macrophages are associated 
with wound healing and have pro-tumorigenic properties11,98,135. Macrophage activation is dependent 
upon the colon tumor microenvironment5,136,137 and pathways that regulate this are incompletely 
understood8,135. Studies have implicated NF-κB signaling138-140 and other pathways141,142. 
 We demonstrated that EGFR signaling regulates macrophage activation across various stimuli 
in Chapter 2. EGFR phosphorylation occurs in macrophages and has major effects on expression of 
both M1 and M2 macrophage activation markers143. Importantly, we determined that EGFR signaling 
occurs in human gastric macrophages from gastritis to gastric adenocarcinoma (Chapter 2), leading us 
to speculate that EGFR signaling in macrophages may also have a role in CAC. EGFR signaling has 
been    most    commonly    studied    within    the    context    of    epithelial    cell    function   and   has   been   linked   to 
	  colorectal cancer initiation and progression70-72. The impact of EGFR protein levels and signaling 
capacity is an area of ongoing investigation70-72.  
Here, we demonstrate that EGFR signaling in macrophages has a profound effect on 
development of CAC. Early, inflammation-mediated stages of colon carcinogenesis in humans were 
marked by EGFR phosphorylation in macrophages. Myeloid-specific Egfr knockout mice exhibited 
decreased tumor multiplicity and tumor burden, while epithelial-specific Egfr knockout mice had no 
differences in phenotype. Loss of Egfr in myeloid cells resulted in decreased M2 and M1 macrophage 
activation, and decreased angiogenesis. Thus, EGFR signaling in macrophages may represent a 
potential target for therapeutic intervention in CAC. 
 
3.2 Results 
EGFR signaling occurs in human colonic macrophages during pre-cancerous stages of CAC 
 The majority of studies related to EGFR signaling during CRC have focused on epithelial cells70-
73,77. Instead, we sought to determine if human colonic macrophages had detectable levels of pEGFR, a 
marker of active EGFR signaling, during IBD and associated CAC. We utilized an IBD-associated 
cancer TMA from Vanderbilt University Medical Center, which contained cases of inactive and active 
ulcerative colitis, dysplasia, and colitis-associated carcinoma144. pEGFR levels in CD68+ macrophages 
were detected via immunofluorescence staining (Figure 18A) and quantified with CellProfiler image 
analysis software (http://www.cellprofiler.com). We observed a low percentage of CD68+pEGFR+ 
macrophages in inactive colitis that was significantly increased in active colitis and dysplasia (Figure 
18B and 18C). The percentage of CD68+pEGFR+ macrophages was lower in CAC than in active colitis 
and dysplasia (Figure 18B and 18C). The histopathologic diagnosis of inactive colitis indicates an 
absence of neutrophils, but is typically characterized by expansion of the lamina propria immune cell 
compartment and relative dropout of the epithelium. As such, no differences in the overall percentage 
of macrophages were detected between disease groups (Appendix B, Figure 1). These data indicate 
that pEGFR is present in macrophages during pre-cancerous events associated with colonic 
inflammation, implying that EGFR signaling in macrophages has an important role in macrophage 
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Figure 18. Macrophages have high levels of pEGFR Y1068 during inflammation driven, pre-
cancerous stages of inflammatory bowel disease (IBD)-associated-colorectal cancer in human 
colonic tissues. (a) Representative hematoxylin and eosin (H&E)-stained images and representative 
immunofluorescence images of colonic tissues from the Vanderbilt University Medical Center IBD-
associated colorectal cancer TMA. Red = CD68. Green = pEGFR Y1068. Yellow = Merge. Blue = 
DAPI. Scale bars = 50 µm. (b) Quantification of the percentage of CD68+pEGFR+ cells among the total 
number of cells in each individual core in the TMA, as determined by CellProfiler. (c) Quantification of 
the percentage of CD68+pEGFR+ cells among the total number of CD68+ cells in each individual core in 
the TMA. For (a-c), n = 10 inactive colitis (normal or quiescent histology) samples, 14 active colitis 
(mild, moderate or severe histology) samples, 18 dysplasia samples, and 14 colorectal cancer samples. 
For (B-C), *P < 0.05, **P < 0.01 by one-way ANOVA with Kruskal-Wallis test, followed by Mann-
Whitney U test. 	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  function during initiation of carcinogenesis. It should be noted that, as expected, pEGFR staining was 
also abundant in colonic epithelial cells (CECs; Figure 18A). 
 
EGFR signaling in macrophages contributes to AOM-DSS-induced colon tumorigenesis  
 We next sought to directly determine the role of EGFR signaling in macrophages during colon 
carcinogenesis. We utilized mice containing myeloid-specific, Egfr deletion (Egfr∆mye) driven by LysM-
Cre, which we have extensively characterized in models of gastric and colonic inflammation143, and the 
appropriate control mice (Egfrfl/fl). Egfrfl/fl and Egfr∆mye mice were subjected to the AOM-DSS model of 
CAC145,146. The AOM-DSS protocol utilized is outlined in Appendix B, Figure 2. No tumors were 
observed in the AOM-only or DSS-only groups, nor were differences in histologic colitis detectable 
between genotypes in the DSS-only group (data not shown). The lack of difference in the histologic 
colitis between genotypes in the DSS-only group is likely due to the prolonged recovery period, 
resulting in low colitis scores. Only data from the control and AOM-DSS groups are presented herein.	  
 AOM-DSS-treated Egfr∆mye mice had significantly decreased tumor multiplicity and tumor 
burden, measured as the sum of the area of each tumor, versus AOM-DSS-treated Egfrfl/fl mice (Figure 
19A and 19B). Further, Egfr∆mye mice were significantly protected from development of high-grade 
dysplasia, developing a maximum of low-grade dysplasia (Figure 19C). Representative H&E-stained 
images demonstrate the decrease in tumor size and protection from high-grade dysplasia in Egfr∆mye 
mice (Figure 19D). The myeloid-specific, Egfr knockout was maintained throughout the entire AOM-
DSS protocol, as immunofluorescence images reveal the presence of many CD68+tEGFR+ colonic 
macrophages in tissues from AOM-DSS-treated Egfrfl/fl mice, while only CD68+tEGFR– colonic 
macrophages are detectable in Egfr∆mye tissues (Figure 19E). Taken together, these data indicate that 
EGFR in myeloid cells is a potent promoter of tumorigenesis in mice.  
 Additionally, Egfr∆mye mice demonstrated significantly decreased histologic colitis with AOM-DSS 
versus Egfrfl/fl mice (Figure 19F). In conjunction with decreased histologic colitis, Egfr∆mye mice exhibited 
significant protection from weight loss associated with each cycle of DSS, as compared to Egfrfl/fl mice 
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Figure 19. Egfr∆mye mice are significantly protected from tumorigenesis and dysplasia in the 
AOM-DSS model of colon tumorigenesis. (a) Tumor multiplicity was assessed by gross visual 
inspection, utilizing a dissecting microscope. (b) Tumor burden was determined by the addition of the 
calculated area of each identified tumor, as assessed with an electronic caliper for both length and 
width. (c) Percentage of cases with either no adenoma, low-grade dysplasia (LGD), and high-grade 
dysplasia (HGD) determined by a gastrointestinal pathologist (M. Kay Washington) in a blinded 
manner. By Chi Square test, *P < 0.05.  §P < 0.05 versus Egfrfl/fl; ##P < 0.01 versus Egfrfl/fl. n = 9-12 
AOM-DSS-treated animals per genotype. (d) Representative H&E-stained images from AOM-DSS-
treated mice. Scale bars = 100 µm. (e) Representative immunofluorescence images of tEGFR from 
AOM-DSS-treated mice. Red = CD68. Green = tEGFR. Yellow = Merge. Blue = DAPI. Scale bars = 50 
µm. Solid arrows indicate CD68+tEGFR+ macrophages. Open arrows indicate CD68+tEGFR– 
macrophages. White box indicates zoomed area. n = ≥ 3 mice per genotype assessed. (f) Histologic 
colitis was determined by M.K.W. (g) Percentage of initial body weight was assessed at the indicated 
time points. *P < 0.05, **P < 0.01, ***P < 0.001 versus Egfrfl/fl AOM-DSS by two-way ANOVA with 
Bonferroni post-test (ANOVA significance = P < 0.001). In (a), (b), and (f), *P < 0.05, **P < 0.01 by one-
way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. In (a), (b), (f), and (g), n = 7-9 
control and 9-12 AOM-DSS-treated mice per genotype.  
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  (Figure 19G). These data indicate that Egfr∆mye mice are protected from the pro-inflammatory effects of 
the AOM-DSS model, which contributes to decreased CAC.  
To assess the role of epithelial-specific EGFR in colon tumorigenesis, Foxa3cre/+ mice were 
crossed with Egfrfl/fl mice. Forkhead box A3 (Foxa3) is expressed in all gastrointestinal epithelial cells 
from mouth to anus147,148. Isolated, naïve CECs from Egfrfl/fl mice crossed with Foxa3cre/+ mice 
demonstrated absence of tEGFR (Appendix B, Figure 3A). Despite a report indicating that Foxa3 is 
expressed in hematopoietic progenitor cells149, we found no detectable deletion of EGFR in naïve 
splenocytes (Appendix B, Figure 3B), or BMmacs (Appendix B, Figure 3C). Thus, we termed these 
mice Egfr∆GIepi, indicative of the epithelial-specific Egfr deletion in the gastrointestinal tract. It should be 
noted that direct comparisons of Egfr∆mye mice and Egfr∆GIepi mice are not possible because Egfr∆GIepi 
mice are on a mixed background, while Egfr∆mye mice are on a congenic C57BL/6 background.  
When subjected to the AOM-DSS protocol, Egfrfl/fl (littermate controls of the Egfr∆GIepi mice, and 
not the same as Egfrfl/fl mice utilized in studies with Egfr∆mye mice) and Egfr∆GIepi mice exhibited no 
differences in tumor multiplicity and tumor burden (Appendix B, Figure 4A and 4B). Moreover, Egfrfl/fl 
and Egfr∆GIepi mice had similar susceptibility to low- and high-grade dysplasia (Appendix B, Figure 4C). 
Representative H&E-stained images reveal tumors of similar size and severity of dysplasia (Appendix 
B, Figure 4D).  
Lack of differences between Egfrfl/fl and Egfr∆GIepi mice could be due to inefficient CRE-mediated 
excision of Egfr. However, loss of EGFR signaling was maintained in Egfr∆GIepi epithelial cells during 
AOM-DSS treatment (Appendix B, Figure 4E). pEGFR immunoperoxidase staining is robust in epithelial 
cells and immune cells in Egfrfl/fl mice, but is restricted to immune cells in Egfr∆GIepi mice (Appendix B, 
Figure 4E). In addition, no differences were observed in histologic colitis between Egfrfl/fl and Egfr∆GIepi 
mice (Appendix B, Figure 4F). Egfrfl/fl and Egfr∆GIepi mice also displayed similar weight loss during each 
cycle of DSS (Appendix B, Figure 4G). Taken together, EGFR signaling in immune cells, but not in 
epithelial cells, is critical for the promotion of tumorigenesis in mice. 
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  EGFR signaling in macrophages enhances the innate immune response in colon tumors 
 The AOM-DSS model utilizes inflammation to drive tumorigenesis145,146,150. Based on decreased 
histologic colitis, combined with decreased tumor multiplicity and burden in Egfr∆mye mice, we sought to 
determine the nature of the innate immune response within the tumor microenvironment during AOM-
DSS-induced CAC. We assessed 32 cytokines/chemokines via Luminex Multiplex Array. Analytes that 
were not different between genotypes or undetectable are in Appendix B, Table 1. 
 The C-C ligand chemokines, CCL3 (MIP-1α) and CCL4 (MIP-1β) protein levels were 
significantly decreased in Egfr∆mye tumors versus Egfrfl/fl tumors (Figure 20A). CCL3 and CCL4 are 
chemoattractants for innate immune cells, and are produced by macrophages151.  Additionally, levels of 
the C-X-C ligand chemokines, CXCL9 (MIG) and CXCL10 (IP-10), were diminished in Egfr∆mye tumors 
(Figure 20A). CXCL9 and CXCL10 are also primarily produced by macrophages152, but induce T cells 
infiltration153. CCL3, CCL4, CXCL9, and CXCL10 were induced to a similar degree in Egfrfl/fl and 
Egfr∆GIepi tumors, and no differences were detected between genotypes (Appendix B, Figure 5A). Taken 
together, the decreases in CCL3, CCL4, CXCL9, and CXCL10 are indicative of decreased macrophage 
responses that result in decreased innate and adaptive immune cell infiltration in tumor areas. These 
significant decreases in macrophage-driven immune responses indicate the essential role of myeloid 
EGFR in driving CAC. 
 In addition, Egfr∆mye tumors demonstrated significant differences in cytokine levels (Figure 20B 
and 20C). Leukemia inhibitory factor (LIF), a cytokine with pleiotropic effects on immune function, was 
decreased in Egfr∆mye tumors (Figure 20B). LIF protein levels were induced to a similar degree in Egfrfl/fl 
and Egfr∆GIepi tumors (Appendix B, Figure 5B). LIF overexpression is associated with poor prognosis in 
colorectal cancer154,155, and decreased LIF levels in Egfr∆mye tumors are consistent with the decreased 
tumor multiplicity and burden. Moreover, colony stimulating factor 1 (CSF1; M-CSF) and IL-1α were 
significantly decreased in Egfr∆mye tumors (Figure 20C), but not altered between Egfrfl/fl and Egfr∆GIepi 
tumors (Appendix B, Figure 5C). CSF1 and IL-1α are produced by activated macrophages140,156-158, and 
CSF1 represents a key factor in macrophage activation and downstream function. Taken together, the 
decreases in these three cytokines indicate an overall downregulation of immune/inflammatory 
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Figure 20. Egfr∆mye mice have significantly decreased cytokine and chemokine production 
within colon tumors. In a-c, protein levels were assessed by Luminex Multiplex Array from 
colonic tissues a 77 days post-AOM injection. (a) Levels of the C-C motif and C-X-C motif 
chemokines CCL3 (MIP-1α), CCL4 (MIP-1β), CXCL9 (MIG), and CXCL10 (IP-10). (b) Levels of the 
pleiotropic cytokine, LIF. (c) Levels of cytokines produced by activated macrophages, CSF1 (M-
CSF) and IL-1α. In all panels, *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA with Kruskal-
Wallis test, followed by Mann-Whitney U test. In all panels, n = 5 control tissues and 6-9 tumors 
with paired non-tumor area per genotype. 
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  responses within tumors lacking EGFR in myeloid cells, and imply that macrophage EGFR is a central 
driver of tumorigenesis in an inflammation-dependent model. 
 To further investigate the effects of reduced chemokine production, we assessed populations of 
immune cells by immunohistochemistry with the following markers: macrophages (CD68), neutrophils 
(myeloperoxidase, MPO), T cells (CD3), and B cells (CD45R). Abundance of these cells was scored in 
non-tumor and tumor tissue, and combined for an overall score. Consistent with decreased CCL3 and 
CCL4 levels (Figure 20A), there were significantly diminished macrophages and neutrophils in AOM-
DSS-treated Egfr∆mye mice versus Egfrfl/fl mice (Figure 21A and 21B). T cell abundance was also 
significantly decreased  in  AOM-DSS-treated  Egfr∆mye  mice  (Figure 21C),  consistent  with diminished 
CXCL9 and CXCL10 in these mice (Figure 20A). B cells were not different between genotypes (Figure 
21D). Taken together, these data show diminished immune cell infiltration in the Egfr∆mye mice, which is 
dependent upon EGFR signaling in myeloid cells. 
 
EGFR signaling in macrophages enhances M2 activation in colon tumors 
Because macrophages were likely the major source of several of the chemokines and cytokines 
which were significantly reduced in Egfr∆mye tumors, we hypothesized that loss of EGFR led to altered 
macrophage activation in the tumor microenvironment. M2 macrophages are tumor-associated 
macrophages and have pro-tumorigenic properties2,3,11,98. Thus, the decrease in tumor multiplicity and 
burden could be due to a diminished M2 macrophage response in Egfr∆mye tumors. 
Indeed, protein levels of IL-4, IL-10, and IL-13, drivers of M2 activation2,3,11,98, were significantly 
upregulated in Egfrfl/fl tumors and decreased in Egfr∆mye tumors (Figure 22A). Moreover, mRNA levels of 
the M2 markers, Arg1 and Il10, were also increased in Egfrfl/fl tumors and decreased in Egfr∆mye tumors 
(Figure 22B). Significant decreases in both the levels of cytokines that induce M2 activation and the 
expression of M2 macrophage markers indicate diminished M2 macrophage activation in Egfr∆mye mice, 
consistent with reduced colon tumorigenesis. 
Egfrfl/fl and Egfr∆GIepi tumors did not demonstrate differences in IL-4 or IL-10 levels (Appendix B, 
Figure 6A), nor were differences detectable in Arg1 and Il10 mRNA levels (Appendix B, Figure 6B). IL-
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Figure 21. Egfr∆mye mice have significantly decreased macrophage, neutrophil and T cell 
infiltration during AOM-DSS treatment. (a) Quantification of CD68+ macrophage abundance with 
representative immunoperoxidase images of CD68 staining in AOM-DSS-treated mice. (b) 
Quantification of myeloperoxidase+ (MPO) neutrophil abundance with representative 
immunoperoxidase images of MPO staining in AOM-DSS-treated mice. (c) Quantification of CD3+ T cell 
abundance with representative immunoperoxidase images of CD3 staining in AOM-DSS-treated mice. 
(d) Quantification of CD45R+ B cell abundance with representative immunoperoxidase images of 
CD45R staining in AOM-DSS-treated mice. Scoring of immune cell abundance was performed by 
M.B.P. as described. In all panels, scale bars = 50 µm. In all panels, n = 3 control and 5 AOM-DSS-
treated mice per genotype. In all panels, *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA with 
Newman-Keuls post-test after the data were square-root transformed. 
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Figure 22. Egfr∆mye mice demonstrate decreased M2 macrophage activation during colon 
tumorigenesis. (a) Protein levels of the M2 stimuli, IL-4, IL-10, and IL-13, were assessed by Luminex 
Multiplex Array from colonic tissues 77 days post-AOM injection. n = 5 control tissues and 6-9 tumors 
with paired non-tumor area per genotype. (b) mRNA levels of M2 markers, Arg1 and Il10, were 
assessed by qRT-PCR from colonic tissues 77 days post-AOM injection. n = 6-8 control tissues and 8-
10 tumors with paired non-tumor area per genotype. In (a) and (b), *P < 0.05, **P < 0.01, ***P < 0.001 
by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. (c) mRNA levels of M2 
markers, Arg1, Chil3, and Il10, were assessed by qRT-PCR in BMmacs 24 h post-treatment with 
classical M2 stimuli, IL-4 (10 ng/mL) and IL-10 (10 ng/mL). n = 5 biological replicates per genotype. In 
(c), *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA with Newman-Keuls post-test. (d) 
Representative western blot of pSTAT6 levels in BMmacs stimulated with the M2 stimulus, IL-4 (10 
ng/mL), for the indicated times. n = 3 biological replicates. (e) Representative images of pSTAT6 
immunoperoxidase staining in AOM-DSS-treated tissues. Scale bar = 50 µm. n = 3 mice per genotype. 
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  13 was detected at very low levels in Egfrfl/fl and Egfr∆GIepi tumors, but no significant differences were 
detected (Appendix B, Table 2). These data correlate with the finding that Egfrfl/fl and Egfr∆GIepi mice do 
not have significant differences in development of CAC.  
To confirm that Egfr deletion in myeloid cells resulted in decreased M2 activation, we isolated 
BMmacs from Egfrfl/fl and Egfr∆mye mice and stimulated them ex vivo with IL-4 and IL-10. Markers of M2 
macrophage activation were assessed by RT-PCR. IL-4/IL-10 stimulation led to a significant induction 
of Arg1, Chil3, and Il10 in both Egfrfl/fl and Egfr∆mye BMmacs (Figure 22C). Importantly, Arg1, Chil3, and 
Il10 mRNA levels were significantly decreased in Egfr∆mye BMmacs (Figure 22C), consistent with the 
findings in Egfr∆mye tumors. Together, these data further suggest that EGFR signaling regulates M2 
macrophage activation. 
 To address the mechanism by which macrophage EGFR signaling alters M2 activation, we 
isolated BMmacs from Egfrfl/fl and Egfr∆mye mice, stimulated them ex vivo with IL-4, and assessed 
phospho-STAT6 (pSTAT6), a known mediator of M2 activation17. Egfr∆mye BMmacs exhibited decreased 
pSTAT6 levels when compared to Egfrfl/fl BMmacs (Figure 22D). Similarly, AOM-DSS-treated Egfr∆mye 
tissues demonstrated reduced pSTAT6 levels in immune cells (Figure 22E). These data reveal a 
potential link between EGFR and STAT6 in regulating M2 activation in macrophages. 
 
Macrophage-specific EGFR signaling also augments M1 activation in colon tumors 
 Alterations in M2 macrophage activation in Egfr∆mye mice were not unexpected, given the close 
association between M2 macrophages and the tumor microenvironment135,136. However, we also 
observed significant alterations in both the levels of cytokines that induce M1 activation and in M1 
markers in Egfr∆mye tumors. 
 IFN-γ and TNF-α potently induce M1 macrophage activation7. Protein levels of both IFN-γ and 
TNF-α were significantly upregulated in AOM-DSS-induced tumors in Egfrfl/fl mice and significantly 
reduced in Egfr∆mye tumors (Figure 23A), indicative of decreased capacity for M1 macrophage 
activation. mRNA levels of M1 markers Nos2 and Il1b were upregulated in Egfrfl/fl tumors, and 
significantly decreased in Egfr∆mye tumors (Figure 23B). This decrease in M1 macrophage activation 
67
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Figure 23. Egfr∆mye mice demonstrate decreased M1 macrophage activation during colon 
tumorigenesis. (a) Protein levels of M1 stimuli, IFN-γ and TNF-α, were assessed by Luminex Multiplex 
Array from colonic tissues 77 days post-AOM injection. n = 5 control tissues and 6-9 tumors with paired 
non-tumor area per genotype. (b) mRNA levels of M1 markers, Nos2 and Il1b, were assessed by qRT-
PCR from colonic tissues 77 days post-AOM injection. n = 6-8 control tissues and 8-10 tumors with 
paired non-tumor area per genotype. (c) Protein levels of the M1 marker, IL-1β, were assessed by 
Luminex Multiplex Array from colonic tissues 77 days post-AOM injection. n = 5 control tissues and 6-9 
tumors with paired non-tumor area per genotype. In (a-c), *P < 0.05, **P < 0.01, ***P < 0.001 by one-
way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. (d) mRNA levels of M1 
markers, Nos2, Il1b, and Tnfa, were assessed by qRT-PCR in bone marrow derived macrophages 
(BMmacs) 24 h post-treatment with classical M1 stimuli, IFN-γ (200 U/mL) and TNF-α (10 ng/mL). n = 5 
biological replicates per genotype. In (d), *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA with 
Newman-Keuls post-test. (e) Representative western blot of pRELA (pp65) levels in BMmacs 
stimulated with the M1 stimuli, IFN-γ (200 U/mL) and lipopolysaccharide (10 ng/mL), for the indicated 
times. n = 3 biological replicates. (e) Representative confocal immunofluorescence images of 
cytoplasmic and nuclear RELA (p65) in AOM-DSS-treated tissues. Green = cytoplasmic RELA. 
White/Aqua = nuclear RELA. Blue = DAPI. Scale bar = 40 µm, Scale bar in inset = 10 µm. n = 3 mice 
per genotype. 	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  was confirmed at the protein level, as IL-1β protein was also significantly decreased in Egfr∆mye tumors 
(Figure 23C). Protein levels of IFN-γ and TNF-α were detectable in Egfrfl/fl and Egfr∆GIepi tumors, but 
were not different between genotypes (Appendix B, Figure 7A). mRNA levels of Nos2 and Il1b 
(Appendix B, Figure 7B), as well as IL-1β protein levels, were upregulated in Egfrfl/fl and Egfr∆GIepi 
tumors, but again were not different between genotypes.  
 To assess the role of EGFR signaling in M1 activation, we isolated BMmacs from Egfrfl/fl and 
Egfr∆mye mice and stimulated ex vivo with IFN-γ and TNF-α for 24 h. M1 stimulation resulted in robust 
expression of M1 markers Nos2, Il1b, and Tnfa (Figure 23D). Importantly, mRNA expression of Nos2, 
Il1b, and Tnfa was significantly reduced in Egfr∆mye BMmacs versus Egfrfl/fl BMmacs (Figure 19D), 
indicating that EGFR signaling is equally critical for M1 and M2 activation. Intriguingly, M1 activation 
may have critical role in colon tumorigenesis in this model that is regulated by EGFR signaling. 
 In Chapter 2, we have demonstrated that EGFR signaling is upstream of NF-κB in macrophages 
during Helicobacter pylori infection143. Moreover, we have reported that there is enhanced nuclear 
translocation of RELA (also known as p65) in two different models of colitis159. Thus, we hypothesized 
that EGFR and NF-κB signaling may regulate M1 activation. We isolated BMmacs from Egfrfl/fl and 
Egfr∆mye mice, stimulated with IFN-γ and lipopolysaccharide, and assessed phospho-RELA (pRELA) 
levels. Egfr∆mye BMmacs had diminished pRELA levels versus Egfrfl/fl BMmacs (Figure 23E). Moreover, 
AOM-DSS-treated Egfr∆mye tissues had markedly decreased RELA nuclear translocation in lamina 
propria cells (Figure 23F). Thus, EGFR signaling activates the NF-κB pathway to regulate M1 
activation. 
 
EGFR signaling in macrophages enhances angiogenesis in colon tumors 
 Angiogenesis is a hallmark of carcinogenesis160, and is an essential means by which colon 
tumor growth is supported161,162. Several cytokines, including vascular endothelial growth factor (VEGF) 
A and CXCL1 (KC, GROα), the murine equivalent of CXCL8 (IL-8)163, contribute to angiogenesis164-167. 
70
	  M1 macrophages are an important source of CXCL1168 and both M1 and M2 macrophages are 
important sources of VEGFA169. 
 Based on i) decreased tumor multiplicity/burden, and ii) decreased M2 and M1 macrophage 
activation in Egfr∆mye mice, we hypothesized that angiogenesis may be impaired, contributing to 
diminished tumorigenesis. Egfr∆mye tumors had decreased mRNA levels of Cxcl1 and Vegfa (Figure 
24A) and altered protein levels of CXCL1 and VEGF (Figure 24B) versus Egfrfl/fl tumors. Egfrfl/fl and 
Egfr∆GIepi tumors did not demonstrate any differences in mRNA or protein levels of these markers 
(Appendix B, Figure 8). Additionally, M1-activated Egfr∆mye BMmacs expressed significantly less Cxcl1 
and Vegfa (Appendix B, Figure 9A) and M2-activated Egfr∆mye BMmacs expressed less Vegfa 
(Appendix B, Figure 9B) versus Egfrfl/fl BMmacs. These data confirm that macrophages are a potential 
source of CXCL1 and VEGF, and that EGFR signaling is critical for expression of these pro-angiogenic 
mediators. 
 To confirm that decreased pro-angiogenic cytokines was accompanied by decreased 
angiogenesis, we performed immunoperoxidase staining for CD31, a marker of vascular endothelial 
cells170. Representative images demonstrate significantly enhanced angiogenesis in AOM-DSS-treated 
Egfrfl/fl versus Egfr∆mye mice (Figure 24C). Notably, angiogenesis in AOM-DSS-treated Egfr∆mye mice 
was not different than angiogenesis in control Egfrfl/fl and Egfr∆mye mice (Figure 24C). Both the number 
of CD31+ blood vessels per case (Figure 24D) and the total area of CD31+ blood vessels (Figure 24E) 
were significantly decreased in AOM-DSS-treated Egfr∆mye mice versus Egfrfl/fl mice. Thus, decreases in 
pro-angiogenic cytokine production were associated with decreased angiogenesis in Egfr∆mye mice. 
Decreased angiogenesis likely contributed to diminished tumorigenesis in this CAC model. 
 
3.3 Discussion 
EGFR signaling is a commonly studied pathway in carcinogenesis59,69-71,74, although most 
studies related to EGFR signaling have been performed in epithelial cells59,69-71,74. This study outlines 
an important role for EGFR signaling in macrophages during inflammatory colon tumorigenesis (Figure 
25). Herein, we demonstrate that EGFR signaling occurs in human macrophages during pre-cancerous 
71
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Egfr∆mye mice demonstrate decreased pro-angiogenic chemokine/cytokine production 
and angiogenesis during colon tumorigenesis. (a) mRNA levels of the pro-angiogenic chemokine, 
Cxcl1, and the pro-angiogenic cytokine, Vegfa, were assessed by qRT-PCR from colonic tissues 77 
days post-AOM injection. n = 6-8 control tissues and 8-10 tumors with paired non-tumor area per 
genotype. (b) Protein levels of pro-angiogenic chemokine, CXCL1, and pro-angiogenic cytokine, VEGF, 
were assessed by Luminex Multiplex Array from colonic tissues 77 days post-AOM injection. n = 5 
control tissues and 6-9 tumors with paired non-tumor area per genotype. In (a) and (b), *P < 0.05, **P < 
0.01, ***P < 0.001 by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. (c) 
Representative images of CD31+ blood vessel immunohistochemistry in colonic tissues. Scale bars = 
50 µm. (d) Quantification of the total number of CD31+ blood vessels in (c). n = 3 control colonic tissues 
and 4-5 AOM-DSS-treated colonic tissues per genotype. (e) Quantification of the total CD31+ blood 
vessel area within tissues in (c). n = 3 control colonic tissues and 4-5 AOM-DSS-treated colonic tissues 
per genotype. In (d) and (e), ***P < 0.001 by one-way ANOVA with Newman-Keuls post-test. 
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  stages of ulcerative colitis and dysplasia, both of which are marked by active inflammation8,134. Based 
on diminished CD68+pEGFR+ cells in CAC, we posit that EGFR signaling in human macrophages may 
be essential for initiation of inflammation-associated tumorigenesis. Myeloid-specific knockout of Egfr 
significantly protected mice from tumorigenesis in the AOM-DSS model of CAC. Intriguingly, 
gastrointestinal epithelial cell-specific knockout of Egfr did not have a phenotype that was significantly 
different from wild-type mice. Protection from tumorigenesis in Egfr∆mye mice was accompanied by 
restricted M2 and M1 macrophage activation, which likely contributed to decreased angiogenesis due 
to less production of pro-angiogenic cytokines and chemokines (Figure 25). These data point to a 
currently underappreciated role for EGFR signaling in myeloid cells, particularly macrophages, in 
promoting CAC. 
 A previous study utilizing Wa5 mice, which carry a dominant-negative allele that impairs EGFR 
signaling, demonstrated that EGFR signaling inhibited CAC171, the opposite of our current result. It 
should be noted that differences in colon tumorigenesis were only significant when Wa5 mice were 
crossed with Il10–/– mice171. Il10–/– mice may have limitations as a model for CAC, because effects of 
the Il10 deletion can be modulated by bacterial infections172,173. The AOM-DSS model is solely 
dependent upon inflammation as a driver of carcinogenesis172,173. The previous work that demonstrated 
a protective role for EGFR in colon tumorigenesis also utilized the AOM-DSS model of colon 
tumorigenesis, but noted no significant differences in tumor multiplicity171. Moreover, the Wa5 allele 
affects all cell types, while our models used herein were myeloid- and gastrointestinal epithelial-cell-
specific. Taken together, our study provides a strong body of evidence that EGFR signaling in 
macrophages is a critical component of CAC. 
 EGFR signaling appears to mediate M1 and M2 macrophage activation. Importantly, we 
demonstrated via multiple methods in a previously published study that EGFR signaling in 
macrophages had no effect on apoptosis143. Thus, the phenotypes observed are due to alterations in 
macrophage function, not cell viability. While the finding that decreased M2 activation, which is highly 
pro-tumorigenic11,74,135, correlated with decreased tumor multiplicity and burden was not unexpected, 
the dramatic alteration of M1 activation was somewhat surprising. However, there are potential reasons 
73
 
Figure 25. Summary of findings related to EGFR signaling in macrophages during colitis-
associated carcinogenesis (CAC). EGFR activation occurs in macrophages during CAC, leading to 
NF-κB (RELA; p65) signaling and STAT6 signaling. NF-κB signaling leads to M1 gene expression, and 
STAT6 signaling leads to M2 gene expression. M1 activation leads to i) CXCL1 and TNF-α production, 
which recruit polymorphonuclear cells (PMNs) and increase colitis; ii) NOS2-mediated NO production, 
leading to reactive nitrogen species (RNS)-mediated DNA damage; and iii) CXCL1 production, which 
can promote angiogenesis. M2 activation leads to VEGFA production, which can also promote 
angiogenesis. Together, these effects contribute to increased risk for development of CAC.   
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  why M1 activation may have an important role in tumorigenesis. Firstly, as we demonstrated, M1 
macrophages are an important source of pro-angiogenic cytokines (VEGF) and chemokines (CXCL1). 
Secondly, M1 macrophages are a potent source of NOS2 (as shown herein) and NO2,3,143. It has been 
proposed that NO, a RNS, promotes colon tumorigenesis by causing DNA mutations and DNA 
instability8,10. Our work demonstrates that EGFR signaling has a role in promoting both M1 and M2 
activation, potentially working synergistically to promote colon tumorigenesis. 
 In sum, our study outlines a novel role for EGFR signaling in macrophages during CAC. Robust 
EGFR signaling in human macrophages in stages leading to colitis-associated cancer indicates that 
macrophage pEGFR may serve as a potential biomarker for colorectal cancer risk in colitis patients. 
Moreover, our previous work showed that TNF-α induced EGFR signaling in macrophages143. Thus, 
one potential benefit of anti-TNF treatment, frequently used in IBD patients, may be suppression of 
macrophage EGFR signaling. Further studies are imperative to further assess the critical role that 
EGFR activation plays in immune cells in patients at risk for progression to colon cancer. 
 
3.4 Materials and Methods 
 
Reagents 
Reagents used for cell culture were from Invitrogen (Carlsbad, CA, USA). Reagents for RNA extraction 
were from Qiagen (Valencia, CA, USA); those for cDNA synthesis and RT-PCR were from Bio-Rad 
(Hercules, CA, USA). Murine M-CSF, IFN-γ, IL-4, and IL-10 were from PeproTech (Rocky Hill, NJ, 
USA). Murine TNF-α was from Thermo Fisher Scientific (Waltham, MA, USA). Azoxymethane and LPS 
were from Sigma-Aldrich (St. Louis, MO, USA). DSS was from TdB Consultancy (Uppsala, Sweden). 
 
Antibodies 
See Appendix B, Table 4 for information regarding antibodies. 
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  Cells and Culture Conditions 
BMmacs were isolated and utilized as described in Chapter 2. Following differentiation, cells were 
placed in complete DMEM, supplemented with 10% FBS, 2 mM L-glutamine, 25 mM HEPES, and 10 
mM sodium pyruvate for studies with IFN-γ, TNF-α, IL-4, IL-10, or LPS. Stimulation times and doses 
are indicated in figure legends. 
 
Animal Studies 
Egfrfl/fl and Egfr∆mye mice were utilized as described in Chapter 2. C57BL/6 Egfrfl/fl mice were crossed to 
CD-1/DBA Foxa3cre/+ mice obtained from Timothy Wang (Columbia University Medical Center)174, to 
generate Egfr∆GIepi mice. As Egfr∆GIepi mice contain one Cre allele, littermates were utilized for all 
experiments. Study approval is as described in Chapter 2. 
 
Male mice, aged 6-12 weeks, were utilized for all studies. Samples sizes were based on previous AOM-
DSS studies from our laboratory. Mice were not removed from the cages into which they were weaned. 
No other criteria were utilized for selection or randomization. Mice were subjected to the AOM-DSS 
colon tumorigenesis model144,145. Mice received one intraperitoneal AOM injection (12.5 mg/kg) on Day 
0, and three doses of 4% DSS in their drinking water on Days 5, 26, and 47. The first two cycles of DSS 
lasted for 5 days, and the third for 4 days. Mice were weighed every 7 days from the start of the first 
DSS cycle and on Day 0 to determine the AOM dosage. Mice were sacrificed on Day 77.  
 
Rarely, Egfr∆mye mice developed an enlarged spleen that was not attributable to AOM-DSS treatment. 
These mice were excluded from further analysis. 
 
Tumor multiplicity was determined by visual inspection via dissecting microscope. Tumor burden was 
determined by the summation of tumor area, assessed by electronic caliper. Histologic colitis and 
dysplasia were determined by a gastrointestinal pathologist, M. Kay Washington in a blinded manner.  
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  Human Tissues 
The IBD-associated CAC human TMA was utilized as described144. 
 
Real-Time PCR 
RNA isolated, cDNA synthesis, and RT-PCR was performed as described in Chapter 2. See Appendix 
B, Table 3 for primers utilized. 
 
Western Blot Analysis 
Western blot analysis was performed as described in Chapter 2. 
 
Luminex Multiplex Array 
Luminex Multiplex Array was performed as described in Chapter 2. 
 
 
Immunofluorescence Staining for tEGFR and CD68, and RELA 
 
Staining for tEGFR and CD68 in both the TMA and in murine tissues was performed as described143, 
with the following exceptions in murine tissue. An initial blocking step was performed with Background 
Sniper (Biocare Medical), followed by incubation with anti-tEGFR. A second blocking step was 
performed with the Fab fragment of murine IgG for 15 min, followed 3% goat serum for 15 min, with 
subsequent incubation with anti-CD68. All other steps were as described. RELA staining and confocal 
microscopy was performed as described159. 
 
Immunoperoxidase Staining for pEGFR Y1068 
Staining for pEGFR in human colonic biopsies was performed as described74. 
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  Immunoperoxidase Staining 
CD68, MPO, and pSTAT6 
After overnight heating at 37°C, sections were deparaffinized in xylene and rehydrated in graded 
alcohols. Sections were incubated with primary antibody overnight at room temperature. After washing, 
incubation with anti-rabbit HRP-polymer was performed for 30 min. Sections were rinsed and incubated 
with streptavidin-HRP (Biocare Medical, Concord, CA, USA) for 30 min.  
 
CD3, CD45R, and CD31 
Heat-induced antigen retrieval was performed on the Leica Bond Max using Epitope Retrieval 2 
solution for 10 min (CD3, CD31) and 20 min (CD45R). Slides were incubated with primary antibody for 
1 h and incubated with secondary antibody for 15 min. CD31 Images were captured using a high 
throughput Leica SCN400 Slide Scanner automated digital image system. Tissue samples were 
mapped using Ariol® Review software. The numbers and areas of CD31+ blood vessels were 
determined in the Ariol® software. 
 
Scoring of CD68, MPO, CD3, and CD45R Immunoperoxidase Staining 
Slides were scored in a blinded manner by a gastrointestinal pathologist (M. Blanca Piazuelo) Samples 
were evaluated for staining in non-tumor and tumor areas using the following scale: 0=scarce positive 
cells, 1=low abundance of positive cells, 2=moderate abundance of positive cells, and 3=high 
abundance of positive cells. The two scores were combined for a highest possible score of 6. 
 
Purification of colonic epithelial cells 
Purification of colonic epithelial cells was performed as described143. 
 
Statistical Analysis 
Data represent mean ± S.E.M. Where data were normally distributed, two-tailed Student’s t test was 
used to determine significance in experiments with only two groups, and one-way ANOVA with the 
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  Newman-Keuls test was used to determine significant differences between multiple test groups. In 
Figure 4, the data were square root transformed to ensure normal distribution prior to statistical 
analysis. In other cases where data were not normally distributed, a one-way ANOVA with Kruskal-
Wallis test, followed by a Mann-Whitney U test, was performed. Please see Appendix B, Table 5 for all 
relevant P values as determined by Kruskal-Wallis test. Statistical analysis of all weight loss curves was 
performed by two-way ANOVA with Bonferroni post-test. All statistics were performed in Prism 5.0 
(GraphPad Software, San Diego, CA, USA). A P value of < 0.05 was considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79
	   80 
CHAPTER 4 
TRIM28 IS A DOWNSTREAM TARGET OF EGFR IN MACROPHAGES 
 
4.1 Introduction 
 EGFR signaling can encompass many different downstream pathways59,60,71. The studies 
outlined in Chapter 2 and Chapter 3 identified NF-κB signaling (Figure 13 and Figure 23), MAPK1/3 
signaling (Figure 14) and STAT6 signaling (Figure 22) as being downstream of EGFR in macrophages. 
Next, we sought to determine other unique pathways that are downstream of EGFR in macrophages, 
especially considering that EGFR signaling in macrophages is a highly understudied area. Identification 
of pathways downstream of EGFR that are specific to macrophages may provide highly specific targets 
in the treatment of chronic inflammatory conditions.  
 
4.2 Results 
To address questions related to downstream signaling targets of EGFR in macrophages, we 
utilized the unbiased, phospho-proteomics based, SILAC approach. Three two-plex SILAC assays were 
performed in RAW 264.7 cells. Cells either treated with gefitinib (gefitinib only), infected with H. pylori 
PMSS1 (PMSS1 only), or treated with gefitinib and infected with H. pylori PMSS1 (PMSS1 + gefitinib) 
were labeled with “heavy” amino acids. Untreated, uninfected cells were labeled with “light” amino 
acids, and aliquots were utilized as the control sample in each two-plex SILAC experiment. Each SILAC 
experiment was performed in duplicate. The experimental design is outlined in Figure 26A. 
 Between two independent experiments, We identified 11,081 total phospho-peptides in the 
gefitinib only group, 12,088 total phospho-peptides in the PMSS1 only group and 12,997 total phospho-
peptides in the PMSS1 + gefitinib group. There was significant overlap in the number of unique 
phospho-proteins identified between each replicate experiment, indicating a high degree of fidelity in 
these experiments (Figure 26B).  
Upon completion of each set of SILAC experiments, the data from each replicate were 
normalized  and  phospho-peptides  common  to  both  replicates  were  compiled  for further  analysis.   The  
 
Figure 26. Schematic overview of SILAC experimental set-up and phosphopeptides identified in 
replicate experiments. (A) Diagram of experimental set-up for SILAC. (B) Venn diagrams depicting 
the number of phosphoproteins identified in each data set, both unique to one experimental replicate 
and overlapping between replicate experiments. (C) Scatterplots with normalized histograms 
demonstrating the degree of overlap in identified phosphopeptides in each experimental replicate.  
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normalized and combined datasets were then examined and we selected phospho-peptides for further 
analysis that met the following criteria. First, the gefitinib only data set was filtered such that phospho-
peptides that had a positive or negative fold change of ≤ 1.2 were selected. Second, the PMSS1 only 
data set was filtered such that phospho-peptides that had a positive or negative fold change of ≥ 1.5 in 
the PMSS1-only cells were selected. The PMSS1 + gefitinib group was not filtered in any way so that 
phospho-peptides that were both affected or unaffected by gefitinib treatment and H. pylori infection 
could be identified. Finally, the phospho-peptides that were present in each replicate of the three data 
sets were selected and combined, provided they met the aforementioned criteria. The analysis pipeline 
is outlined in Figure 27A. We identified 104 unique phospho-peptides that were altered by H. pylori 
PMSS1 infection, but not altered by gefitinib treatment alone, according to the aforementioned criteria 
(Figure 27B). The data set was then manually curated to identify phospho-peptides that were altered by 
gefitinib treatment during H. pylori infection. 
Once these parameters were applied, several phospho-peptides were selected for validation by 
western blotting. Phosphorylation of TRIM28 S473 was identified as being induced by H. pylori infection 
and significantly decreased in abundance by gefitinib treatment, during H. pylori infection (Figure 27B 
and Figure 28A). Western blotting confirmed the findings from the SILAC data sets. Indeed, TRIM28 
pS473 is upregulated during H. pylori PMSS1 infection in RAW 264.7 cells, and gefitinib treatment 
reduces TRIM28 pS473 levels at multiple timepoints (Figure 28A-28D). Additionally, these data related 
to the phosphorylation of TRIM28 S473 was confirmed in both WT BMmacs treated with gefitinib and 
Egfrfl/fl and Egfr∆mye BMmacs (Figure 28E, 28F, and 28G). TRIM28 is a known transcriptional repressor 
in macrophages175,176 and may represent a unique pathway by which EGFR signaling modulates 
macrophage activation. Further studies related to the role of TRIM28 pS473 in macrophages during H. 
pylori infection are planned. 
Furthermore, two additional phospho-peptides – ribosomal protein S6 (RPS6) S235/236 and stathmin 
(STMN1) S25 – were confirmed via western blotting. RPS6 pS235/236 was induced by H. pylori 
infection and decreased with gefitinib treatment by both SILAC (Figure 29A) and western blotting 
(Figure  29B  and  29C).   STMN1  pS25  is  induced  by  H.  pylori  infection,  but  is unaffected  by   gefitinib	  
 
Figure 27. Pipeline of SILAC data analysis and identification of downstream targets of EGFR 
signaling during H. pylori infection of macrophages. (A) Pipeline of data analysis of phospho-
peptides identified in SILAC analysis. The gefitinib only, PMSS1 only, and PMSS1 + gef. replicate 
experiments were combined prior to this analysis. (B) Scatterplot with normalized histogram 
demonstrating potential targets of interest that were up- or down-regulated by ≥1.5 fold versus control 
samples in the PMSS1 group. Red dot = TRIM28 pS473. 
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Figure 28. TRIM28 is a potential downstream target of EGFR signaling in macrophages. (A) 
Median fold change of TRIM28 pS473 in RAW 264.7 cells in replicate SILAC experiments in the 
gefitinib, PMSS1, and PMSS1 + gefitinib groups at 30 min p.i. (B) Representative western blot of 
TRIM28 pS473 levels in RAW 264.7 cells at indicated time points p.i. with H. pylori PMSS1 ± 10 µM 
gefitinib. n = 3 biological replicates. (C) Densitometric analysis of TRIM28 pS473 levels at 15, 30, and 
60 min p.i. from (B). * P < 0.05, ** P < 0.01, *** P < 0.001 by two-tailed Student’s t test. (D) 
Densitometric analysis of the kinetics of TRIM28 pS473 levels from (B). ** P < 0.01, *** P < 0.001 by 
one-way ANOVA with Newman-Keuls post-test. (E) Representative western blot of TRIM28 pS473 
levels in WT BMmacs at indicated time point p.i. with H. pylori PMSS1 ± 10 µM gefitinib. n = 3 biological 
replicates. (F) Densitometric analysis of TRIM28 pS473 from (E). * P < 0.05 by two-tailed Student’s t 
test. (G) Representative western blot of TRIM28 pS473 levels in Egfrfl/fl and Egfr∆mye BMmacs at 
indicated time point p.i. with H. pylori PMSS1. n = 2 biological replicates. 
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Figure 29. Validation of additional targets identified in SILAC experiments. (A) Median fold 
change of RPS6 pS235/236 in RAW 264.7 cells in replicate SILAC experiments in the gefitinib, PMSS1, 
and PMSS1 + gefitinib groups at 30 min p.i. (B) Representative western blot of RPS6 pS235/236 levels 
in RAW 264.7 cells at indicated time points p.i. with H. pylori PMSS1 ± 10 µM gefitinib. n = 3 biological 
replicates. (C) Densitometric analysis of RPS6 pS235/236 levels at 15, 30, and 60 min p.i. from (B). * P 
< 0.05 by two-tailed Student’s t test. (D) Median fold change of STMN1 pS25 in RAW 264.7 cells in 
replicate SILAC experiments in the gefitinib, PMSS1, and PMSS1 + gefitinib groups at 30 min p.i. (E) 
Representative western blot of STMN1 pS25 levels in RAW 264.7 cells at indicated time points p.i. with 
H. pylori PMSS1 ± 10 µM gefitinib. n = 3 biological replicates. (F) Densitometric analysis of STMN1 
pS25 levels at 15, 30, and 60 min p.i. from (E). 	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treatment by both SILAC (Figure 29D) and western blotting (Figure 29E and 29F). These data confirm 
the robustness of the SILAC experiments and demonstrate that further studies related to the phospho-
peptides identified via SILAC are valid. 
 
4.3 Discussion 
The data discussed above are preliminary in nature. Two replicate SILAC analyses were 
performed, with limited follow-up studies. Further bioinformatic analyses are currently ongoing to create 
a more global understanding of the proteins involved in signaling downstream of EGFR in 
macrophages. Such studies will allow for mapping of pathways from the entire SILAC dataset and a 
better understanding of the relationships between identified phospho-peptides. Moreover, further 
analysis will provide insight into the kinases involved in the phosphorylation of identified peptides. 
Overall, the goal is to understand the role of EGFR signaling in macrophages on a global scale. 
 
4.4 Materials and Methods 
 
Reagents 
All reagents for SILAC analysis were purchased from Fisher Scientific (Waltham, MA, USA). 
 
Cell Culture 
To label RAW 264.7 cells with the “light” and “heavy” amino acids, RAW cells were passaged in DMEM 
(Cat. no. PI-89985) with 10% dialyzed stem cell FBS (Cat. no. PI-88212), 2 mM L-glutamine, 25 mM 
HEPES, 10 mM sodium pyruvate, 0.23 mg/mL L-proline (Cat. no. PI-88211) and the following for either 
“light” or “heavy” cells. LIGHT: 0.1 mg/mL L-lysine-2HCl (Cat. no. PI-89987) and 0.1 mg/mL L-arginine-
HCl (Cat. no. PI-89989). HEAVY:  0.1 mg/mL L-lysine-2HCl, 13C6 and 15N2 (Cat. no. PI-88209) and 0.1 
mg/mL L-arginine-HCl, 13C6 and 15N4 (Cat. no. PI-89990). Following eight passages of cells in the 
“light” and “heavy” SILAC media, cells were tested for labeling by mass spectrometry. For SILAC, > 
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95% of proteins must be labeled with either “light” or “heavy” amino acids. Additional passages and 
labeling checks were performed as needed to achieve at least 95% labeling.  
 
Once labeling was completed, “light” cells were utilized for untreated, uninfected control cells and 
“heavy” cells were utilized for gefitinib only cells, H. pylori PMSS1 only cells, and H. pylori PMSS1 + 
gefitinib cells. Cells were pre-treated for 1 h with 10 µM gefitinib and then infected for 30 min at an MOI 
of 100.  
 
For confirmatory studies following SILAC analysis, culture of RAW 264.7 cells and BMmacs was 
performed as described in Chapter 2. Culture and usage of H. pylori PMSS1 was performed as 
described in Chapter 2. 
 
Lysis of cells for SILAC 
Following infection, cells were lysed in 50 mM Tris-HCl (pH 7.6), 150 nM NaCl, 1% NP-40, 2 mM EDTA 
in water. No protease or phosphatase inhibitors were added to lysis buffer. 1 mg protein was utilized for 
SILAC analysis. 
 
Mass Spectrometry and SILAC analysis 
The mass spectrometry and subsequent SILAC analysis was performed as previously described74. 
 
Western Blotting 
Western blotting was performed as described in Chapter 2.	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CHAPTER 5 
ODC IN MACROPHAGES DURING BACTERIAL INFECTION 
 
5.1 Introduction 
Polyamine metabolism is a process critical for life occurring within all mammalian cell types84,85. 
Polyamines have ubiquitous roles in many cellular functions, including growth, proliferation, and 
differentiation85. Importantly, polyamines have also been implicated in the alteration of histone 
modifications and chromatin structure and thus might broadly affect DNA stability and 
transcription90,92,93. The production of the three major polyamines – putrescine, spermidine, and 
spermine – is tightly regulated and centers on the rate-limiting enzyme, ODC84,97. ODC utilizes the 
substrate, L-ornithine, to produce putrescine via a decarboxylation reaction84,97. Given its essential and 
central role in regulating polyamine metabolism within cells, ODC has been highly studied and 
implicated in several malignancies, including breast, colorectal, and gastric cancer91,177-180. However, 
most of the studies related to ODC have been focused on its role in epithelial cell function, leaving 
many questions surrounding the role of ODC in immune cells unanswered. 
In particular, macrophages are a significant component of the innate immune cell compartment 
and play wide-ranging roles in immune surveillance, responses to pathogens, wound healing, 
embryonic development, and regulation of the tumor microenvironment2,3. An essential step in the 
responses to pathogens is macrophage activation. Macrophages have the capacity to alter 
cytokine/chemokine production and various other functions along the spectrum of M1 or M2 activation 
based on the stimulus detected2,3,143. M1 macrophages represent a highly pro-inflammatory and anti-
microbial subset of macrophages2,3,143. M2 macrophages have various roles in wound repair, anti-
parasitic responses, control of inflammation, and have been implicated in tumor development and 
growth7,11,98. The role of ODC has been well characterized in M2 macrophage responses to various 
parasitic and fungal infections181-183, but the role of ODC in macrophages during M1 responses have 
been less well studied184. We have demonstrated that ODC expression is upregulated during bacterial 
infections47,95,113,185, but the role in macrophage activation patterns requires further investigation. 
	  To address this question, we utilized Helicobacter pylori, a globally pervasive human pathogen 
that represents the single greatest risk factor in the development of gastric cancer21,23,27,102. H. pylori 
establishes a chronic infection in humans, which can be recapitulated in mice143, marked by continuous, 
low-grade inflammation and host tolerance of the pathogen9,40,41,111. We also utilized the C. rodentium 
infectious colitis model113,131. C. rodentium is an enteric bacterial pathogen that forms attaching and 
effacing lesions in the colon and is similar to enteropathogenic Escherichia coli infection in humans104. 
As macrophages are known to have a critical role in H. pylori-mediated gastritis20,143 and C. rodentium 
colitis143, we sought to interrogate the specific role of ODC in macrophages during these enteric 
infections, utilizing a myeloid/macrophage-specific Odc knockout mouse.  
In this study, we have uncovered a novel mechanism by which ODC and its product, putrescine, 
regulates macrophage activation and function. We show that macrophage-derived ODC plays a critical 
role in the inhibition of M1 macrophage activation to promote persistence of infection. This defect in M1 
macrophage activation is directly regulated by polyamine production that modulates chromatin 
structure, as determined by alterations in histone modification markers in vitro and in vivo, which 
prevents pro-inflammatory gene transcription.  
 
5.2 Results 
Myeloid-specific ODC deletion enhances gastritis and bacterial killing during H. pylori infection 
 As we have previously demonstrated that ODC plays a significant role in macrophage function 
during H. pylori infection in vitro47,95,186, we hypothesized that macrophage-derived ODC would have 
significant effects on H. pylori pathogenesis, specifically in the regulation of gastric inflammation. As H. 
pylori is a human pathogen, we first assessed ODC levels in mononuclear cells in gastric biopsies from 
H. pylori-infected patients with chronic active gastritis from Colombia, where overall risk of gastric 
cancer is high33,37. We found that H. pylori infection leads to a significant increase in ODC levels in 
mononuclear cells, which includes abundant expression in cells with the appearance of macrophages 
(Figure 30A and 30B).  
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Figure 30. Odc∆mye mice have significantly increased histologic gastritis, but significantly 
decreased H. pylori burden after chronic infection. (a) Representative immunoperoxidase 
staining for ODC in human gastric biopsies from patients with normal mucosa and with H. pylori-
positive gastritis. Scale bars = 50 µm. (b) Quantification of the percentage of ODC+ mononuclear 
cells in gastric biopsies from (a). n = 4 normal biopsies and 20 H. pylori+ gastric biopsies with 
chronic active gastritis. *P<0.05 by Mann-Whitney U test. H.P.F. = high power field. (c) 
Representative immunofluorescence images of ODC from gastric biopsies in (a) and (b). Green = 
ODC, Red = CD68, Yellow = Merge, Blue = DAPI. Closed arrows indicate CD68+ODC+ 
macrophages. Boxed area indicates image shown in higher magnification. Scale bars = 50  µm. 
Note that different cases were utilized for representative images in (a) and (c). (d) Quantification of 
the number of CD68+ODC+ cells in the cases from (c). n = 5 normal biopsies and 10 H. pylori+ 
gastric biopsies with chronic active gastritis. **P<0.05 by Student’s t test. (e) Histologic gastritis 
scores were assessed 4 mo p.i. by a gastrointestinal pathologist in a blinded manner according to 
the updated Sydney System. (f) Representative H&E images from infected mice in (e). Scale bars 
= 100  µm. (g) Colonization of H. pylori SS1 was assessed by serial dilution and culture 4 mo p.i. In 
(e) and (g) *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA with Newman-Keuls post-test. n = 
8-10 uninfected and 15-19 H. pylori SS1-infected mice per genotype. (h) Correlation between 
histologic gastritis in (e) and H. pylori SS1 colonization levels in (g). Correlation and significance 
determined by Pearson’s product-moment correlation test. (i) Representative immunofluorescence 
images of ODC from infected mice in (e) and (g). Green = ODC, Red = CD68, Yellow = Merge, 
Blue = DAPI. Closed arrows indicate CD68+ODC+ macrophages. Open arrows indicate 
CD68+ODC– macrophages. Scale bars = 50  µm. Data displayed as mean ± S.E.M. 
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  To confirm that human macrophages express increased ODC during H. pylori infection, we 
performed immunofluorescence staining for ODC and CD68, a macrophage marker, on a subset of the 
cases from Colombia. Control staining in which no primary anti-ODC antibody was utilized was 
performed to confirm the specificity of the staining (Appendix C, Figure 1A). As expected, the number of 
CD68+ macrophages was increased in the H. pylori+ cases when compared to the normal cases 
(Appendix C, Figure 1B). While there was no difference in the number of CD68+ODC– macrophages 
between normal and H. pylori+ cases (Appendix C, Figure 1C), we found a significant increase in the 
number of CD68+ODC+ cells in the H. pylori-infected cases versus control cases (Figure 30C and 30D). 
Moreover, the percentage of CD68+ODC+ macrophages per the total number of CD68+ macrophages 
was significantly higher in H. pylori+ cases (Appendix C, Figure 1D) These data indicate that H. pylori 
infection is associated with upregulated ODC in human gastric macrophages, which led us to 
hypothesize that ODC has an important role in regulating macrophage function during infection. 
 To investigate the role of macrophage-derived ODC further, we generated mice with a myeloid-
specific deletion of Odc, by crossing C57BL/6 Odcfl/fl mice with myeloid-specific LysMcre/cre driver mice, 
yielding the Odc∆mye mouse (Appendix C, Figure 2A). We assessed Odc mRNA levels in CD11b+ 
myeloid cells and CD11b– non-myeloid cells from the gastric lamina propria of mice infected with H. 
pylori PMSS1 for 48 h, the peak of gastric macrophage infiltration97,110, as well as in gastric epithelial 
cells (GECs). Importantly, only the CD11b+ lamina propria cells demonstrated induction of Odc during 
H. pylori infection, which was ablated in Odc∆mye CD11b+ cells (Appendix C, Figure 2B). Notably, Odc 
was not induced in CD11b– cells or GECs, and Odc mRNA levels were not altered in these cells 
derived from the Odcfl/fl and Odc∆mye mice (Appendix C, Figure 1C), consistent with the specificity of the 
knockout. We also demonstrated sufficient Odc knockdown in primary BMmacs by RT-PCR and 
western blotting during H. pylori infection (Appendix C, Figure 2C, 2D, 2E).  
Additionally, expression levels of Lyz2, the gene on which the CRE recombinase was placed, 
and Cre were assessed in H. pylori SS1-infected gastric tissues and in H. pylori PMSS1-infected 
BMmacs from Odcfl/fl, Odc∆mye, and LysMcre/cre mice. At 4 mo p.i., gastric Lyz2 mRNA was nearly 
undetectable, while Cre mRNA was abundant in both infected and uninfected Odc∆mye gastric tissue 
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  (Appendix C, Figure 3A). Conversely, Lyz2 was induced upon infection in Odcfl/fl gastric tissues and no 
Cre was detected (Appendix C, Figure 3A). These data were recapitulated in BMmacs from Odcfl/fl, 
Odc∆mye, and LysMcre/cre mice (Appendix C, Figure 3B). The maintenance of the Lyz2 deletion and of 
high Cre expression during acute and chronic infection confirms the durability of the Odc deletion over 
time143.  
 Upon confirmation of Odc knockdown in myeloid cells, Odcfl/fl, Odc∆mye, and LysMcre/cre mice were 
investigated for their response to infection with H. pylori SS1 for 4 mo, a model of chronic H. pylori 
infection47,103,143,185. Odc∆mye mice demonstrated significantly enhanced acute and chronic histologic 
gastritis, as compared to either Odcfl/fl or LysMcre/cre mice (Figure 30E and 30G). Consistent with 
previous studies111,112,143,185 in which colonization and gastritis are typically inversely related, the 
enhanced gastritis was correlated with significantly decreased H. pylori burden in Odc∆mye mice (Figure 
30G and 30H), indicating that ODC has an important role in regulating anti-microbial inflammation in the 
stomach. Importantly, there were no detectable phenotypic differences between the Odcfl/fl or LysMcre/cre 
mice, confirming all phenotypes are being driven by Odc deletion (Figure 30E-30H).  
 ODC knockout was confirmed by immunofluorescence in CD68+ gastric macrophages from 
chronically-infected gastric tissues from Odcfl/fl, Odc∆mye, and LysMcre/cre mice. ODC co-localized with 
CD68+ macrophages in both Odcfl/fl and LysMcre/cre gastric tissues, while ODC was not expressed in 
CD68+ cells in Odc∆mye gastric tissues (Figure 30I). Control staining in which no primary anti-ODC 
antibody was utilized confirmed the specificity of the immunofluorescence (Appendix C, Figure 4). 
These data further confirmed successful deletion of Odc in macrophages, as well as maintenance of 
the knockout over time and during infection.  
 We next sought to determine if the role of ODC in macrophages was specific to H. pylori 
pathogenesis. Odc expression was also upregulated in BMmacs exposed to C. rodentium and was 
markedly attenuated in Odc∆mye BMmacs (Appendix C, Figure 5A). Odcfl/fl and Odc∆mye mice were 
inoculated with C. rodentium for 14 days. As in the chronic H. pylori model, Odc∆mye mice exhibited 
significantly increased levels of histologic inflammation and injury, represented by higher colitis scores, 
as compared to Odcfl/fl mice (Appendix C, Figure 5B and 5C). Moreover, tissues from Odc∆mye mice had 
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  increased colon weight as a percentage of body weight on the day of sacrifice (Appendix C, Figure 5D), 
which is a marker of increased disease severity131. The significant increases in colitis and disease 
severity were concordant with the increased histologic gastritis observed in the H. pylori model, 
indicating that the role of ODC in regulating macrophage activation responses is conserved across 
various bacterial infections. However, differences in C. rodentium burden were not detected in colonic 
tissues between Odcfl/fl and Odc∆mye mice (Appendix C, Figure 5E); this finding is consistent with our 
prior reports that while diminished immune response can result in increased colonization106,143, 
increased inflammation does not lead to decreased colonization in this model187. 
 
ODC deletion augments pro-inflammatory cytokine and chemokine production in vivo 
 Our in vivo findings demonstrated that macrophage-derived ODC has an anti-inflammatory role 
during bacterial pathogenesis. Thus, we hypothesized that the loss of ODC in macrophages leads to 
enhanced innate immune responses to H. pylori. We utilized a Luminex Multiplex Array to assess 25 
distinct chemokines and cytokines in gastric tissues from chronically-infected Odcfl/fl, Odc∆mye, and 
LysMcre/cre mice. Nine analytes were significantly increased at the protein level in H. pylori-infected 
Odc∆mye gastric tissues, when compared to Odcfl/fl or LysMcre/cre gastric tissues. C-C motif ligand  
chemokines, CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES), and C-X-C motif 
ligand (CXCL) chemokines, CXCL1 (GROα, KC), CXCL2 (MIP2), and CXCL10 (IP-10), were all 
significantly increased in Odc∆mye gastric tissues (Figure 31). The enhanced chemokine production 
suggests that the deletion of macrophage ODC has a role in enhancing immune cell infiltration into the 
stomach, contributing to the significantly increased inflammation. Additionally, the cytokines IL-17 and 
TNF-α were detected at significantly higher levels in Odc∆mye gastric tissues at 4 mo p.i. (Figure 31). IL-
17 is a hallmark of the Th17 response188, especially in H. pylori infection143, indicating an enhanced pro-
inflammatory T cell response to H. pylori and a diminished ability to control infection124 under conditions 
of macrophage Odc deletion. Many cell types can produce TNF-α, especially M1-activated 
macrophages3. Analytes that were either not induced by infection in any of the genotypes, were not 
significantly different between genotypes, or were not detected are listed in Appendix C, Table 1. 
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Figure 31. Cytokines and chemokines are significantly increased in Odc∆mye gastric tissues. 
Protein levels of the cytokines and chemokines CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 
(RANTES), CXCL1 (KC/GRO-α), CXCL2 (MIP-2), CXCL10 (IP-10), IL-17, and TNF-α were assessed 
by Luminex Multiplex Array in gastric tissues 4 mo p.i. with H. pylori SS1. *P<0.05, **P<0.01, 
***P<0.001 by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitey U test. n = 4 
uninfected and 8-9 H. pylori SS1-infected mice per genotype. Data displayed as mean ± S.E.M 
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  ODC deletion leads to enhanced M1 macrophage activation during bacterial infections 
 The increased TNF-α levels in the context of myeloid-specific Odc deletion led us to 
hypothesize that ODC normally serves to suppress M1 macrophage activation. Thus, enhanced M1 
responses in Odc∆mye mice would have the potential to orchestrate the highly pro-inflammatory immune 
response to both H. pylori and C. rodentium. To test our hypothesis, we expanded upon a previously 
utilized panel of genes marking M1 and M2 macrophage activation143,185 and assessed expression 
levels of each marker in chronically-infected gastric tissues from Odcfl/fl, Odc∆mye, and LysMcre/cre mice. 
mRNA expression of M1 activation markers, Il1b, Il6, Il12a (Il12p35), Il12b (Il12p40), Tnfa, and Nos2, 
were induced during H. pylori infection in gastric tissues from each genotype (Figure 32A). Expression 
of each of these genes was markedly increased in Odc∆mye versus Odcfl/fl or LysMcre/cre gastric tissues 
(Figure 32A). Additionally, C. rodentium-infected colonic tissues demonstrated an induction of M1 
marker expression that was further increased in Odc∆mye colonic tissues (Appendix C, Figure 6A). Taken 
together, these data demonstrate that the loss of ODC in myeloid cells significantly magnifies M1 
macrophage activation in response to bacterial enteric pathogens. 
 Markers of M2 activation were also assessed in gastric and colonic tissues from H. pylori-
infected mice. The following panel of M2 markers was utilized: Arg1, Chil3 (Ym1), Retnla (Relma), Il10, 
Tgfb, and Tnfsf14 (Light). H. pylori infection does not typically induce a robust M2 macrophage 
response143,185. Indeed, M2 genes Arg1, Chil3, Retnla, Il10, and Tgfb were not significantly induced in 
Odcfl/fl or LysMcre/cre gastric tissues (Appendix C, Figure 7A). Tnfsf14 was significantly induced in Odcfl/fl 
and LysMcre/cre gastric tissues, but was significantly decreased in Odc∆mye gastric tissues (Appendix C, 
Figure 7A). Since Tnfsf14 was the only M2 gene upregulated in infected gastric tissues, these data 
indicate that H. pylori infection does not induce a significant M2 response in mice during chronic 
infection. 
Interestingly, Odc∆mye mice demonstrated enhanced Arg1 expression in whole gastric tissue 
during H. pylori infection (Appendix C, Figure 7A); ARG1 is upstream of ODC and its upregulation may 
potentially represent a response to the loss of putrescine production by ODC in the myeloid-specific 
Odc knockout mice. However, based on previous studies, macrophages are not the likely source of 
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Figure 32. Odc deletion in macrophages enhances M1 macrophage activation during H. pylori 
infection. (a) mRNA levels of pro-inflammatory cytokines Il1b, Il6, Il12a, Il12b, Tnfa, and the gene 
Nos2 were assessed by RT-PCR in gastric tissues 4 mo p.i. with H. pylori SS1. *P<0.05, **P<0.01. n = 
3 uninfected and 5 H. pylori SS1-infected mice per genotype. (b) mRNA levels of pro-inflammatory 
cytokines Il1b, Il6, Il12a, Il12b, Tnfa, and Nos2 were assessed by RT-PCR in bone marrow-derived 
macrophages (BMmacs) 24 h p.i. with H. pylori PMSS1. *P<0.05, **P<0.01. Statistical significance in 
(a) and (b) was calculated by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U 
test. n = 6 mice per genotype. Note that the y-axis values for Il1b, Il6, and Nos2 have been divided by a 
factor of 1000. All samples were analyzed as fold change against Odcfl/fl uninfected control samples. No 
differences were observed in the fold changes for uninfected samples from all genotypes. (c) Secreted 
levels of IL-1β, IL-6, IL-12p70, and TNF-α were measured by ELISA from supernatants of BMmacs 24 
h p.i. with H. pylori PMSS1. *P<0.05, **P<0.01 by one-way ANOVA with Newman-Keuls post-test. n = 
3-6 mice per genotype. Note that none of the cytokines displayed were detected in supernatants from 
uninfected BMmacs. (d) Representative western blot of NOS2 levels in BMmacs 24 h p.i. with H. pylori 
PMSS1. n = 3 biological replicates. (e) Measurement of NO2– from BMmac supernatants 24 h p.i. with 
H. pylori PMSS1. ***P<0.001 by one-way ANOVA with Newman-Keuls post-test. n = 4 mice per 
genotype. Data displayed as mean ± S.E.M. 	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  Arg1 in these tissues113,115. Moreover, Arg1 mRNA levels were significantly higher in Odc∆mye GECs 
than in Odcfl/fl GECs following H. pylori infection (Appendix C, Figure 7B), indicating that epithelial cells 
may be the source of increased Arg1. Taken together, these data indicate that ODC does not have a 
major role in regulating M2 activation, but that Odc deletion in macrophages allows for enhanced M1 
activation.  
To confirm the specificity of these findings to macrophages, we assessed macrophage 
activation in BMmacs from each of the genotypes infected ex vivo with either H. pylori or C. rodentium. 
As in the gastric tissues, Il1b, Il6, Il12a, Il12b, Tnfa, and Nos2 mRNA levels were significantly increased 
in Odc∆mye BMmacs infected with H. pylori (Figure 32B). Representative M1 genes, Il1b, Tnfa, and Nos2 
were also increased in C. rodentium-infected Odc∆mye BMmacs (Appendix C, Figure 8) versus Odcfl/fl or 
LysMcre/cre BMmacs. Moreover, Odc∆mye BMmacs had significantly increased secreted levels of IL-1β, IL-
6, IL-12p70, and TNF-α (Figure 32C), as well as increased NOS2 protein levels (Figure 32D) and NO 
production (Figure 32E) in response to H. pylori infection. Densitometry further confirmed the significant 
increase in NOS2 protein levels in Odc∆mye BMmacs (Appendix C, Figure 9). These data clearly 
demonstrate enhanced M1 macrophage activation at the functional level in Odc-deficient macrophages.  
M2 marker gene expression revealed a more complicated picture in H. pylori-infected BMmacs. 
Arg1, Chil3, Retnla, and Tnfsf14 were not induced by H. pylori infection, regardless of genotype 
(Appendix C, Figure 10A). However, H. pylori infection induced Il10 and Tgfb mRNA expression, which 
was significantly increased in Odc∆mye BMmacs versus the control genotypes (Appendix C, Figure 10A). 
Protein levels of IL-10 confirmed the mRNA data, while TGF-β secretion was not altered between 
genotypes (Appendix C, Figure 10B). As M1 activation was consistently increased in both gastric 
tissues and BMmacs from Odc∆mye mice, and M2 activation was not, these data indicate that ODC is a 
key regulator of M1 macrophage activation during bacterial infections. In contrast, the potential role of 
ODC in M2 activation during bacterial infections is much less apparent. 
To determine if the role of ODC was conserved in human macrophages, we utilized THP1 cells, 
a human monocytic cell line that can be differentiated into macrophages with PMA. We determined that 
H. pylori infection induced ODC expression at the mRNA and protein levels (Appendix C, Figure 11A, 
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  B). We then treated THP1 cells with DFMO, an irreversible and specific ODC inhibitor186, for 3 or 5 days 
and then infected with H. pylori PMSS1 for 6 h. We assessed M1 and M2 activation by RT-PCR. 
DFMO-treated, H. pylori-infected THP1 cells had a significant increase in induction of IL1B, IL12A, 
IL12B, and TNFA when compared to untreated, H. pylori-infected cells (Appendix C, Figure 11C). IL10 
expression was induced by infection, but DFMO treatment did not further alter expression (Appendix C, 
Figure 11D). Importantly, the data related to M1 marker expression demonstrate that ODC also has a 
role in regulating M1 activation in human macrophages. 
Macrophage activation can occur in many settings beyond the context of bacterial 
infection2,3,7,98. We next sought to determine the global role of ODC in macrophage activation in 
BMmacs by utilizing prototypical stimuli of M1 and M2 activation that are not dependent upon bacterial 
infection. An M1 response was induced by stimulation with IFN-γ and LPS3 and an M2 response was 
elicited via stimulation with IL-43. M(IFN-γ/LPS) macrophages from Odc∆mye mice, as with H. pylori- or C. 
rodentium-infected macrophages, demonstrated significantly increased Il1b, Tnfa, and Nos2 expression 
as compared to Odcfl/fl or LysMcre/cre BMmacs  (Appendix C, Figure 12A). Interestingly, M(IL-4) 
macrophages from Odc∆mye mice had further upregulation of Arg1 and Chil3 (Appendix C, Figure 12B). 
Thus, ODC has the capacity to regulate subsets of macrophage activation in a stimulus-dependent 
manner. These data demonstrate the central role of ODC in regulating macrophage activation in 
general.  
 
The role of ODC in macrophages is dependent upon the polyamine, putrescine. 
 As the rate-limiting enzyme in polyamine synthesis, ODC converts L-ornithine to the polyamine, 
putrescine47,84,186, which can then be converted into spermidine and spermine. We determined 
putrescine, spermidine, and spermine levels by liquid chromatography-mass spectrometry (LC-MS) 
using deuterated d8-polyamines as internal standards. Deletion of Odc resulted in significantly 
diminished putrescine and spermidine levels in macrophages at 6 h and 24 h p.i. (Figure 33A). Odc 
deletion resulted in modest spermine accumulation (Figure 33A), which has been demonstrated 
previously during ODC inhibition with DFMO91. Moreover, H. pylori infection resulted in increased 
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Figure 33. The effects of Odc deletion in macrophages are due to putrescine depletion. (a) 
Measurement of polyamine levels in BMmacs 6 h and 24 h p.i. with H. pylori PMSS1 by mass 
spectrometry. ***P<0.001 by one-way ANOVA with Newman-Keuls post-test. n = 3-4 mice per 
genotype. (b) mRNA levels of M1 cytokines Il1b, Tnfa, and Nos2 were assessed by RT-PCR in 
BMmacs 24 h p.i. with H. pylori PMSS1 ± 25 mM putrescine added 60 min prior to infection. (c) 
Measurement of NO2– from BMmac supernatants 24 h p.i. with H. pylori PMSS1 ± 25  µM putrescine 
added 60 min prior to infection. (d) mRNA levels of the M2 cytokine, Tgfb1, were assessed by RT-PCR 
in BMmacs 24 h p.i. with H. pylori PMSS1 ± 25 µM putrescine added 60 min prior to infection. In (b-d),  
**P<0.01, ***P<0.001 vs. Odcfl/fl + PMSS1; @@P<0.01, @@@P<0.001 vs. Odcfl/fl + PMSS1 + 
putrescine; §§P<0.01, §§§P<0.001 vs. Odc∆mye + PMSS1 by one-way ANOVA with Newman-Keuls 
post-test. n = 4 biological replicates. Data displayed as mean ± S.E.M. 	  
100
	  putrescine levels and decreased spermine levels in Odcfl/fl BMmacs at 24 h p.i. (Figure 33A), indicating 
that infection can modulate polyamine metabolism. 
We hypothesized that addition of excess putrescine to the Odc∆mye BMmacs would serve to 
complement the deletion of Odc and reverse the enhanced M1 activation during H. pylori infection. 
Indeed, H. pylori-stimulated expression of Nos2, Il1b, and Tnfa in Odc∆mye BMmacs was no longer 
statistically increased compared to Odcfl/fl BMmacs when putrescine was added to the cells (Figure 
33B). Moreover, the addition of putrescine significantly reduced NO production from infected Odc∆mye 
BMmacs, such that it was no longer significantly higher than NO production from Odcfl/fl BMmacs 
(Figure 33C). Putrescine had no effect on gene expression in Odcfl/fl BMmacs (Figure 33B, 33C, 33D). 
Intriguingly, the addition of putrescine had no effect on M2 macrophage activation (Appendix C, Figure 
13), beyond its effect on Tgfb (Figure 33D).  
 
ODC deletion in macrophages also enhances NLRP3-inflammasome activation. 
 IL-1β is the secreted effector protein of the NLR family, pyrin domain containing (NLRP) 3-
driven inflammasome189. As we observed enhanced Il1b gene expression, we hypothesized that ODC 
may also affect NLRP3-inflammasome activation. We first assessed mRNA levels of NLRP3-
inflammasome markers – Nlrp3 and caspase 1 (Casp1), in both gastric tissues and BMmacs from 
Odcfl/fl, Odc∆mye, and LysMcre/cre mice. As expected, Nlrp3 and Casp1 expression was significantly higher 
in Odc∆mye mice during H. pylori infection than in the control genotypes in both chronically-infected 
gastric tissue and acutely-infected BMmacs (Appendix C, Figure 14A and 14C). Additionally, the levels 
of total IL-1β in H. pylori-infected gastric tissues were significantly increased in Odc∆mye mice (Appendix 
C, Figure 14B). Both pro- IL-1β (Appendix C, Figure 14D) and secreted IL-1β (Figure 32C) levels were 
substantially higher in Odc∆mye BMmacs. The role of ODC in regulating NLRP3-inflammasome 
activation is also dependent upon putrescine production, as the addition of excess putrescine 
substantially decreased Nlrp3 and Casp1 expression in Odc∆mye BMmacs, such that expression was no 
longer statistically different than Nlrp3 and Casp1 levels in Odcfl/fl BMmacs (Appendix C, Figure 14E). 
These data indicate that the combination of increased expression of Il1b and NLRP3 inflammasome 
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  constituents are contributing to increased IL-1β levels. Moreover, IL-1β is a potent pro-inflammatory 
cytokine189 and thus may be substantially contributing to the enhanced histologic gastritis observed in 
Odc∆mye mice following chronic H. pylori infection.  
 
ODC deletion promotes histone modifications leading to euchromatin formation and 
transcription. 
 To this point, our studies have implicated ODC in macrophages as a major regulator of gastric 
inflammation, cytokine and chemokine production, and M1 macrophage activation. Overall, our data 
indicate that mice with Odc-deficient macrophages exhibit a substantial increase in pro-inflammatory 
gene transcription. Previous studies have demonstrated that both ODC and the polyamines generated 
have the ability to influence histone modifications and, therefore, regulate gene transcription190,191. To 
gain an understanding of the role of ODC in altering macrophage gene transcription in response to 
bacterial infection, we assessed histone modifications at histone 3, lysine 4 (H3K4), known to be found 
at enhancer regions192, as well as, H3K9, which is a specific residue known to mark global alterations in 
chromatin structure and gene transcription levels193. Specifically, H3K4 mono-methylation (H3K4me1) 
is associated with primed, active enhancers and upregulated transcriptional levels192. H3K9 acetylation 
(H3K9ac) is associated with euchromatin formation and increased gene expression, while H3K9 di-/tri-
methylation (H3K9me2/3) is associated with heterochromatin formation and decreased gene 
expression193. Under conditions of H. pylori infection, Odc∆mye BMmacs demonstrated significantly 
increased H3K4me1 and H3K9ac levels and decreased H3K9me2/3 levels versus Odcfl/fl BMmacs 
(Figure 34A and 34B), indicative of enhanced gene transcription and correlating with the observed 
alterations in macrophage activation patterns in the present study. Importantly, a marked increase in 
H3K9 acetylation was noted in CD68+ gastric macrophages from H. pylori-infected Odc∆mye mice versus 
H. pylori-infected Odcfl/fl mice (Figure 34C). Similar alterations in H3K9 acetylation and methylation 
were observed in C. rodentium-infected BMmacs (Appendix C, Figure 15). Intriguingly, these changes 
in H3K4me1, H3K9ac, and H3K9me2/3 levels only significantly occurred upon H. pylori or C. rodentium 
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Figure 34. Odc deletion in macrophages alters H3K4 and H3K9 modifications during H. pylori 
infection. (a) Representative western blot of H3K4me1, H3K9ac, and H3K9me2/3 levels in BMmacs 24 
h p.i. with H. pylori PMSS1. n = 3 biological replicates. (b) Densitometric analysis of H3K4me1, 
H3K9ac, and H3K9me2/3 levels in (a). *P<0.05, ***P<0.001 by one-way ANOVA with Newman-Keuls 
post-test. n = 3 biological replicates. (c) Representative immunofluorescence images of H3K9ac in H. 
pylori-infected gastric tissues 4 mo. p.i. Green = H3K9ac, Red = CD68, Blue = DAPI. Scale bars = 50 
µm. Boxed area indicates image shown at higher magnification. Scale bar = 10 µm. n = 3 biological 
replicates per genotype. Note that a cell is considered double positive if the cell surface is red and the 
nucleus is green. (d) Expression of Gapdh and Iap was assessed by RT-PCR in BMmacs from Odcfl/fl 
and Odc∆mye mice 24 h p.i. with H. pylori PMSS1 with subsequent ChIP with the denoted antibodies. 
*P<0.05. n = 3 biological replicates. (e) Expression of Il1b, Il6, Tnfa, and Nos2 promoter sequences 
was assessed by RT-PCR in BMmacs from Odcfl/fl and Odc∆mye mice 24 h p.i. with H. pylori PMSS1 with 
subsequent ChIP with the denoted antibodies. *P<0.05. n = 3 biological replicates. In (d) and (e), 
statistical significance was calculated by one-way ANOVA with Newman-Keuls post-test on square-root 
transformed data. Data displayed as mean ± S.E.M. 	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  infection, implying that the alterations in histone modifications are specific to the macrophage response 
to stimulation and not occurring during basal conditions. 
 As with the expression of markers of M1 macrophage and NLRP3-inflammasome activation, the 
addition of putrescine reversed the histone modifications in Odc∆mye BMmacs, such that they then 
resembled the H3K9ac and H3K9me2/3 levels in Odcfl/fl BMmacs during H. pylori infection (Appendix C, 
Figure 16). The addition of excess spermidine or spermine, the other two principal polyamines, did not 
change H3K9ac or H3K9me2/3 levels in either Odcfl/fl or Odc∆mye BMmacs (Appendix C, Figure 16), 
indicating that putrescine plays a more critical role in regulating histone modifications during H. pylori 
infection in macrophages. 
 To verify that the loss of ODC in macrophages was directly affecting transcription of the pro-
inflammatory M1 markers through H3K9 alterations- namely enhanced acetylation and diminished 
methylation, we performed chromatin immunoprecipitation (ChIP), followed by RT-PCR in Odcfl/fl and 
Odc∆mye BMmacs. ChIP was performed with both anti-H3K9ac and anti-H3K9me3 antibodies in order to 
assess gene expression during both chromatin modifications. Immunoprecipitation with an anti-H3K9ac 
antibody resulted in significantly increased glyceraldehyde 3-phosphate dehydrogenase (Gapdh) 
expression in H. pylori-infected Odc∆mye BMmacs (Figure 34D). Gapdh expression is a marker of 
transcriptionally active euchromatin194. Gapdh was not substantially immunoprecipitated with an anti-
H3K9me3 antibody (Appendix C, Figure 17A), consistent with this gene representing a maker of 
euchromatin rather than heterochromatin. Inversely, immunoprecipitation with an anti-H3K9me3 
antibody demonstrated significantly decreased expression of inhibitor of apoptosis (Iap), a marker 
indicative of heterochromatin195, in H. pylori-infected Odc∆mye BMmacs versus H. pylori-infected Odcfl/fl 
BMmacs (Figure 34D). Moreover, Iap was not markedly immunoprecipitated with an anti-H3K9ac 
antibody (Appendix C, Figure 16A). Myogenic differentiation 1 (Myod1) is indicative of transcriptionally 
inactive euchromatin194 and was unchanged between genotypes with immunoprecipitation with either 
antibody (Appendix C, Figure 17B). Taken together, these data demonstrate that the loss of ODC leads 
to an enhancement in transcriptionally active euchromatin levels during infection and a decrease in 
heterochromatin levels, which would result in enhanced gene transcription. 
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   To test if alterations in chromatin modifications were specifically altering pro-inflammatory gene 
expression, we also assessed Il1b, Il6, Tnfa, and Nos2 promoter levels by ChIP-PCR. Il1b, Il6, Tnfa, 
and Nos2 promoter levels were significantly increased in Odc∆mye BMmacs versus Odcfl/fl BMmacs 
during H3K9ac immunoprecipitation (Figure 34E), and were not significantly immunoprecipitated with 
an anti-H3K9me3 antibody (Appendix C, Figure 18). Taken together, these data verify that chromatin 
alterations during Odc deletion in macrophages drive enhanced pro-inflammatory gene expression, 
which then contributes to increased immune cell activation, exhibited as enhanced histologic gastritis 
that leads to diminished H. pylori bacterial burden. 
 
ODC driven histone modifications are essential for alterations in M1 macrophage activation. 
 Finally, to determine if histone modifications, specifically methylation and acetylation events, are 
the mechanism by which the loss of ODC alters M1 macrophage activation, we utilized pharmacological 
inhibitors of histone methylation and acetylation in Odcfl/fl and Odc∆mye BMmacs and assessed 
expression of M1 macrophage activation markers.  
BIX 01924 is a selective inhibitor of euchromatic histone lysine methyltransferase 2 (EHMT2; 
also known as G9a histone methyltransferase), which is known to interact specifically with H3K9196. We 
hypothesized that inhibition of EHMT2 would remove the inhibitory methylation present in Odcfl/fl 
BMmacs, leading to increased expression of M1 macrophage activation markers. Indeed, BIX 01924 
treatment resulted in significantly increased Il1b, Tnfa, and Nos2 expression in Odcfl/fl BMmacs during 
H. pylori infection (Figure 35A). As expected, treatment with BIX 01924 did not significantly alter M1 
marker expression in Odc∆mye BMmacs (Figure 35A). Moreover, BIX 01924 treatment did not alter M2 
macrophage activation marker expression in either genotype (Appendix C, Figure 19A). These data 
further support the concept that that the loss of ODC in the Odc∆mye BMmacs allowed for potentiation of 
M1 marker expression by relieving the methylation of H3K9, therefore leading to increased immune 
response and gastric inflammation. 
Anacardic acid is a selective inhibitor of lysine acetyltransferase 2A (KAT2A; also known as 
GCN5), which has been previously shown to interact with H3K9197. Inhibition of KAT2A significantly 
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Figure 35. Alterations in histone modifications and chromatin structure in ODC-deficient 
macrophages alters M1 macrophage activation during H. pylori infection. (a) mRNA levels of pro-
inflammatory cytokines Il1b, Tnfa, and Nos2 were assessed by RT-PCR in BMmacs 24 h p.i. with H. 
pylori PMSS1 ± 5 µM BIX 01924 added 60 min prior to infection. *P<0.05, **P<0.01, ***P<0.001 by 
one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. n = 5 mice per genotype. 
(b) mRNA levels of pro-inflammatory cytokines Il1b, Tnfa, and Nos2 were assessed by RT-PCR in 
BMmacs 24 h p.i. with H. pylori PMSS1 ± 10 µM anacardic acid added 60 min prior to infection. 
***P<0.001 by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. n = 5 mice 
per genotype. Data displayed as mean ± S.E.M. 	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  reduced M1 marker expression in Odc∆mye BMmacs, such that expression was similar to M1 marker 
expression in Odcfl/fl BMmacs during H. pylori infection (Figure 35B). Anacardic acid treatment did not 
alter M1 marker gene expression in H. pylori-infected Odcfl/fl BMmacs (Figure 35B). Additionally, 
anacardic acid did not alter the expression of M2 macrophage markers, again indicating that the role of 
ODC in regulating histone modifications is specific to the M1 response (Appendix C, Figure 19B).  
Taken together, these studies demonstrate that loss of ODC in macrophages leads to an M1 
response that is driven by ODC/putrescine-mediated histone modifications that alter chromatin 
structure and the capacity for active gene transcription. This increased M1 response is a key 
orchestrator of the increased gastric inflammatory response. 
 
5.3 Discussion 
ODC and polyamines have been well studied in epithelial cells within the context of cancer and 
in macrophages within the context of parasitic and fungal infections. The present study now reveals a 
novel mechanism by which ODC and its product, putrescine, regulate M1 macrophage activation via 
alterations of histone modifications to directly alter pro-inflammatory gene expression during bacterial 
infection (Figure 36). We demonstrate that loss of ODC in macrophages has profound effects on M1 
macrophage activation and thus, on the pathogenesis of both H. pylori and C. rodentium in mice. We 
further demonstrate that deletion of ODC leads to alterations in H. pylori survival during gastric 
infection, implicating ODC in macrophages as a mediator of bacterial persistence within a host. This is 
a critical advancement of our understanding of the immune privilege that is associated with this 
particular infection, as long-term persistence is the hallmark of H. pylori infection and is directly linked to 
damaging inflammation and increased cancer risk9,40,111. 
  ODC is detectable in abundance in human gastric myeloid cells during H. pylori infection, 
indicating the potential importance of the enzyme in regulating the host response to the pathogen47. 
Previous studies demonstrated that pharmacologic inhibition of ODC with DFMO diminished both 
inflammation and H. pylori colonization in mice47,186, although it should be noted that we have shown 
that DFMO can have direct inhibitory effects on H. pylori186.  Based on the robust induction of ODC in 
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Figure 36. Summary of findings related to ODC in macrophages during H. pylori infection. The 
production of the polyamines – putrescine, spermidine, and spermine – is tightly regulated. Solute 
carrier family 7, member 2 (SLC7A2) imports L-arginine into cells. L-arginine is converted to L-ornithine 
by arginase 2 (ARG2). Ornithine decarboxylase (ODC) converts L-ornithine to putrescine. Putrescine is 
converted to spermidine and spermine by spermidine synthase (SRM) and spermine synthase (SMS), 
respectively. H. pylori infection leads to the induction of ODC via mitogen activated kinase (MAPK) 1/3 
(ERK1/2) signaling. ODC-mediated putrescine production alters the modifications on lysine (K) 4 and 
K9 of histone 3 (H3). Putrescine leads to the replacement of H3K4 mono-methylation (me1) and H3K9 
acetylation (ac), which activate transcription, with H3K9 di-/tri-methylation (me2/3), which represses 
transcription. The increase in H3K9me2/3, and decrease in H3K4me1 and H3K9ac leads to diminished 
M1 gene expression. Decreased M1 gene expression leads to decreased gastritis, allowing for H. pylori 
survival. Persistent H. pylori infection and chronic active gastritis creates a vicious cycle, leading to 
gastric cancer. 
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  macrophages during H. pylori infection95, we anticipated that myeloid-specific deletion of ODC might 
result in decreased inflammation and decreased colonization. However, we observed significantly 
increased inflammation, accompanied by a reduction in H. pylori colonization.  We attribute this finding 
to dramatically enhanced M1 macrophage activation, upregulated cytokine and chemokine expression, 
and significantly increased production of NO, which is a potent anti-microbial mediator. Clearly, ODC 
expression in macrophages actually impairs the host response. The ability of H. pylori to upregulate 
ODC, via MAPK1/3 and MYC signaling95,97, is advantageous for the creation of a less inflammatory 
environment in which the pathogen can establish a persistent infection. However, even in the tolerant 
environment, persistent infection is still accompanied by chronic inflammation, leading to increased risk 
for gastric cancer40,41,111. Thus, inhibition of ODC may prove to be a potential target to enhance the 
clearance of long-term infection. 
 C. rodentium-infected Odc∆mye mice also had substantially increased disease severity, again 
attributable to increased M1 macrophage activation. Several previous studies have demonstrated that 
the severity of colitis is positively correlated with C. rodentium colonization113,187,198,199. The fact that 
colonization was not different in our model, despite increased colitis, potentially indicates that 
colonization was actually impaired, as we would have expected increased colonization accompanying 
increased colitis. The concordance in macrophage activation patterns and histologic inflammation 
between the H. pylori and C. rodentium models in our study, combined with the studies with classical 
M1 and M2 stimuli, indicate that the role of ODC in macrophages is broadly applicable across various 
models of mucosal inflammation and is an important mediator of general macrophage activation and 
biology in mice and humans. 
 ODC serves as such a potent mediator of macrophage function via its role in the alteration of 
chromatin structure and gene transcription. ODC and polyamines are known to modulate chromatin 
modifications, DNA stability, and gene expression90,92,93. However, we have now demonstrated for the 
first time that ODC and polyamines have the ability to directly regulate the expression of pro-
inflammatory genes within the context of bacterial infections. This is a critical expansion of our 
understanding of macrophage activation and function. Putrescine is the product of the enzymatic 
110
	  conversion of L-ornithine by ODC. In our study, putrescine, but not spermidine or spermine, was 
capable of reversing the activation patterns observed in Odc∆mye BMmacs infected with either H. pylori 
or C. rodentium. These studies indicate that putrescine is a potent regulatory molecule in macrophage 
activation. Further studies are required to determine the mechanism by which putrescine modulates 
histone modifications. 
 In summary, our work outlines a new role for ODC in regulating macrophage activation during 
bacterial infections. ODC is a well-known mediator of cancer risk across various types of cancer, 
including gastric and colorectal cancers91,177-180. Importantly, chronic inflammation contributes to the 
process of carcinogenesis and we now implicate ODC as having a role in the establishment of chronic 
inflammation by tempering the M1 macrophage response to bacterial pathogens. A novel finding in the 
current study is that these phenotypes are due to the alteration of chromatin structures by modifications 
of putrescine levels within macrophages. These studies provide further impetus for studies related to 
the role of ODC in macrophages as a potential pathway to better understanding the etiology, 
prevention, and treatment of inflammatory diseases and associated cancer risk. 
 
5.4 Materials and Methods 
 
Reagents 
All reagents used for cell culture were from Invitrogen (Carlsbad, CA, USA). Reagents for RNA 
extraction are from Qiagen (Valencia, CA, USA). Reagents for cDNA synthesis and RT-PCR were 
purchased from Bio-Rad (Hercules, CA, USA). The following reagents were obtained from PeproTech 
(Rocky Hill, NJ, USA): murine recombinant M-CSF; murine recombinant IFN-γ; murine recombinant IL-
4. The following reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA): LPS from 
Escherichia coli O111:E4; anacardic acid (2-hydroxy-6-pentadecylbenzoic acid, 6-pentadecylsalicylic 
acid); putrescine; spermine; spermidine; putrescine-d4 (1,4-diaminobutane-2,2,3,3-d4 dihydrochloride); 
spermidine-d8 (spermidine-(butane-d8) trihydrochloride); and spermine-d8 (spermine-(butane-d8) 
tetrahydrochloride). Dansyl chloride was obtained from Acros Organics (Geel, Belgium). BIX01924 (2-
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  (hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-N-[1-(phenylmethyl)-4-piperidinyl]-4-
quinazolinamine trihydrochloride) was obtained from Fisher Scientific (Waltham, MA, USA).  
 
Antibodies 
See Appendix C, Table 2 for information regarding antibodies utilized for this study. 
 
Bacteria, Cells, Culture Conditions, and Infections 
Helicobacter pylori PMSS1 and SS1 were cultured as previously described in Chapter 2. C. rodentium 
was cultured as previously described in Chapter 2. 
 
BMmacs were isolated and differentiated as previously described in Chapter 2. THP1 cells were utilized 
as described in Chapter 2. 
 
All pharmacological inhibitors (except DFMO) or polyamines were added 1 h before infection. Cells 
were infected at a MOI of 100 for H. pylori studies and at a MOI of 10 for C. rodentium studies. All 
infection studies were performed with live bacteria. 
 
Animal Studies 
Odcfl/fl mice were generated and provided by John L Cleveland (Moffitt Cancer Center) Odc∆mye mice 
were generated by crossing Odcfl/fl mice with LysMcre/cre mice from our stock of breeding colonies. 
Animals were used under protocol M/10/155, approved by the IACUC at Vanderbilt University. 
 
All in vivo H. pylori studies were performed as described in Chapter 2. 
 
On rare occasions, Odc∆mye and LysMcre/cre mice would develop a substantially enlarged spleen that was 
not attributable to H. pylori or C. rodentium infection, as control mice would also manifest this condition. 
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  If marked splenomegaly was observed at time of sacrifice, that mouse was excluded from further 
analysis. 
 
Real-Time PCR 
RNA isolation, cDNA synthesis, and RT-PCR were performed as described in Chapter 2. See Appendix 
C, Table 3 for primers utilized in this study. 
 
Western Blot Analysis 
Western blot analysis was performed as previously described in Chapter 2. See Appendix C, Table 2 
for all antibodies used in this study with accompanying information regarding dilutions utilized. 
 
Luminex Multiplex Array 
Luminex Multiplex Array was performed as previously described in Chapter 2. 
 
ELISAs 
The following R&D DuoSet ELISA kits were utilized for cytokine measurements: IL-1β (DY401), TNF-α 
(DY410), IL-6 (DY406), IL-12p70 (DY419), IL-10 (DY417), and TGF-β (DY1679). All ELISAs were 
performed according to kit instructions. 
 
Measurement of Nitric Oxide 
The concentration of the oxidized metabolite of NO, nitrite (NO2—) was assessed by the Griess reaction 
as previously described in Chapter 2. 
 
DFMO Studies in THP1 Cells 
THP1 cells were treated with 5 mM DFMO in T-75 flasks for 3 or 5 days. Cells were then counted, 
plated, and treated with 10 ng/mL PMA for 18 h to differentiate the cells into macrophages. 5 mM 
DFMO was maintained in the media during PMA treatment. Following differentiation, cells were place in 
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  antibiotic-, PMA-, and DFMO-free media and infected with H. pylori PMSS1 (MOI = 100) for 6 h. All 
RNA and protein assays were performed as described above.  
 
Immunofluorescence Staining for ODC, CD68, and H3K9ac in Murine Tissues 
Immunofluorescence staining for ODC, CD68, and H3K9ac in murine tissues was performed utilizing a 
staining protocol that was previously described143, with the following alterations. As the source for each 
of the three antibodies is rabbit, tissues were blocked with 5% goat serum and rabbit Fab fragment for 
30 minutes at room temperature following incubation in primary and secondary antibodies for either 
ODC or H3K9ac prior to incubation with anti-CD68. A secondary anti-rabbit antibody with an Alexa488 
tag was utilized. Slides were imaged using a SPOT RT slider camera system (Diagnostic Instruments, 
Inc., Sterling Heights, MI, USA) on a Nikon E800 microscope (Nikon, Inc. Melville, NY, USA). Images 
were all modestly adjusted in ImageJ with the brightness and contrast tool. 
 
Immunoperoxidase Staining for ODC 
Staining for ODC in human gastric biopsies was performed as previously described47. 
 
Immunofluorescence Staining for ODC and CD68 Human Tissues 
Immunofluorescence staining for ODC and CD68 in human tissues was performed utilizing a staining 
protocol that was previously described143. Quantification of CD68+ODC+ and CD68+ODC– cells was 
performed by four blinded observers and the scoring was averaged. 
 
Human Tissues 
De-identified human gastric samples from Colombia were obtained and utilized as previously 
described143. All patients participating in studies in Colombia were enrolled with informed consent, and 
the de-identified coded tissues were provided under nonhuman exemptions approved by the Vanderbilt 
University Institutional Review Board. 
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  Purification of gastric epithelial cells and gastric macrophages 
Purification of gastric epithelial cells and gastric macrophages was performed as previously 
described143.  
 
Measurement of Polyamines 
All studies related to polyamine measurements were conducted in serum-free media. Putrescine, 
spermidine, and spermine were quantified by LC-MS using a Thermo TSQ Vantage Triple Quadrupole 
instrument operated in positive ion mode. Cell pellets were extracted using acetonitrile/20 mM NH4OAc 
pH 8 (70:30). Extracts were derivatized by reaction with 20 mM dansyl chloride in 100 mM NaHCO3 pH 
10 for 20 min. Polyamines were quantified using deuterated internal standards d4-putrescine, d8-
spermidine, and d8-spermine. 
 
ChIP-PCR 
Chromatin immunoprecipitation (ChIP) was performed utilizing the EpiTect Chip ChIP-Grade Antibody 
Kit – H3K9ac (Qiagen, cat. no. GAM-1209) and the EpiTect Chip ChIP-Grade Antibody Kit – H3K9me3 
(Qiagen, cat. no. GAM-6204). All reagents were provided in the EpiTect Chip One-day Kit (Qiagen, cat. 
no. 334471). All kit instructions were followed as stated, including PCR master mix set-up and 
recommended PCR protocol. Primers for Gapdh and Myod1 were provided with the ChIP antibody kits 
listed above. Primers for Il1b, Il6, Tnfa, and Nos2 promoter sites are listed in Appendix C, Table 3. 
 
Statistical Analysis 
All the data shown represent the mean ± S.E.M. At least three biological replicates were performed for 
all studies utilizing cell culture. Where data was normally distributed, two-tailed Student’s t test was 
used to determine significance in experiments with only two groups, and one-way ANOVA with the 
Newman-Keuls test was used to determine significant differences between multiple test groups. In 
cases where data were not normally distributed, a one-way ANOVA with Kruskal-Wallis test, followed 
by a Mann-Whitney U test, was performed, unless otherwise noted. All statistics were performed in 
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  GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). A P value of < 0.05 was considered 
to be significant. 
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CHAPTER 6 
 
SUMMARY, FUTURE DIRECTIONS, AND FINAL CONCLUSIONS 
 
 Macrophages represent an extremely diverse subset of innate immune cells, with functions 
spanning the gamut from development to immune surveillance and clearance of pathogens to 
maintenance of tissue homeostasis. Macrophages fill a highly necessary niche within mammalian life, 
but when left uncontrolled can contribute to malignancies. As this dissertation has demonstrated, the 
mechanisms by which macrophage activation is controlled are of significant importance in furthering our 
understanding of disease pathology, both within the context of bacterial infections and carcinogenesis. 
Clearly, both EGFR and ODC have profound, but opposite, roles in regulating macrophage activation 
across various stimuli. The overall findings of this dissertation are outlined in Figure 37 and described in 
more detail in the subsequent sections. 
 
6.1 Summary and Future Directions  
 Chapter 2 outlined the role of EGFR signaling in the regulation of macrophage activation and 
function during bacterial infections. H. pylori is one of the most prevalent and successful human 
pathogens and the single greatest risk factor for gastric cancer, and macrophages are an essential 
component of H. pylori pathogenesis. As such, the study of macrophage activation within this context is 
especially important. EGFR signaling proved to be critical for M1 and Mreg activation during H. pylori 
infection, and for M2 activation during stimulation with IL-4. Importantly, EGFR signaling was also 
important in macrophage activation during C. rodentium infection and treatment with known 
macrophage stimuli (IFN-γ, LPS, IL-4, and IL-10).  
The studies presented in Chapter 2 have revealed a profound role of EGFR signaling in 
macrophages during both bacterial infection and carcinogenesis. Yet, many questions remain 
unanswered and further studies are required to better understand the role of EGFR signaling in 
macrophages. 	  
 
 
 
 
 
 
 
 
Figure 37. Summary of the main findings of this dissertation. A. Epidermal growth factor receptor 
(EGFR) signaling is initiated during both H. pylori infection and colon carcinogenesis. Phosphorylation 
occurs at tyrosine (Y) 1068 via a ligand-dependent mechanism and at serine (S) 1046/47 via a ligand-
independent mechanism. EGFR signaling then induces mitogen-activated protein kinase (MAPK) 1/3 
signaling, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, and Signal 
transducer and activator of transcription (STAT) 6 signaling, depending upon the cytokine 
milieu/stimulus detected. MAPK1/3 signaling and NF-κB signaling lead to M1 activation and STAT6 
signaling leads to M2 activation. M1 activation contributes to the establishment of a persistant 
inflammatory state, while M2 activation enhances angiogenesis. The combination of M1 and M2 
activation contribute to carcinogenesis. B. H. pylori infection leads to the induction of ornithine 
decarboxylase (ODC). ODC converts L-ornithine into putrescine, one of the three main polyamines. 
Putrescine alters histone 3 (H3) modifications by an unknown mechanism. In putrescine replete 
conditions, H3 has abundant di-/tri-methylation (me2/3) on lysine 9 (K9), while H3K4 mono-methylation 
(me1) and H3K9 acetylation (ac) are not present. This combination of histone modifications leads to 
decreased M1 activation because of decreased transcription of pro-inflammatory genes. A diminished 
M1 response leads to bacterial persistence and reduced, but not absent, gastritis in vivo. 
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  While the role of EGFR in regulating macrophage activation is clear, the activation of EGFR 
signaling in macrophages remains largely unknown. Our studies have implicated both ligand-
independent activation of EGFR signaling through TNF-α signaling (Figure 8G) and ligand-dependent 
signaling via an unknown mechanism. Further studies are required to better understand the mechanism 
by which EGFR transactivation occurs. Canonical EGFR signaling is mediated by one of seven known 
ligands62. Our studies have demonstrated that EGF and HB-EGF do not lead to significant 
phosphorylation at Y1068, the marker of canonical activation. However, further studies with the five 
remaining ligands need to be performed. To determine if bacterial or host factors are necessary to 
activate EGFR signaling, supernatants from cultures of H. pylori, macrophages, and epithelial cells can 
be applied to macrophages to determine if soluble constituents from either bacterial or host cells are 
necessary for activation. Phospho-peptide mapping by mass spectrometry can be performed to gather 
unbiased data regarding EGFR phosphorylation at various tyrosines, serines, and threonines to better 
inform further studies related to EGFR transactivation. 
Furthermore, future studies related to the role of EGFR signaling in gastric cancer are 
necessary. The AOM-DSS model of colon carcinogenesis is a highly tractable model used routinely in 
many laboratories. However, few models exist in which to interrogate gastric cancer in mice. The 
Mongolian gerbil model of gastric cancer is not feasible to study the role of EGFR signaling in 
macrophages, as cell-specific tools and reagents do not exist. Thus, our laboratory is working to create 
an FVB/N insulin-gastrin (INS-GAS) mouse strain that carries the myeloid-specific Egfr deletion (INS-
GAS:Egfr∆mye). INS-GAS mice are a model of hypergastrinemia that results in hyperplasia, dysplasia, 
and occasionally gastric carcinoma200. Currently, the Egfr∆mye mice are being crossed with WT FVB/N 
mice to ensure the mice are on the correct background. Once the background alteration is 
accomplished, FVB/N Egfr∆mye will be crossed with FVB/N INS-GAS mice, and appropriate controls will 
be derived from the INS-GAS:Egfr∆mye mice. Once all necessary genotypes are created, chronic H. 
pylori infections will be initiated and endpoint parameters of histologic gastritis, hyperplasia, dysplasia, 
and carcinoma will be assessed. These studies will definitively address questions related to the role of 
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  EGFR signaling in macrophage in gastric carcinogenesis. However, these studies are several years 
away due to the complicated nature of the mouse strains being created. 
Beyond bacterial infection, Chapter 3 demonstrated that EGFR signaling in macrophages had a 
significant role in colon carcinogenesis, even more so than EGFR signaling in epithelial cells, the 
canonical cell type in which EGFR signaling is studied. Taken together, these data indicate that EGFR 
is a master regulator of macrophage biology. This has broad implications in our understanding of the 
etiology of inflammation-mediated diseases. However, our understanding of the role of EGFR in 
regulation of macrophage activation in human macrophages in vivo remains extremely limited. 
Thus, further studies linking EGFR signaling, macrophage activation, and carcinogenesis in 
humans are necessary. We plan to perform serial sectioning of gastric and CAC TMAs available at 
Vanderbilt University Medical Center. Sections will be stained for CD68 and pEGFR or NOS2 (M1 
marker) or ARG1 (M2 marker) for immunofluorescence imaging on the Ariol platform. Following 
imaging, CellProfiler will be utilized to quantify CD68+pEGFR+ macrophages, M1 macrophages, and M2 
macrophages in each section. Correlations can then be made between the level of EGFR signaling in 
macrophages and the activation state of macrophages in both gastric and colon cancers. Moreover, 
primary human blood monocyte-derived macrophages can be studied in vitro to further elucidate the 
role of EGFR signaling in human macrophages. These studies would serve to begin to address the role 
of EGFR signaling in macrophage activation in humans during carcinogenesis and may provide 
biomarkers for stratification of cancer risk or therapeutic targets for intervention during cancer. 
 Chapter 4 represents the newest direction of research related to the role of EGFR signaling in 
macrophages. SILAC analysis allowed for an unbiased and global view of signaling pathways that are 
affected by EGFR in macrophages. While these studies are still in an early stage, they may prove 
highly informative and may produce novel therapeutic targets for intervention in inflammatory diseases. 
Once more bioinformatic analyses are complete, future studies will be focused on elucidating the 
mechanism by which EGFR signaling modulates candidate pathways and how those pathways 
contribute to the regulation of macrophage activation and function. 
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   The overarching theme of this dissertation was to elucidate mechanisms by which macrophage 
activation is regulated. EGFR signaling is now known to be a pro-inflammatory pathway, enhancing M1 
macrophage activation. However, Chapter 5 demonstrated that the role of ODC and polyamines is to 
downregulate M1 macrophage activation during H. pylori and C. rodentium infection and promote an 
anti-inflammatory response in vivo. For the first time, ODC, and its product, putrescine, were 
demonstrated to directly regulate the transcription of pro-inflammatory genes by modulating histone 
structure. ODC has been widely studied within the context of carcinogenesis, but not within bacterial 
infection. These findings demonstrate the profound effect that polyamines have on macrophage 
function, which should be extended to other inflammation-mediated diseases, including cancer. ODC is 
already a known therapeutic target in the treatment of cancer, but these studies suggest that ODC 
inhibition could be useful in the treatment of diseases, like persistent bacterial infections, which require 
a more potent pro-inflammatory and anti-microbial response. While the studies presented within 
Chapter 5 have elucidated a novel role for ODC and polyamines in the regulation of macrophage 
activation, several unanswered questions remain. 
 Firstly, ODC is the rate-limiting enzyme for synthesis of putrescine from L-ornithine. Putrescine 
can then be converted into spermidine and spermine. It was surprising that only the addition of excess 
putrescine, and not spermidine or spermine, was able to complement phenotypes related to gene 
expression and histone modifications in Odc∆mye BMmacs. The in vivo relevance of this finding remains 
unclear. Thus, chronic H. pylori SS1 infections in Odcfl/fl and Odc∆mye mice should be performed with 
and without putrescine supplementation. There is one previous study that utilized a 1% putrescine 
solution in the drinking water to provide mice with excess putrescine201. Such a study could be 
performed in our model of H. pylori infection to confirm the critical role for putrescine specifically in 
regulating macrophage activation. It would also be interesting to conduct studies in which the 
polyamine content of the diet is highly controlled. Our laboratory is currently using defined diets with 
varying levels of L-arginine which is upstream of polyamine synthesis and observing substantial effects 
on C. rodentium-induced colitis. A diet with defined polyamines could potentially be synthesized for 
these studies. 
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   Moreover, the exact mechanism by which putrescine leads to alterations in histone 
modifications is unknown. It is important to know what proteins putrescine interacts with, and where 
those proteins are within the cell. I propose treating macrophages with radiolabeled putrescine, 
infecting with H. pylori across a time course, and then extracting protein lysates from control and 
infected cells. Following extraction of the protein lysate, mass spectrometry could be utilized to identify 
proteins that are interacting with the radiolabeled putrescine. Follow-up studies can be performed on 
relevant identified proteins to better understand the mechanism by which putrescine is influencing 
histone modifications and gene expression.  
 Thirdly, the study presented in Chapter 5 was limited to macrophages and no questions were 
addressed related to the interaction between ODC-deficient macrophages and adaptive immune cells. 
GLNs and isolated gastric CD4+ T cells from chronically infected mice can be utilized to interrogate the 
role of ODC and polyamine production in macrophages in the initiation and establishment of T helper 
responses in the stomach. These studies will provide critical information regarding the relationship 
between macrophages and T cells in the context of polyamine metabolism. 
 Finally, the role of ODC in macrophages in carcinogenesis remains unknown. C. rodentium 
infection in Odc∆mye mice resulted in exacerbated colitis (Appendix C, Figure 5), providing a rationale for 
utilization of the AOM-DSS model of colitis-associated carcinogenesis in these mice. I hypothesize that 
the enhanced M1 macrophage activation noted in the C. rodentium model will translate to enhanced 
tumorigenesis, as the loss of M1 activation proved to be protective in the Egfr∆mye AOM-DSS studies. 
Alternatively, the enhanced M1 response in ODC deficient macrophages may prove to be anti-
tumorigenic. Clearly, these are questions that need to be addressed further. 
 
6.2 Final Conclusions 
 While pro-inflammatory EGFR and anti-inflammatory ODC represent opposite sides of the 
spectrum in controlling macrophage activation, these studies leave the clear impression that there is 
much knowledge to be gained about macrophage biology. EGFR and ODC are both highly studied 
proteins in epithelial cells, but the studies presented herein have only begun to scratch the surface of 
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their roles in macrophage biology. Further investigation is needed to better delineate the roles of each 
of these proteins in the regulation of macrophage function within every niche in which macrophages 
operate. Ultimately, these studies could lead to novel therapeutic targets to better treat and potentially 
prevent inflammation-mediated diseases and their long-term sequelae, especially carcinoma, in 
humans. 
As the studies in this Chapters 2-4 have made clear, EGFR signaling robustly occurs within 
macrophages under various conditions, and this signaling has profound effects on macrophage 
activation and function. Given the ubiquitous nature of EGFR signaling in other cell types and the 
central role of this signaling pathway in many disease states, EGFR signaling in macrophages should 
be a topic of intense study. Moreover, the data presented in these chapters demonstrate that EGFR 
signaling in macrophages is as critical for disease progression – especially in CAC – as signaling within 
epithelial cells.  
ODC is equally as central to life and cellular function as EGFR and polyamine metabolism has 
been widely studied for decades, and polyamines are known to have ubiquitous effects on cellular 
function84,85. The studies presented in Chapter 5 provide novel insight into the role of ODC and its 
product, putrescine, in the regulation of macrophage activation at the transcriptional level. Polyamines 
have been known to influence transcription for some time90,92,93, but this is the first instance where such 
regulation has relevance in bacterial infection models and across various known macrophage stimuli. 
These data provide evidence that polyamine metabolism is a key regulator of macrophage function, 
which could be relevant in many disease models that involve persistent inflammation.  
As our understanding of carcinogenesis has improved, the role of inflammation has come to the 
forefront7-9,82,133,134,136,160,202. Macrophages contribute significantly to inflammation because they serve as 
both initiators of innate immune responses and recruit adaptive immune cells in order to establish 
chronic inflammation7. Advances in our understanding of the regulation of macrophage activation and 
function may identify potential points of chemotherapeutic intervention in persons with chronic 
inflammatory states. Controlling inflammation may be the key to prevent both gastric and colorectal 
cancers,     especially     as    the    risks     both     are   significantly     augmented    by    chronic     inflammatory 
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states8,9,133,135,202.  EGFR and ODC represent two halves of the same question in that EGFR promotes 
M1 macrophage activation, while ODC tempers M1 macrophage activation. The data presented herein 
provide a compelling rationale for further studies related to proteins that are not traditionally thought to 
be mediators of macrophage activation and function. Perhaps by expanding our perception of what is 
thought to be relevant within immune cells, as opposed to other cell types, we may gain a better 
understanding of the etiology, prevention, and treatment of inflammatory diseases and associated 
cancer risk. 
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Appendix A, Figure 1. Mononuclear cells in human gastritis tissues have high levels of 
pEGFR. Representative image of a gastric tissue core from the Vanderbilt University Medical 
Center human tissue microarray (TMA) assessed for pEGFR expression by 
immunoperoxidase staining. Middle and right images are magnifications of the area in the 
yellow box in the left image. Yellow arrows indicate pEGFR+ mononuclear cells. Scale bars = 
100 µM. n = 41 gastritis samples. 
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Appendix A, Figure 2. CD68+pEGFR+ macrophages are present in human cases of 
gastric cancer. (A) Representative hematoxylin and eosin (H&E) and immunofluorescence 
images for cases of intestinal type and diffuse type gastric adenocarcinoma from the 
Vanderbilt University Medical Center human TMA. Red = CD68, Green = EGFR pY1068, 
Yellow = merge and Blue = DAPI. Scale bars = 50 µM. White arrows indicate CD68+pEGFR+ 
macrophages. n = 12 normal samples, 35 intestinal-type cancer, and 35 diffuse-type cancer. 
(B) Quantification of the percentage of CD68+pEGFR+ macrophages per the total number of 
cells in each individual core. **P < 0.01, ***P < 0.001 vs. Normal. n = 12 normal samples, 35 
intestinal-type cancer, and 35 diffuse-type cancer. (C) Quantification of the percentage of 
CD68+pEGFR+ macrophages per the total number of CD68+ cells in each individual core. *P < 
0.05. n = 12 normal samples, 41 gastritis samples, 11 intestinal metaplasia samples, 35 
intestinal-type cancer, and 35 diffuse-type cancer. In (B) and (C), statistical significance was 
calculated by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. 
Note: The “Normal” data displayed in Panels B and C is the same “Normal” data as in Figure 
1D, since there was only one set of normal biopsies on the TMA. 
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Appendix A, Figure 3. pEGFR levels in CD68+ macrophages and CD68— cells are 
correlated in pre-cancerous stages, but not during cancer. (A) Quantification of the 
percentage of CD68—pEGFR+ cells per the total number of cells in each individual core from 
the TMA utilized in Figure 1 and in Appendix A, Figures 1 and 2. *P < 0.05, **P < 0.01. 
Statistical significance was calculated by one-way ANOVA with Kruskal-Wallis test, followed by 
Mann-Whitney U test. (B) Overall correlation between CD68+pEGFR+ macrophages and 
CD68—pEGFR+ cells; data are from all cores in the TMA. (C) Correlation between 
CD68+pEGFR+ macrophages and CD68—pEGFR+ cells in each core in cases within the same 
histologic stage of disease. Correlation in (B) and (C) was calculated using the Spearman’s 
rank correlation coefficient. In all panels, n = 12 normal samples, 41 gastritis samples, 9 
intestinal metaplasia samples, 35 intestinal-type cancer, and 35 diffuse-type cancer. 
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Appendix A, Figure 4. EGFR phosphorylation in macrophages is ligand-independent 
and TNF-α dependent at the pS1046/47 residue. (A) Representative western blot of EGFR 
pS1046/47 in RAW 264.7 cells at 30 min p.i. ± anti-TNF-α neutralizing antibody (10 ng/mL) 
with H. pylori PMSS1 infection. Recombinant murine TNF-α (20 ng/mL) also stimulates 
pS1046/47 at 30 min post-stimulation. n = 3 biological replicates. (B) Densitometric analysis of 
the levels of pS1046/47 in (A). *P < 0.05 vs. uninfected, untreated control. §P < 0.05 vs. 
untreated, PMSS1-infected cells. n = 3 biological replicates. Statistical significance was 
calculated by one-way ANOVA with Newman-Keuls post-test. 
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Appendix A, Figure 5. Confirmation of EGFR deletion in Egfr∆mye bone marrow-derived 
macrophages and gastric macrophages before and after infection with H. pylori. (A) 
Representative DNA gel of PCR confirmation of Egfr excision in Egfr∆mye bone marrow-derived 
macrophages (BMmacs) 24 h post-infection (p.i.) with H. pylori PMSS1. n = 3 biological 
replicates. (B) Representative western blot confirming tEGFR knockdown in Egfr∆mye BMmacs 
24 h p.i. with H. pylori PMSS1. (C) Densitometric analysis of tEGFR levels from (B). **P < 0.01, 
***P < 0.001. Statistical significance was calculated by Student’s t test between uninfected 
Egfrfl/fl and Egfr∆mye BMmacs and between infected Egfrfl/fl and Egfr∆mye BMmacs. (D) 
Confirmation of tEGFR knockdown in F4/80+CD11b+ gastric macrophages (Gmacs) from 
Egfr∆mye mice 48 h p.i. with H. pylori SS1 by flow cytometry. ***P < 0.001. n = 3 uninfected and 
5 H. pylori SS1 infected mice per genotype. (E) Assessment of the total number of 
F4/80+CD11b+ Gmacs in the stomachs of Egfrfl/fl and Egfr∆mye mice from (D) by flow cytometry. 
***P < 0.001. n = 3 uninfected and 5 H. pylori SS1 infected mice per genotype. Statistical 
significance in (D) and (E) was calculated by one-way ANOVA with Newman-Keuls post-test. 
(F) Assessment of tEGFR levels in pan-cytokeratin+ gastric epithelial cells from the same 
Egfrfl/fl and Egfr∆mye mice in (D) and (E). n = 3 uninfected and 5 H. pylori SS1 infected mice per 
genotype. (G) Representative flow cytometry tracings of tEGFR staining, including a rabbit IgG 
isotype control from (D). The population of interest was first selected by gating on the 
F4/80+CD11b+ cells and then assessing tEGFR-FITC staining. 
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Appendix A, Figure 6. Egfr∆mye gastric tissues and BMmacs have no Lysm expression 
and substantial Cre expression. (A) Lysm and Cre mRNA levels were assessed by RT-PCR 
in Egfrfl/fl, Egfr∆mye, and LysMCre/Cre gastric tissues 4 mo p.i. with H. pylori SS1. **P < 0.01, ***P 
< 0.001. n = 3 uninfected and 8 infected mice per genotype. (B) Lysm and Cre mRNA levels 
were assessed by RT-PCR in Egfrfl/fl, Egfr∆mye, and LysMCre/Cre BMmacs 24 h p.i. with H. pylori 
PMSS1. **P < 0.01, ***P < 0.001. n = 3 biological replicates per genotype. Statistical 
significance in all panels was calculated by one-way ANOVA with Newman-Keuls post-test.  
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Appendix A, Figure 7. Egfr∆mye mice have increased bacterial burden and decreased 
disease pathology during acute H. pylori infection. (A) Acute gastritis, specifically scoring 
neutrophilic infiltrate, was assessed 1 mo p.i by a gastrointestinal pathologist, according to the 
updated Sydney System, in a blinded manner. *P < 0.05. n = 8-10 uninfected and 15-21 H. 
pylori PMSS1 infected mice per genotype. (B) Colonization levels of H. pylori PMSS1 were 
assessed 1 mo p.i. by serial dilution and culture. *P < 0.05, **P < 0.01. n = 15-21 H. pylori 
PMSS1 infected mice per genotype. Significance in all panels was calculated by one-way 
ANOVA with Newman-Keuls post-test. 
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Appendix A, Figure 8. Egfr∆mye mice have increased bacterial burden and decreased 
clinical disease severity during C. rodentium infection. (A) Colonization levels of C. 
rodentium in colonic tissues were assessed 14 d p.i. by serial dilution and culture. *P < 0.05.  n 
= 8-10 uninfected and 19-20 C. rodentium infected mice per genotype. Statistical significance 
was calculated by Student’s t test (B) Percentage of initial body weight was assessed on each 
day of the 14-day infection model. *P < 0.01, §P < 0.001 vs. Egfrfl/fl C. rodentium. n = 8-10 
uninfected and 19-20 C. rodentium infected mice per genotype. Statistical significance was 
calculated by one-way ANOVA with the Kruskal-Wallis test, followed by Mann-Whitney U test. 
(C) Representative immunofluorescence images of pEGFR from infected mice in (A) and (B). 
Green = EGFR pY1068, Red = CD68, Yellow = merge, Blue = DAPI. Arrows indicate 
CD68+pEGFR+ macrophages. Scale bars = 50 µM. n ≥ 3 mice per genotype. 
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Appendix A, Figure 9. Markers of M2 activation are not significantly altered in Egfr∆mye 
gastric tissue during infection with H. pylori. Arg1 and Chil3 mRNA expression was 
assessed by RT-PCR in gastric tissues 4 mo p.i. with H. pylori SS1. *P < 0.05. n = 3 uninfected 
and 5 H. pylori SS1 infected mice per genotype. Significance was calculated by one-way 
ANOVA with Newman-Keuls post-test.  
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Appendix A, Figure 10. Markers of M1 activation are significantly decreased in Egfr∆mye 
colonic tissue during C. rodentium infection. Nos2, Tnfa, and Il1b mRNA expression were 
assessed by RT-PCR in colonic tissue 14 d p.i. *P < 0.05, **P < 0.01. n = 5 uninfected and 7-8 
C. rodentium infected mice per genotype. Statistical significance was calculated by one-way 
ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. 
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Appendix A, Figure 11. Isolation and differentiation of macrophages and dendritic cells 
from murine bone marrow. (A) Representative flow cytometry scatter plots demonstrating 
populations of CD11b+F4/80+ BMmacs. (B) Representative flow cytometry scatter plots 
demonstrating populations of CD11b+CD11c+ bone marrow derived dendritic cells (BMDCs). In 
both panels, n = 4 biological replicates. 
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Appendix A, Figure 12. Markers of Mreg activation are significantly decreased during H. 
pylori infection, but markers of M2 activation are not significantly altered in EGFR 
signaling-deficient BMmacs. (A) Il10 and Tgfb mRNA levels were assessed by RT-PCR in 
wildtype (WT) BMmacs ± 10 µM gefitinib 24 h p.i. with H. pylori PMSS1. **P < 0.01, ***P < 
0.001. n = 4 biological replicates. (B) Il10 and Tgfb mRNA levels were assessed by RT-PCR in 
Egfrfl/fl and Egfr∆mye BMmacs 24 h p.i. with H. pylori PMSS1. ***P < 0.001. n = 4 mice per 
genotype. Statistical significance in (A) and (B) was calculated by one-way ANOVA with 
Newman-Keuls post-test. (C) Arg1 and Chil3 mRNA levels were assessed by RT-PCR in WT 
BMmacs ± 10 µM gefitinib 24 h p.i. with H. pylori PMSS1. n = 4 biological replicates. (D) Arg1 
and Chil3 mRNA levels were assessed by RT-PCR in Egfrfl/fl and Egfr∆mye BMmacs 24 h p.i. 
with H. pylori PMSS1. n = 4 mice per genotype.  
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Appendix A, Figure 13. M1 and Mreg activation markers are significantly decreased in 
EGFR signaling-deficient BMmacs infected with C. rodentium. (A) mRNA levels M1 
activation markers, Nos2, Il1b, and Tnfa, were assessed by in WT BMmacs ± 10 µM gefitinib 6 
h p.i. by RT-PCR. **P < 0.01, ***P < 0.001. n = 5 biological replicates. (B) mRNA levels Mreg 
activation markers, Il10, and Tgfb, were assessed in WT BMmacs ± 10 µM gefitinib 6 h p.i. by 
RT-PCR. ***P < 0.001. n = 5 biological replicates. Statistical significance in all panels was 
calculated by one-way ANOVA with Newman-Keuls post-test. 
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Appendix A, Figure 14. EGFR signaling regulates macrophage activation during 
stimulation with classical M1, M2, and Mreg activation stimuli. (A) Nos2, Il1b, and 
Tnfa mRNA levels were assessed by RT-PCR in Egfrfl/fl and Egfr∆mye BMmacs 24 h post 
stimulation with IFN-γ (200 U/mL) and LPS (10 ng/mL). ***P < 0.001. n = 3 mice per genotype. 
(B) Arg1, Chil3, and Retnla mRNA levels were assessed by RT-PCR in Egfrfl/fl and Egfr∆mye 
BMmacs 24 h post stimulation with IL-4 (10 ng/mL). *P < 0.05, **P < 0.01. n = 3 mice per 
genotype. (C) Il10 and Tgfb mRNA levels were assessed by RT-PCR in Egfrfl/fl and Egfr∆mye 
BMmacs 24 h post stimulation with IL-10 (10 ng/mL). ***P < 0.001. n = 3 mice per genotype. 
Statistical significance in all panels was calculated by one-way ANOVA with Newman-Keuls 
post-test.  
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Appendix A, Figure 15. EGFR inhibition enhances bacterial survival by inhibiting NO 
production and NO-mediated killing. RAW 264.7 cells and H. pylori PMSS1 were co-
cultured across Transwell Filter supports for 24 h. (A) H. pylori survival was assessed by serial 
dilution and culture from Transwell filter supports above RAW 264.7 cells ± 10 µM gefitinib. *P 
< 0.05. n = 5 biological replicates. (B) Percent of bacteria that survived NO-mediated killing 
based on the initial MOI of 100 and the bacteria cultured in (A). **P < 0.01. n = 5 biological 
replicates. Statistical significance in (A) and (B) was calculated by Student’s t test. (C) A set of 
control conditions for these assays. Culture of H. pylori PMSS1 in DMEM + 10% FBS does not 
result in bacterial death. Gentamicin treatment served as a positive control, leading to 100% 
bacterial death. Treatment of H. pylori PMSS1 with 10 µM gefitinib did not result in bacterial 
death. n = 5 biological replicates. (D) Measurement of NO2— from RAW 264.7 cell 
supernatants ± 10 µM gefitinib 24 h p.i. with H. pylori PMSS1. *P < 0.05. n = 5 biological 
replicates. Statistical significance was calculated by one-way ANOVA with Newman-Keuls 
post-test. 
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Appendix A, Figure 16. EGFR inhibition cells does not affect phagocytosis of H. pylori 
PMSS1. (A) Confirmation of Egfr knockdown by siRNA in RAW 264.7 cells by western blot. n = 
2 biological replicates. (B) The amount of H. pylori PMSS1 that was phagocytosed by RAW 
264.7 cells ± 10 µM cytochalasin D (CytoD) at 1 h and 3 h p.i. was assessed by serial dilution 
and culture. ***P < 0.001. Statistical significance was calculated by one-way ANOVA with 
Newman-Keuls post-test. n = 3 biological replicates. Scr = scrambled siRNA. Egfr = Egfr 
siRNA. (C) The amount of H. pylori that was phagocytosed by RAW 264.7 cells ± 10 µM 
gefitinib at 1 h and 3 h p.i. was assessed by serial dilution and culture. n = 3 biological 
replicates. (D) Confirmation that gentamicin treatment (200 µg/mL) for 30 min kills >99% of H. 
pylori PMSS1 and that 10 µM gefitinib treatment for 1 h and 0.1% saponin treatment for 30 min 
kills <1% of H. pylori PMSS1. n = 3 biological replicates. 
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Appendix A, Figure 17. EGFR knockdown or inhibition does not affect apoptosis of 
macrophages during H. pylori PMSS1 infection. (A) Confirmation of Egfr knockdown by 
siRNA in RAW 264.7 cells by western blot. n = 2 biological replicates. (B) Percentage of 
Annexin-V+7-AAD+ RAW 264.7 cells ± Egfr siRNA knockdown 24 h p.i. with H. pylori PMSS1. n 
= 3 biological replicates. CHex = cyclohexamide (5 µg/mL). (C) Percentage of Annexin-V+7-
AAD+ RAW 264.7 cells ± 10 µM gefitinib 24 h p.i. with H. pylori PMSS1. n = 3 biological 
replicates. CHex = cyclohexamide (5 µg/mL). (D) Percentage of Annexin-V+7-AAD+ WT 
BMmacs ± 10 µM gefitinib 24 h p.i. with H. pylori PMSS1.  n = 3 biological replicates. (E) 
Percentage of Annexin-V+7-AAD+ Egfrfl/fl and Egfr∆mye BMmacs 24 h p.i. with H. pylori PMSS1. 
n = 3 biological replicates. (F) Percentage of F4/80+CD11b+Annexin-V+7-AAD+ Gmacs from 
Egfrfl/fl and Egfr∆mye mice 48 h p.i. with H. pylori SS1. **P < 0.01. n = 3 uninfected and 5 H. 
pylori PMSS1 infected mice per genotype. (G) Number of F4/80+CD11b+ Gmacs from Egfrfl/fl 
and Egfr∆mye mice 48 h p.i. with H. pylori SS1. **P < 0.01. n = 3 uninfected and 5 H. pylori 
PMSS1 infected mice per genotype. Statistical significance in (F)-(G) was calculated by one-
way ANOVA with Newman-Keuls post-test. (H) Representative immunofluorescence images of 
cleaved caspase 3 staining in Egfrfl/fl and Egfr∆mye gastric tissues 4 mo p.i. with H. pylori SS1. 
Green = cleaved caspase 3, Red = CD68, Yellow = merge, Blue = DAPI. Arrows indicate 
CD68+cleaved caspase 3+ macrophages. Scale bars = 50 µM. n ≥ 3 mice per genotype. 
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Appendix A, Figure 18. EGFR inhibition or knockout does not affect cytokine production 
or antigen presentation by bone marrow-derived dendritic cells. (A) mRNA levels of 
prototypical dendritic cell cytokines, Tnfa, Il6, Il12b (Il12p40), and Il10, were assessed by RT-
PCR 24 h p.i. with H. pylori PMSS1 in WT BMDCs ± 10 µM gefitinib. n = 4 biological replicates. 
(B) mRNA levels of prototypical dendritic cell cytokines, Tnfa, Il6, Il12b, and Il10, were 
assessed by RT-PCR 24 h p.i. with H. pylori PMSS1 in Egfrfl/fl and Egfr∆mye BMDCs. n = 4 mice 
per genotype. (C) Antigen presentation ability was assessed by determining levels of surface 
H2-Ab1 (MHCII) on Egfrfl/fl and Egfr∆mye CD11c+ BMDCs 24 h p.i. with H. pylori PMSS1. n = 4 
biological replicates. (D) Representative flow cytometry scatter plots for H. pylori-infected 
Egfrfl/fl and Egfr∆mye BMDCs from (C). n = 4 biological replicates. 
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Appendix A, Figure 19. EGFR inhibition leads to markedly decreased NF-κB signaling. 
(A) Representative western blot of MyD88 protein levels in WT BMmacs ± 10 µM gefitinib. n = 
3 biological replicates. (B) Representative western blot of pIKBK (pIKK) and tIKBK (tIKK) 
protein levels in WT BMmacs ± 10 µM gefitinib. n = 3 biological replicates. (C) Representative 
western blot of pNFKBIA (pIκB) protein levels in WT BMmacs ± 10 µM gefitinib. n = 3 
biological replicates. (D) Representative western blot of tRELA (p65) protein levels in the 
cytoplasm and nucleus of WT BMmacs ± 10 µM gefitinib. n = 3 biological replicates. (E) 
Densitometric analysis of tRELA protein levels the cytoplasm in (D) n = 3 biological replicates. 
(F) Densitometric analysis of tRELA levels in the nucleus in (D). ***P < 0.001. n = 3 biological 
replicates. Statistical significance was calculated by Student’s t test.  
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Appendix A, Figure 20. Macrophage EGFR signaling has a modest effect on the Th1 
response to H. pylori 4 mo p.i. (A) Ifng mRNA expression was assessed by RT-PCR in 
Egfrfl/fl, Egfr∆mye, and LysMCre/Cre gastric tissues 4 mo p.i. with H. pylori SS1. *P < 0.05. n = 3 
uninfected and 6 H. pylori SS1 infected mice per genotype. (B) Assessment of CD4+IFN-γ+ T 
cells from gastric lymph nodes (GLN) of Egfrfl/fl and Egfr∆mye mice 4 mo p.i. by flow cytometry. 
Isolated T cells were cultured in 96-well plates containing 5 µg/mL anti-CD3 and 1 µg/mL anti-
CD28. Cells were then stimulated with 20 ng/mL PMA and 1 µg/mL ionomycin for 4 h. *P < 
0.05. n = 3 uninfected and 6-7 H. pylori SS1 infected mice per genotype. (C) Tbx21 (Tbet) and 
Ifng mRNA expression was assessed by RT-PCR from magnetically selected CD4+ T cells 
from the gastric lamina propria of Egfrfl/fl and Egfr∆mye mice 4 mo p.i. *P < 0.05, **P < 0.01. n = 
3 uninfected and 6-7 H. pylori SS1 infected mice per genotype. Statistical significance in all 
panels was calculated by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney 
U test. 
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Appendix A, Figure 21. Macrophage EGFR signaling results in IL23a expression in 
gastric tissues and primary macrophages in response to H. pylori. Il23a (Il23p19) mRNA 
expression was assessed by RT-PCR in Egfrfl/fl and Egfr∆mye BMmacs 24 h p.i. with H. pylori 
PMSS1. *P < 0.05 vs. Egfrfl/fl control BMmacs. §P < 0.05 vs. PMSS1-infected Egfrfl/fl BMmacs. 
n = 4 mice per genotype. Statistical significance in all panels was calculated by one-way 
ANOVA with Newman-Keuls post-test. 
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Appendix A, Figure 22. Macrophage EGFR signaling has a modest effect on Th1, Th17, 
and Treg responses to H. pylori 2 mo p.i. (A) Assessment of CD4+IFN-γ+ T cells from GLNs 
of Egfrfl/fl and Egfr∆mye mice 4 mo p.i. by flow cytometry. Isolated T cells were cultured in 96-
well plates containing 5 µg/mL anti-CD3 and 1 µg/mL anti-CD28. Cells were then stimulated 
with H. pylori French-pressed lysate for 4 h. *P < 0.05. (B). Tbx21 (Tbet) and Ifng mRNA 
expression was assessed by RT-PCR from magnetically selected CD4+ T cells from the gastric 
lamina propria of Egfrfl/fl and Egfr∆mye mice 4 mo p.i. *P < 0.05, **P < 0.01. (C) Assessment of 
CD4+IL-17+ T cells from GLNs of Egfrfl/fl and Egfr∆mye mice 4 mo p.i. by flow cytometry. Cells 
isolated and stimulated as in (A). (D) Rorc (Rorgt) and Il17a mRNA expression was assessed 
by RT-PCR from magnetically-selected CD4+ T cells from the gastric lamina propria of Egfrfl/fl 
and Egfr∆mye mice 4 mo p.i. *P < 0.05. (E) Assessment of CD4+CD25+FOXP3+ T cells from 
GLNs of Egfrfl/fl and Egfr∆mye mice 4 mo p.i. by flow cytometry. Cells isolated and stimulated as 
in (A). (F) Foxp3, Il10, and Tgfb mRNA expression was assessed by RT-PCR from 
magnetically selected CD4+ T cells from the gastric lamina propria of Egfrfl/fl and Egfr∆mye mice 
4 mo p.i. *P < 0.05, **P < 0.01. In all panels, n = 2-3 uninfected and 6-8 H. pylori SS1 infected 
mice per genotype. Statistical significance in all panels was calculated by one-way ANOVA 
with Kruskal-Wallis test, followed by Mann-Whitney U test. 
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Analyte 
Concentration of Analyte (pg/mg protein); Mean ± S.E.M. 
Egfrfl/fl Egfr∆mye LysMCre/Cre 
Uninfected H. pylori 
SS1 
Uninfected H. pylori 
SS1 
Uninfected H. pylori 
SS1 
CCL2 4.10 ± 1.70 24.20 ± 
6.78 * 
14.26 ± 
3.98 
16.14 ± 
4.21 
15.59 ± 
1.01 
26.08 ± 
4.75 
CCL11 50.62 ± 
9.20 
47.73 ± 
6.00 
54.40 ± 
2.95 
47.32 ± 
4.33 
41.25 ± 
4.79 
59.80 ± 
7.42 
CSF1 2.83 ± 0.49 4.69 ± 0.31 2.85 ± 0.37 4.08 ± 0.44 4.50 ± 1.81 3.62 ± 0.37 
CSF2 1.21 ± 0.54 0.74 ± 0.16 1.73 ± 0.88 1.18 ± 0.59 1.42 ± 1.15 2.55 ± 0.93 
CSF3 4.29 ± 0.60 8.54 ± 1.56 4.54 ± 0.89 5.68 ± 0.62 4.42 ± 1.19 8.19 ± 0.70 
IFNG 2.63 ± 0.45 4.57 ± 1.21 2.90 ± 0.31 2.68 ± 0.30 2.61 ± 0.04 3.38 ± 0.38 
IL-1α 48.07 ± 
6.10 
38.85 ± 
5.73 
44.49 ± 
5.58 
43.36 ± 
5.05 
35.06 ± 
3.76 
42.53 ± 
5.07 
IL-1β 4.21 ± 1.23 9.75 ± 1.72 
* 
4.96 ± 1.36 7.20 ± 1.30 9.01 ± 2.27 10.37 ± 
1.19 
IL-2 2.63 ± 0.42 2.78 ± 0.27 2.53 ± 0.27 2.22 ± 0.32 2.57 ± 0.14 2.62 ± 0.19 
IL-6 0.70 ± 0.38 1.33 ± 0.36 0.91 ± 0.19 1.13 ± 0.24 0.70 ± 0.35 1.58 ± 0.26 
IL-7 0.97 ± 0.19 1.85 ± 0.35 1.73 ± 0.39 1.20 ± 0.30 1.74 ± 0.36 2.28 ± 0.21 
IL-9 0.36 ± 0.25 15.24 ± 
2.82 *** 
0.51 ± 0.25 4.75 ± 1.89 
§ 
0.34 ± 0.13 26.17 ± 
10.92 
IL-10 3.25 ± 0.52 3.23 ± 0.50 4.84 ± 0.80 3.42 ± 0.79 4.31 ± 1.40 5.05 ± 1.47 
IL-
12p40 
0.16 ± 0.06 0.34 ± 0.11 0.29 ± 0.05 0.13 ± 0.02A 0.27 ± 0.07 0.38 ± 0.05 
aa 
IL-
12p70 
11.33 ± 
2.94 
12.95 ± 
3.59 
8.12 ± 3.31 9.20 ± 1.09 11.72 ± 
0.24 
11.40 ± 
1.08 
IL-15 5.29 ± 2.09 7.09 ± 1.53 5.22 ± 2.13 3.93 ± 0.90 6.51 ± 1.53 7.75 ± 0.58 
IL-17 0.98 ± 0.18 4.94 ± 0.49 
** 
1.33 ± 0.25 3.03 ± 0.78 0.89 ± 0.14 5.51 ± 1.16 
TNF-a 1.22 ± 0.23 3.10 ± 1.13 1.49 ± 0.20 1.44 ± 0.18 1.65 ± 0.05 2.70 ± 0.45 
VEGFA 3.23 ± 0.31 4.47 ± 0.60 4.11 ± 0.82 3.71 ± 0.22 2.98 ± 0.19 4.24 ± 0.33 
Analytes Not Detected: CXCL2, IL-3, IL-4, IL-5, IL-13, LIF, LIX 
 
Appendix A, Table 1. Luminex analytes that did not demonstrate significant differences 
in gastric tissue between Egfrfl/fl, Egfr∆mye and LysMCre/Cre mice. 32 distinct analytes were 
assessed in gastric tissue from uninfected and infected mice from each of the three genotypes. 
Listed are the analytes that showed no significant differences as a result of infection, no 
significant differences between genotypes or were not detected. Egfrfl/fl: n = 5 uninfected, 11 
infected. Egfr∆mye: n = 3 uninfected, 8 infected. LysMCre/Cre: n = 2 uninfected, 9 infected. * P < 
0.05, ** P < 0.01 *** P < 0.001 vs. Egfrfl/fl Uninfected. § P < 0.05 vs. Egfrfl/fl H. pylori SS1. aa P 
< 0.01 for. LysMCre/Cre H. pylori SS1 vs Egfr∆mye H. pylori SS1. Statistical significance was 
calculated by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. AP = 
0.07 between Egfrfl/fl H. pylori SS1 and Egfr∆mye H. pylori SS1. 
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Species Target Sequence 
Mouse β-actin F: CCAGAGCAAGAGAGGTATCC R: CTGTGGTGGTGAAGCTGTAG 
Mouse Nos2 F: CACCTTGGAGTTCACCCAGT R: ACCACTCGTACTTGGGATGC 
Mouse Tnfa F: CTGTGAAGGGAATGGGTGTT R: GGTCACTGTCCCAGCATCTT 
Mouse Il1b F: ACCTGCTGGTGTGTGACGTTCC R: GGGTCCGACAGCACGAGGCT 
Mouse Arg1 F: AAGAAAAGGCCGATTCACCT R: CACCTCCTCTGCTGTCTTCC 
Mouse Chia1 F: ACTTTGATGGCCTCAACCTG R: AATGATTCCTGCTCCTGTGG 
Mouse Retnla F: GGGATGACTGCTACTGGGTG R: TCAACGAGTAAGCACAGGCA 
Mouse Il10 F: CCAAGCCTTATCGGAAATGA R: TCACTCTTCACCTGCTCCAC 
Mouse Tgfb F: TCCTTGCCTGCGGAAGTG R: GGAGAGCATTGAGCAGTTCGA 
Mouse Tnfsf14 F: CTGCATCAACGTCTTGGAGA R: GATACGTCAAGCCCCTCAAG 
Mouse EgfrA F: CCTCGTCTGTGGAAGAACTA R: CTCAGCCAGATGATGTTGAC 
Mouse Tbx21 F: GCCAGGGAACCGCTTATATG R: GACGATCATCTGGGTCACATTGT 
Mouse Ifng F: GGCCATCAGCAACAACATAAGCGT R: TGGGTTGTTGACCTCAAACTTGGC 
Mouse Rorc F: CCGCTGAGAGGGCTTCAC R: TGCAGGAGTAGGCCACATTACA 
Mouse Il17a F: ATCCCTCAAAGCTCAGCGTGTC R: GGGTCTTCATTGCGGTGGAGAG 
Mouse Foxp3 F: GAGAGCAGGCAGTTCAGGAC R: CGGGAGCATATACCAGGCAC 
Mouse Il23a F: CCAGCAGCTCTCTCGGAATC R: TCATAGTCCCGCTGGTGC 
Mouse Lysm F: TGGGATCAATTGCAGTGCT R: CACCACCCTCTTTGCACATT 
Mouse Cre F: GATTTCGACCAGGTTCGTTC R: GCTAACCAGCGTTTTCGTTC 
 
Appendix A, Table 2. List of primers used for PCR and RT-PCR. AIndicates primers were 
used to confirm excision of the Egfr alleles in Egfr∆mye mice. 
 
 
 
 
 
163
Antibody Dilution Application Source (Location) 
Rabbit polyclonal anti-
pEGFR Y1068 
1:1,000 WB Cell Signaling (Danvers, MA) 
Cat. No. 2234 
Rabbit polyclonal anti-
pEGFR S1046/47 
1:1,000 WB Cell Signaling (Danvers, MA) 
Cat. No. 2238 
Rabbit polyclonal anti-
tEGFR 
1:5,000 
1:100 
1:50 
WB 
IF 
FC 
Cell Signaling (Danvers, MA) 
Cat. No. 2232 
Mouse monoclonal anti-b-
actin 
1:10,000 WB Sigma-Aldrich (St. Louis, MO) 
Cat. No. A1978 
Rabbit polyclonal anti-
MyD88 
1:1000 WB Cell Signaling (Danvers, MA) 
Cat. No. 3699 
Rabbit polyclonal anti-
pIKBK S176/180 
1:2000 WB Cell Signaling (Danvers, MA) 
Cat. No. 2697 
Rabbit polyclonal anti-tIKBK 1:2000 WB Cell Signaling (Danvers, MA) 
Cat. No. 2682 
Mouse monoclonal anti-
pNFKBIA S32/36 
1:1000 WB Life Technologies (Carlsbad, CA) 
Cat. No. MA515224 
Rabbit polyclonal anti-
tRELA 
1:5,000 WB EMD Millipore (Billerica, MA) 
Cat. No. PC138 
Rabbit polyclonal anti-FBL 1:5,000 WB Santa Cruz (Dallas, TX) 
Cat. No. SC-25397 
Mouse monoclonal anti-
GAPDH 
1:10,000 WB EMD Millipore (Billerica, MA) 
Cat. No. MAB374 
Goat anti-mouse IgG, HRP 
labeled 
1: 30,000 WB Jackson ImmunoResearch (St. 
Louis, MO) Cat. No. 115-035-003 
Goat anti-rabbit IgG, HRP 
labeled 
1:3,000-
1:6,000 
WB Jackson ImmunoResearch (St. 
Louis, MO) Cat. No. 111-035-003 
Rabbit polyclonal anti-NOS2 1:5,000 
1:100 
WB 
FC 
Pierce (Waltham, MA)** 
 
Rabbit polyclonal anti-Clvd 
CASP3 D175 
1:400 IF Cell Signaling (Danvers, MA) 
Cat. No. 9661 
Anti-mouse F4/80-Alexa488 1:100 FC Invitrogen (Carlsbad, CA) 
Cat. No.  
Anti-mouse F4/80-PE 1:100 FC Invitrogen (Carlsbad, CA) 
Cat. No. MF48004 
Anti-mouse CD4-PerCP-
Cy5.5 
1:200 FC Biolegend (San Diego, CA) 
Cat. No. 100540 
Hamster anti-mouse IFNG-
FITC 
1:100 FC BD Biosciences (San Jose, CA) 
Cat. No. 562019 
Rat anti-mouse IL-17A-PE 1:100 FC BD Biosciences (San Jose, CA) 
Cat. No. 561020 
Anti-mouse CD25-PE 1:100 FC eBioscience (San Diego, CA) 
Cat. No. 12-0281-83 
Rat anti-mouse FOXP3-
Alexa488 
1:00 FC BD Biosciences (San Jose, CA) 
Cat. No. 560407 
Mouse monoclonal Pan-
cytokeratin PE 
1:100 FC Abcam (Cambridge, UK) 
Cat. No. AB52460 
164
Rat anti-mouse CD11b-
FITC 
1:100 FC Biolegend (San Diego, CA) 
Cat. No. 101219 
Rant anti-mouse CD11b-
PE-Cy7 
1:100 FC BD Biosciences (San Jose, CA) 
Cat. No. 552850 
Hamster anti-mouse 
CD11c-PE-Cy7 
1:100 FC BD Biosciences (San Jose, CA) 
Cat. No. 558079 
Anti-mouse H2-AB1-PerCP-
Cy5.5 
1:100 FC Biolegend (San Diego, CA) 
Cat. No. 562363 
Goat Anti-rabbit IgG-
Alexa488 
1:200 FC Jackson ImmunoResearch (St. 
Louis, MO) Cat. No. 111-095-003 
Rabbit IgG (isotype control) 1:50 FC Jackson ImmunoResearch (St. 
Louis, MO) Cat. No. 011-000-003 
Rabbit polyclonal anti-
pEGFR 
Pre-diluted IF/IHC Biocare Medical (Concord, CA) 
Cat. No. API 300 
Rabbit HRP Polymer Pre-diluted IF/IHC Biocare Medical (Concord, CA) 
Cat. No. RHRP520 
Goat anti-HRP, Alexa488 1:400 IF Jackson ImmunoResearch (St. 
Louis, MO) 
Cat. No. 123-545-021 
Mouse monoclonal anti-
CD68 
Pre-diluted IF Santa Cruz Biotechnology (West 
Grove, PA) 
Cat. No. SC-7084 
Goat anti-mouse IgG, 
Alexa555 
1:500 IF Life Technologies (Carlsbad, CA) 
Cat. No. A31570 
Rat polyclonal anti-F4/80 1:50 IF Invitrogen (Carlsbad, CA) 
Cat. No. MF48000 
Rabbit anti-rat IgG, TRITC 1:100 IF Sigma-Aldrich (St. Louis, MO) 
Cat. No. T4280 
Mouse Anti-TNF-a 10 ng/mL NEUT Cell Signaling (Danvers, MA) 
Cat. No. 11969 
Mouse Anti-HB-EGF 25 ng/mL NEUT Sigma-Aldrich (St. Louis, MO) 
Cat. No. AF259NA 
 
Appendix A, Table 3. A list of all antibodies used for this study, including the dilution, 
application and company from which the antibodies were purchased. WB = western 
blotting, FC = flow cytometry, IF = immunofluorescence, IHC = immunohistochemistry. NEUT = 
neutralization. **No longer available. 
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Appendix B 
Supplementary Figures for Chapter 3 
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Appendix B, Figure 1. Percentages of macrophages in human CAC TMA. (a) 
Quantification of the percentage of CD68+ cells among the total number of nuclei in each 
individual core in the TMA. For (a-c), n = 10 inactive colitis (normal or quiescent histology) 
samples, 14 active colitis (mild, moderate or severe histology) samples, 12 dysplasia samples, 
and 11 colorectal cancer samples. 
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Appendix B, Figure 2. Schematic of the AOM-DSS protocol utilized in these studies. (a) 
AOM-DSS group: Mice were injected with 12.5 mg/kg AOM on Day 0. Animals then received 3 
cycles of 4% DSS beginning on Day 5 (for 5 days), Day 26 (for 5 days), and Day 47 (for 4 
days). Mice were sacrificed on Day 77 post-AOM injection. (b) DSS only group: Mice did not 
receive an AOM injection, but received 3 cycles of 4% DSS as in the AOM-DSS group. Mice 
were sacrificed on Day 77. (c) AOM only group: Mice were injected with 12.5 mg/kg AOM on 
Day 0 and were then maintained on normal drinking water throughout the protocol. Mice were 
sacrificed on Day 77 post-AOM injection. (d) Control group: Mice did not receive an AOM 
injection nor did mice receive DSS in their drinking water. Mice were sacrificed on Day 77. 
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Appendix B, Figure 3. Egfr∆GIepi colonic epithelial cells demonstrated tEGFR knockout, 
but splenocytes and bone marrow-derived macrophages did not. (a) Representative 
Western blot of tEGFR levels in colonic epithelial cells from naïve Egfrfl/fl and Egfr∆GIepi mice. 
(b) Representative Western blot of tEGFR levels in splenocytes from naïve Egfrfl/fl and 
Egfr∆GIepi mice. (c) Representative Western blot of tEGFR levels in bone marrow-derived 
macrophages (BMmacs) from naïve Egfrfl/fl and Egfr∆GIepi mice. 
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Appendix B, Figure 4. Egfr∆GIepi mice did not demonstrate altered tumorigenesis 
compared to Egfrfl/fl mice. (a) Tumor multiplicity was assessed by gross visual inspection, 
utilizing a dissecting microscope. (b) Tumor burden was determined by the addition of the 
calculated area of each identified tumor, as assessed with an electronic caliper for both length 
and width. (c) Percentage of cases with either no adenoma, low-grade dysplasia (LGD), and 
high-grade dysplasia (HGD) was determined by a gastrointestinal pathologist (M.K.W.) in a 
blinded manner. (d) Representative H&E-stained images from AOM-DSS-treated mice. Scale 
bars = 100 µm. (e) Representative immunoperoxidase images of pEGFR Y1068 from mice in 
(a-f). Scale bars = 50 µm. n = 6 mice per genotype assessed. (f) Histologic colitis was 
determined by M.K.W. in a blinded manner. (g) Percentage of initial body weight was assessed 
at indicated time points. In (a-c) and (f-g), n = 6 control and 14-15 AOM-DSS treated mice per 
genotype.  
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Appendix B, Figure 5. Egfr∆GIepi mice demonstrate no alterations in cytokine and 
chemokine production within tumors. (a) Protein levels of the general C-C motif and C-X-C 
motif chemokines CCL3 (MIP-1α), CCL4 (MIP-1β), CXCL9 (MIG), and CXCL10 (IP-10) were 
assessed by Luminex Multiplex Array from colonic tissues 77 days post-AOM injection. (b) 
Protein levels of the pleiotropic cytokine, LIF, were assessed by Luminex Multiplex Array from 
colonic tissues 77 days post-AOM injection. (c) Protein levels of cytokines produced by 
activated macrophages, CSF1 (M-CSF) and IL-1α were assessed by Luminex Multiplex Array 
from colonic tissues 77 days post-AOM injection. In all panels, n = 5 control tissues and 5-6 
tumors with paired non-tumor area per genotype. In all panels, *P < 0.05, **P < 0.01, ***P < 
0.001 by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test.
171
 
Appendix B, Figure 6 Egfr∆GIepi mice demonstrate no alterations in M2 macrophage 
activation during colon tumorigenesis. (a) Protein levels of M2 stimuli, IL-4 and IL10, were 
assessed by Luminex Multiplex Array from colonic tissues 77 days post-AOM injection. n = 5 
control tissues and 5-6 tumors with paired non-tumor area per genotype. (b) mRNA levels of 
M2 markers, Arg1 and Il10, were assessed by qRT-PCR from colonic tissues 77 days post-
AOM injection. n = 5 control tissues and 5 tumors with paired non-tumor area per genotype. In 
all panels, *P < 0.05, **P < 0.01 by one-way ANOVA with Kruskal-Wallis test, followed by 
Mann-Whitney U test. 
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Appendix B, Figure 7. Egfr∆GIepi mice demonstrate no alterations in M1 macrophage 
activation during colon tumorigenesis. (a) Protein levels of M1 stimuli, IFN-γ and TNF-α, 
were assessed by Luminex Multiplex Array from colonic tissues 77 days post-AOM injection. n 
= 5 control tissues and 5-6 tumors with paired non-tumor area per genotype. (b) mRNA levels 
of M1 markers, Nos2 and Il1b, were assessed by qRT-PCR from colonic tissues 77 d post-
AOM injection. n = 5 control tissues and 5 tumors with paired non-tumor area per genotype. (c) 
Protein levels of M1 marker, IL-1β, were assessed by Luminex Multiplex Array from colonic 
tissues 77 days post-AOM injection. n = 5 control tissues and 5-6 tumors with paired non-
tumor area per genotype. In all panels, *P < 0.05, **P < 0.01 by one-way ANOVA with Kruskal-
Wallis test, followed by Mann-Whitney U test. 
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Appendix B, Figure 8. Egfr∆GIepi mice demonstrate no alterations in pro-angiogenic 
chemokine/cytokine production during colon tumorigenesis. (a) mRNA levels of the pro-
angiogenic chemokine, Cxcl1, and the pro-angiogenic cytokine, Vegfa, were assessed by qRT-
PCR from colonic tissues 77 days post-AOM injection. n = 5 control tissues and 5 tumors with 
paired non-tumor area per genotype. (b) Protein levels of CXCL1 and VEGF were assessed by 
Luminex Multiplex Array from colonic tissues 77 days post-AOM injection. n = 5 control tissues 
and 5-6 tumors with paired non-tumor area per genotype. In all panels, *P < 0.05, **P < 0.01 
by one-way ANOVA with Kruskal-Wallis test, followed by Mann-Whitney U test. 
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Appendix B, Figure 9. Egfr∆mye BMmacs demonstrate significant alterations in Cxcl1 and 
Vegfa mRNA levels during M1 or M2 macrophage activation. (a) mRNA levels of the pro-
angiogenic chemokine, Cxcl1, and the pro-angiogenic cytokine, Vegfa, were assessed by qRT-
PCR in BMmacs 24 h post-stimulation with IFN-γ (200 U/mL) and LPS (10 ng/mL). n = 5 
biological replicates per genotype. (b) mRNA levels of the pro-angiogenic cytokine, Vegfa, 
were assessed by qRT-PCR in BMmacs 24 h post-stimulation with IL-4 (10 ng/mL) and IL-10 
(10 ng/mL). n = 5 biological replicates per genotype. In all panels, *P < 0.05, ***P < 0.001 by 
one-way ANOVA with Newman-Keuls post-test. 
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 Analyte 
Concentration of Analyte (pg/mg protein); Mean ± S.E.M. 
Egfrfl/fl Egfr∆mye 
Control Non-tumor AOM-DSS Control Non-tumor AOM-DSS 
CCL2 3.87 ± 0.40 6.85 ± 1.55 113.5 ± 20.32*** 4.03 ± 1.39 1.36 ± 0.88 
83.90 ± 
17.56## 
CCL5 7.08 ± 1.43 8.15 ± 2.22 2.62 ± 0.45 5.04 ± 0.66 3.06 ± 0.61 0.80 ± 0.11 
CCL11 109.6 ± 48.44 
130.8 ± 
27.15 
145.2 ± 
36.29 
134.6 ± 
27.05 
84.97 ± 
15.02 
113.5 ± 
44.59 
CSF2 0.21 ± 0.88 0.36 ± 0.15 15.65 ± 4.24*** 0.16 ± 0.68 0.20 ± 0.01 
11.06 ± 
2.81# 
CSF3 2.71 ± 0.92 34.29 ± 23.53 
277.1 ± 
108.6** 4.45 ± 0.66 
15.15 ± 
3.15 
366.2 ± 
120.0## 
CXCL2 4.66 ± 0.54 47.66 ± 13.03 
2492 ± 
507.3*** 4.15 ± 0.94 
58.25 ± 
27.15 
1478 ± 
340.1### 
CXCL5 0.04 ± 0.01 15.83 ± 14.49 
117.7 ± 
56.67** 0.04 ± 0.01 0.08 ± 0.01 
10.38 ± 
6.65 
IL-2 1.15 ± 0.21 1.30 ± 0.31 1.85 ± 0.55 0.92 ± 0.15 1.94 ± 0.16 0.81 ± 0.16§ 
IL-5 0.95 ± 0.28 0.84 ± 0.35 0.80 ± 0.26 0.76 ± 0.27 0.42 ± 0.08 0.25 ± 0.07 
IL-6 1.47 ± 0.68 3.77 ± 0.95 548.4 ± 234.2*** 1.33 ± 0.48 5.94 ± 1.74 
465.9 ± 
119.7## 
IL-7 2.14 ± 0.20 2.34 ± 0.33 4.19 ± 0.52* 2.20 ± 0.15 3.01 ± 0.41 1.22 ± 0.39§§§ 
IL-9 32.41 ± 8.75 
41.05 ± 
9.63 
72.04 ± 
19.40 
22.84 ± 
8.14 
39.38 ± 
4.70 
24.90 ± 
2.02§§ 
IL-12B 2.09 ± 0.30 1.59 ± 0.40 1.92 ± 0.44 1.19 ± 0.25 2.68 ± 0.15 1.77 ± 0.26 
IL-15 7.60 ± 1.40 5.86 ± 2.03 3.97 ± 1.06 6.32 ± 0.72 3.55 ± 0.94 1.84 ± 0.51 
IL-17 0.64 ± 0.16 1.79 ± 0.43 24.74 ± 5.71*** 0.45 ± 0.06 1.29 ± 0.45 
18.89 ± 
3.26## 
Not detected: IL-3, IL-12A 
 
Appendix B, Table 1. Luminex analytes that did not demonstrate significant differences 
in colonic tissues from Egfrfl/fl and Egfr∆mye mice. A total of 32 distinct analytes were 
assessed in colonic tissues from control mice and from tumor and adjacent non-tumor tissues 
from mice treated with AOM-DSS. Listed are the analytes that were not significantly induced 
during AOM-DSS treatment, were not relevant to subsequent analyses in the study or 
demonstrated no significant differences between genotypes. n = 5 control and 6-9 non-
tumor/tumor pairs per genotype. *P<0.05, **P<0.01, and ***P< 0.001 versus Egfrfl/fl control. 
#P<0.05, ##P<0.01, and ###P< 0.001 versus Egfr∆mye control. §P<0.05, §§P<0.01, and §§§P< 
0.001 versus Egfrfl/fl AOM-DSS by one-way ANOVA with Kruskal-Wallis test, followed by 
Mann-Whitney U test. 
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 Analyte 
Concentration of Analyte (pg/mg protein); Mean ± S.E.M. 
Egfrfl/fl Egfr∆GIepi 
Control Non-tumor AOM-DSS Control Non-tumor AOM-DSS 
CCL2 9.67 ± 0.99 17.28 ± 2.81 
110.7 ± 
28.54** 
4.705 ± 
0.90 
13.82 ± 
4.94 
144.2 ± 
42.02## 
CCL5 15.08 ± 
1.27 6.39 ± 0.95 
4.75 ± 1.86 9.68 ± 1.47 5.39 ± 1.33 4.57 ± 2.30 
CCL11 136.9 ± 23.32 
196.8 ± 
22.02 
202.4 ± 
32.14 
219.8 ± 
26.30 
360.5 ± 
100.7 
504.0 ± 
125.3 
CSF2 1.30 ± 0.13 0.95 ± 0.42 19.19 ± 7.13** 0.31 ± 0.11 0.45 ± 0.23 
24.77 ± 
8.90## 
CSF3 6.86 ± 4.27 14.93 ± 3.66 
254.3 ± 
126.3** 1.98 ± 0.32 
15.16 ± 
5.50 
262.8 ± 
160.5## 
CXCL2 26.10 ± 16.47 
102.6 ± 
87.36 
1952 ± 
727.4*** 4.54 ± 0.92 
77.22 ± 
53.77 
2186 ± 
625.3## 
CXCL5 2.39 ± 0.19 5.95 ± 2.06 155.3 ± 34.67** 2.28 ± 0.36 4.46 ± 1.14 
116.9 ± 
46.21## 
IL-2 0.72 ± 0.07 2.99 ± 2.17 7.32 ± 5.58 0.71 ± 0.11 1.38 ± 0.68 12.13 ± 10.35 
IL-5 0.62 ± 0.10 0.46 ± 0.06 1.01 ± 0.17 0.54 ± 0.15 0.47 ± 0.12 0.83 ± 0.19 
IL-6 6.15 ± 5.10 4.81 ± 1.16 490.3 ± 275.2* 0.67 ± 0.09 8.56 ± 3.45 
909.9 ± 
517.9## 
IL-7 2.27 ± 0.20 2.72 ± 0.39 3.06 ± 0.27 1.85 ± 0.13 3.62 ± 1.53 2.53 ± 0.28 
IL-9 26.01 ± 3.37 
43.58 ± 
9.70 
72.24 ± 
13.17* 
21.40 ± 
4.24 
29.28 ± 
6.35 
91.55 ± 
25.81## 
IL-12B 1.12 ± 0.41 0.16 ± 0.05 0.50 ± 0.31 0.39 ± 0.16 0.12 ± 0.03 0.62 ± 0.39 
IL-13 0.25 ± 0.20 1.14 ± 0.46 1.07 ± 0.28 0.06 ± 0.02 1.22 ± 0.21 1.36 ± 0.14 
IL-15 7.28 ± 0.27 2.58 ± 0.50 3.72 ± 0.67 5.67 ± 1.17 2.15 ± 0.75 2.56 ± 0.67 
IL-17 0.85 ± 0.43 2.89 ± 0.51 18.02 ± 3.36** 0.35 ± 0.09 1.57 ± 0.66 
11.70 ± 
4.83## 
Not detected: IL-3, IL-12A 
 
Appendix B, Table 2. Luminex analytes that did not demonstrate significant differences 
in colonic tissues from Egfrfl/fl and Egfr∆GIepi mice. A total of 32 distinct analytes were 
assessed in colonic tissues from control mice and from tumor and adjacent non-tumor tissue 
from mice treated with AOM-DSS. Listed are the analytes that were not significantly induced 
during AOM-DSS treatment or demonstrated few or no significant differences between 
genotypes. n = 5 control and 6-9 non-tumor/tumor pairs per genotype. *P<0.05, **P<0.01, and 
***P< 0.001 versus Egfrfl/fl control. ##P<0.01 versus Egfr∆mye control by one-way ANOVA with 
Kruskal-Wallis test, followed by Mann-Whitney U test. 
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Species Target Sequence 
Mouse β-actin F: CCAGAGCAAGAGAGGTATCC R: CTGTGGTGGTGAAGCTGTAG 
Mouse Nos2 F: CACCTTGGAGTTCACCCAGT R: ACCACTCGTACTTGGGATGC 
Mouse Tnfa F: CTGTGAAGGGAATGGGTGTT R: GGTCACTGTCCCAGCATCTT 
Mouse Il1b F: ACCTGCTGGTGTGTGACGTTCC R: GGGTCCGACAGCACGAGGCT 
Mouse Arg1 F: AAGAAAAGGCCGATTCACCT R: CACCTCCTCTGCTGTCTTCC 
Mouse Chil3 F: ACTTTGATGGCCTCAACCTG R: AATGATTCCTGCTCCTGTGG 
Mouse Il10 F: CCAAGCCTTATCGGAAATGA R: TCACTCTTCACCTGCTCCAC 
Mouse  Cxcl1 F: GCTGGGATTCACCTCAAGAA R: CTTGGGGACACCTTTTAGCA 
Mouse Vegfa F: GAGGATGTCCTCACTCGGATG R: GTCGTGTTTCTGGAAGTGAGCAA 
 
Appendix B, Table 3. List of primers used for qRT-PCR. 
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Antibody Dilution Applicatio
n 
Source (Location) 
Rabbit polyclonal anti-pEGFR 
Y1068 
Pre-
diluted 
IHC-P 
IF 
Biocare Medical (Concord, CA) 
Cat. No. API 300 
Rabbit polyclonal anti-tEGFR 1:3,000 
1:100 
WB 
IF 
Cell Signaling (Danvers, MA) 
Cat. No. 2232 
Rat monoclonal anti-CD31 1:100 IHC-P Dianova (Hamburg Germany) 
Cat. No. DIA 310 
Mouse monoclonal anti-b-actin 1:10,000 WB Sigma-Aldrich (St. Louis, MO) 
Cat. No. A1978 
Goat anti-mouse IgG, HRP 
labeled 
1:30,000 WB Jackson ImmunoResearch (St. Louis, 
MO) Cat. No. 115-035-003 
Goat anti-rabbit IgG, HRP 
labeled 
1:3,000 WB Jackson ImmunoResearch (St. Louis, 
MO) Cat. No. 115-035-003 
Mouse monoclonal anti-CD68 Pre-
diluted 
IF Biocare Medical (Concord, CA) 
Cat. No. PM033AA 
Goat anti-mouse IgG, Alexa555 1:500 IF Life Technologies (Carlsbad, CA) 
Cat. No. A31570 
Goat anti-rabbit IgG, Alexa488 1:500 IF Jackson ImmunoResearch (St. Louis, 
MO) 
Cat. No. 111-095-003 
Rabbit HRP Polymer Pre-
diluted 
IF/IHC-P* Biocare Medical (Concord, CA) 
Cat. No. RHRP520 
Donkey anti-HRP, FITC 1:400 IF Jackson ImmunoResearch (St. Louis, 
MO) 
Cat. No. 123-545-021 
Rabbit anti-rat IgG, biotinylated 1:200 IHC-P** Vector Laboratories (Burlingame, CA) 
Cat. No. BA-4000 
Goat anti-rabbit IgG, 
biotinylated 
1:400 IHC-P*** Vector Laboratories (Burlingame, CA) 
Cat. No. BA-1000 
Rabbit polyclonal anti-CD68 1:200 IHC-P Boster Biological Technology 
(Pleasanton, CA) 
Cat. No. PA-1518 
Rabbit polyclonal anti-MPO Pre-
diluted 
IHC-P Biocare Medical (Concord, CA) 
Cat. No. PP-023-AA 
Rabbit monoclonal anti-CD3 1:250 IHC-P Abcam (Cambridge, MA) 
Cat. No. ab16669 
Rat monoclonal anti-CD45R 1:30,000 IHC-P BD Pharmingen (San Jose, CA) 
Cat. No. 553084 
Rabbit polyclonal anti-pSTAT6 
Y941 
1:100 IHC-P Lifespan Biosciences, Inc. (Seattle, 
WA) 
Cat. No. LS-C117487 
 
Appendix B, Table 4. List of all antibodies used for this study, including the dilution, 
application and company/catalog number from which the antibodies were purchased. WB = 
western blotting, IF = immunofluorescence, IHC-P = immunohistochemistry-
immunoperoxidase. * = used for CD68, MPO, and pSTAT6 IHC-P. ** = used for CD45R and 
CD31 IHC-P. *** = used for CD3 IHC-P. 
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Figure Panel P value  Figure Panel P value 
1 b = 0.002  S5 a CCL3: = 0.0005 
CCL4: = 0.0003 
CXCL9: = 0.0003 
CXCL10: = 0.0011 
1 c = 0.008  S5 b < 0.0001 
2 a < 0.0001  S5 c CSF1: = 0.0003 
IL-1a: = 0.0011 
2 b < 0.0001  S6 a IL-4: = 0.0202 
IL-10: = 0.05 
2 d < 0.0001  S6 b Arg1: 0.0012 
Il10: = 0.0049 
3 a CCL3: = 0.0005 
CCL4: = 0.0003 
CXCL9: = 0.0003 
CXCL10: = 0.0011 
 S7 a < 0.0001 
3 b < 0.0001  S7 b Nos2: = 0.0002 
Il1b: = 0.0002 
3 c CSF1: = 0.0003 
IL-1a: = 0.0011 
 S7 c = 0.0004 
5 a IFN-g: = 0.0079 
TNF-a: < 0.0001 
 S8 a = 0.0002 
5 b Nos2: < 0.0001 
Il1b: < 0.0001 
 S8 b < 0.0001 
5 c = 0.0004     
6 a IL-4: = 0.002 
IL-10: = 0.04 
IL-13: = 0.0049 
    
6 b Arg1: < 0.0001 
Il10: = 0.0032 
    
7 a Cxcl1: < 0.0001 
Vegfa: = 0.05 
    
7 b CXCL1: < 0.0001 
VEGF: = 0.0095 
    
 
Appendix B, Table 5. List of all P values derived from Kruskal-Wallis testing. S = Appendix B, 
figure. 
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Appendix C, Figure 1. Immunofluorescence staining for CD68 and ODC in human 
gastric biopsies. (a) Representative images of staining where no primary anti-ODC antibody 
was utilized, in order to confirm specificity of the ODC antibody. Note that the case utilized is 
the same H. pylori+ case as in Figure 1c. Scale bar = 50 µm. (b) Number of CD68+ 
macrophages per tissue area (mm2) as determined by the average counts of 4 blinded 
observers. *P < 0.05 by Student’s t test. n = 5 normal and 10 H. pylori+ cases. (c) Number of 
CD68+ODC– macrophages per tissue area (mm2) as determined in (b). n = 5 normal and 10 H. 
pylori+ cases. (d) Percentage of CD68+ODC+ macrophages per the total number of CD68+ 
macrophages as determined in (b). *P < 0.05 by Student’s t test. n = 5 normal and 10 H. pylori+ 
cases. Data displayed as mean ± S.E.M. 
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Appendix C, Figure 2. Creation of Odc∆mye mice and confirmation of Odc deletion in 
myeloid cells. (a) A schematic representation of the insertion of loxP sites within the Odc 
gene to generate Odcfl/fl mice and the creation of Odc∆mye mice by crossing with LysMcre/cre 
mice, to create a myeloid-specific knockout of Odc. (b) Odc mRNA levels were assessed by 
RT-PCR in isolated gastric lamina propria CD11b+ (myeloid cells), isolated gastric lamina 
propria CD11b– (non-myeloid cells) and gastric epithelial cells from Odcfl/fl and Odc∆mye mice 48 
h p.i. with H. pylori PMSS1. **P < 0.01 versus Odcfl/fl control. §§P < 0.01 versus Odcfl/fl + H. 
pylori PMSS1. n = 3 uninfected and 5 infected mice per genotype. Dashed line indicates basal 
level of Odc mRNA in Odcfl/fl CD11b+ cells. (c) Odc mRNA levels were assessed by RT-PCR in 
Odcfl/fl, Odc∆mye, and LysMcre/cre bone marrow-derived macrophages (BMmacs) 6 h p.i. with H. 
pylori PMSS1. **P < 0.01, ***P < 0.001. n = 3 biological replicates per genotype. Statistical 
significance in (b) and (c) was calculated by one-way ANOVA with Newman-Keuls post-test. 
(d) Representative western blot of ODC levels in Odcfl/fl and Odc∆mye BMmacs at 6 h p.i. with H. 
pylori PMSS1. (e) Quantification of ODC levels from (d). ***P < 0.001. n = 3 biological 
replicates per genotype. Statistical significance was calculated by two-tailed Student’s t test. 
Data displayed as mean ± S.E.M. 
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Appendix C, Figure 3. Odc∆mye gastric tissues and BMmacs have no detectable Lyz2 
expression and robust Cre expression. (A) Lyz2 (also referred to as LysM) and Cre mRNA 
levels were assessed by RT-PCR in Odcfl/fl, Odc∆mye, and LysMcre/cre gastric tissues 4 mo p.i. 
with H. pylori SS1. *P < 0.05, **P < 0.01. n = 3 uninfected and 5 infected mice per genotype. 
(B) Lyz2 and Cre mRNA levels were assessed by RT-PCR in Odcfl/fl, Odc∆mye, and LysMcre/cre 
BMmacs 24 h p.i. with H. pylori PMSS1. ***P < 0.001. n = 3 biological replicates per genotype. 
Statistical significance in all panels was calculated by one-way ANOVA with Newman-Keuls 
post-test. Data displayed as mean ± S.E.M. 
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Appendix C, Figure 4. Immunofluorescence staining for CD68 and ODC in murine 
gastric tissues. (a) Representative images of staining where no primary anti-ODC antibody 
was utilized to confirm specificity of the ODC antibody. Note that the case utilized is the same 
Odcfl/fl case as in Figure 1i. Scale bar = 50 µm.  
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Appendix C, Figure 5. Odc∆mye mice exhibit significantly increased histologic colitis and 
increased disease severity during Citrobacter rodentium infection. (a) Odc mRNA levels 
were assessed by RT-PCR in Odcfl/fl and Odc∆mye BMmacs 6 h p.i. with C. rodentium. ***P < 
0.001. Statistical significance was calculated by one-way ANOVA with Newman-Keuls post-
test. n = 7 biological replicates per genotype.	   (b) Histologic colitis scores were assessed 14 d 
p.i. with C. rodentium by a gastrointestinal pathologist in a blinded manner. *P < 0.05, ***P < 
0.001. n = 6 uninfected and 19-20 C. rodentium-infected mice per genotype. (c) Representative 
H&E images from infected mice in (b). Note the transmural inflammation, crypt abcesses, and 
loss of goblet cells in the Odc∆mye mouse that is not present in the Odcfl/fl mouse. Scale bars = 
100 µm. (d) Colon weight as a percentage of body weight on the day of sacrifice. *P < 0.05, 
***P < 0.001. n = 6 uninfected and 19-20 C. rodentium-infected mice per genotype. In (b), and 
(d), statistical significance was calculated by one-way ANOVA with Newman-Keuls post-test 
on square-root transformed data. (e) Colonization of C. rodentium was assessed by serial 
dilution and culture 14 d p.i. n = 6 uninfected and 19-20 C. rodentium-infected mice per 
genotype. Data displayed as mean ± S.E.M.	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Appendix C, Figure 6. Odc∆mye colonic tissues express significantly increased levels of 
M1 macrophage markers during C. rodentium infection. (a) Il1b, Tnfa, and Nos2 mRNA 
levels were assessed by RT-PCR in Odcfl/fl, Odc∆mye, and LysMcre/cre colonic tissues 14 d p.i. 
with C. rodentium. *P < 0.05, **P < 0.01. n = 3 uninfected and 9 infected mice per genotype. 
Statistical significance was calculated by one-way ANOVA with Newman-Keuls post-test. Data 
displayed as mean ± S.E.M. 
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 Appendix C, Figure 7. Markers of M2 macrophage activation are not substantially 
altered in Odc∆mye gastric tissues during H. pylori infection. (a) Arg1, Chil3, Retnla, Il10, 
Tgfb1, and Tnfsf14 mRNA levels were assessed by RT-PCR in Odcfl/fl, Odc∆mye, and LysMcre/cre 
gastric tissues 4 mo p.i. with H pylori SS1. *P < 0.05, **P < 0.01. n = 3 uninfected and 5 
infected mice per genotype. (b) Arg1 mRNA levels were assessed by RT-PCR Odcfl/fl, and 
Odc∆mye gastric epithelial cells 48 h p.i. with H. pylori PMSS1. *P < 0.05. n = 4 uninfected and 8 
infected mice per genotype. In all panels, statistical significance was calculated by one-way 
ANOVA with Newman-Keuls post-test. Data displayed as mean ± S.E.M. 
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Appendix C, Figure 8. Odc∆mye BMmacs express significantly increased levels of M1 
macrophage markers during C. rodentium infection. (a) Il1b, Tnfa, and Nos2 mRNA levels 
were assessed by RT-PCR in BMmacs from Odcfl/fl and Odc∆mye mice 6 h p.i. with C. 
rodentium. *P < 0.05, **P < 0.01, ***P < 0.001. n = 7 biological replicates per genotype. 
Statistical significance was calculated by one-way ANOVA with Newman-Keuls post-test. Data 
displayed as mean ± S.E.M. 
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Appendix C, Figure 9. Densitometric analysis of NOS2 levels in Odcfl/fl, Odc∆mye, and 
LysMcre/cre BMmacs (a) Densitometric analysis of NOS2 protein levels from the representative 
western blot in Figure 3d. ***P < 0.001. n = 3 biological replicates per genotype. Statistical 
significance was calculated by one-way ANOVA with Newman-Keuls post-test. Data displayed 
as mean ± S.E.M. 
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Appendix C, Figure 10. Markers of M2 macrophage activation are not substantially 
altered in Odc∆mye BMmacs during H. pylori infection. (a) Arg1, Chil3, Retnla, Il10, Tgfb1, 
and Tnfsf14 mRNA levels were assessed by RT-PCR in BMmacs from Odcfl/fl, Odc∆mye, and 
LysMcre/cre mice 24 h p.i. with H pylori PMSS1. *P < 0.05, **P < 0.01. n = 6 mice per genotype. 
(b) Secreted levels of IL-10 and TGF-β1 were measured by ELISA from supernatants of 
BMmacs 24 h p.i. with H. pylori PMSS1. **P < 0.01. n = 6 mice per genotype. In all panels, 
statistical significance was calculated by one-way ANOVA with Newman-Keuls post-test. Data 
displayed as mean ± S.E.M. 
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Appendix C, Figure 11. DFMO-mediated ODC inhibition leads to enhanced M1 
macrophage activation in human THP1 cells during H. pylori infection. (a) ODC mRNA 
was assessed in THP1 cells that were differentiated into macrophages following 18 h treatment 
with PMA (10 ng/mL) and subsequent 6 h infection with H. pylori PMSS1. **P < 0.01. n = 3 
biological replicates. Statistical significance was determined by Student’s t test. (b) 
Representative western blot of ODC protein levels in THP1 cells that were differentiated into 
macrophages following 18 h treatment with PMA (10 ng/mL) and subsequent 6 h infection with 
H. pylori PMSS1. n = 3 biological replicates. (c) IL1B, IL12A, IL12B, and TNFA mRNA levels 
were assessed by RT-PCR in THP1 cells ± DFMO (5 nM) for 3 or 5 d prior to 18 h treatment 
with PMA (10 ng/mL) and subsequent 6 h infection with H. pylori PMSS1. *P < 0.05, **P < 
0.01, ***P < 0.001 versus 3 d ctrl. §P < 0.05, §§P < 0.01 vs. 3 d PMSS1. @@P < 0.01, 
@@@P < 0.001 vs. 5 d ctrl. #P < 0.05, ###P < 0.001 vs. 5 d PMSS1.  n = 3 biological 
replicates. Statistical significance was determined by one-way ANOVA with Newman Keuls 
post-test on square-root transformed data. (d) IL10 mRNA levels were assessed by RT-PCR in 
THP1 cells ± DFMO (5 nM) for 3 or 5 d prior to 18 h treatment with PMA (10 ng/mL) and 
subsequent 6 h infection with H. pylori PMSS1. n = 3 biological replicates. Data displayed as 
mean ± S.E.M. 
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Appendix C, Figure 12. Odc deletion results in enhanced M1 and M2 macrophage 
activation during treatment with classical stimuli. (a) Il1b, Tnfa, and Nos2 mRNA levels 
were assessed by RT-PCR in BMmacs from Odcfl/fl, Odc∆mye, and LysMcre/cre mice 24 h post-
stimulation with IFN-γ (200 U/mL) and LPS (10 ng/mL). *P < 0.05, **P < 0.01, ***P < 0.001. n = 
3 biological replicates per genotype. (b) Arg1 and Chil3 mRNA levels were assessed by RT-
PCR in BMmacs from Odcfl/fl, Odc∆mye, and LysMcre/cre mice 24 h post-stimulation with IL-4 (10 
ng/mL). *P < 0.05, **P < 0.01, ***P < 0.001. n = 3 biological replicates per genotype. Statistical 
significance in all panels was calculated by one-way ANOVA with Newman-Keuls post-test. 
Data displayed as mean ± S.E.M. 
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Appendix C, Figure 13. Addition of excess putrescine does not alter M2 macrophage 
activation marker expression during H. pylori infection. (a) Arg1, Chil3, Retnla, Il10, and 
Tnfsf14 mRNA levels were assessed by RT-PCR in BMmacs from Odcfl/fl, Odc∆mye, and 
LysMcre/cre mice 24 h p.i. with H. pylori PMSS1 ± 25 µM putrescine added 60 min prior to 
infection. n = 4 biological replicates per genotype. Data displayed as mean ± S.E.M. 
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Appendix C, Figure 14. Odc deletion in macrophages enhances NLRP3-inflammasome 
activation during H. pylori infection. (a) mRNA levels of Nlrp3 and Casp1 were assessed by 
RT-PCR in gastric tissues 4 mo p.i. with H. pylori SS1. *P<0.05, **P<0.01, ***P<0.001 by one-
way ANOVA with Kruskal-Wallis post-test, followed by Mann-Whitney U test. n = 3 uninfected 
and 5 H. pylori SS1 infected mice per genotype. (b) mRNA levels of Nlrp3 and Casp1 were 
assessed by RT-PCR in BMmacs 24 h p.i. with H. pylori PMSS1. **P<0.01, ***P<0.001 by one-
way ANOVA with Newman-Keuls post-test. n = 3 mice per genotype. (c) IL-1β protein levels 
were assessed by ELISA in gastric tissues 4 mo p.i. with H. pylori SS1. *P<0.05, **P<0.01, 
***P<0.001 by one-way ANOVA with Kruskal-Wallis post-test, followed by Mann-Whitney U 
test. n = 4 uninfected and 8-9 H. pylori SS1-infected mice per genotype. (d) pro-IL-1β protein 
levels were assessed by western blotting in BMmacs 24 h p.i. with H. pylori PMSS1. n = 4 
mice per genotype. (e) mRNA levels of Nlrp3 and Casp1 were assessed by RT-PCR in 
BMmacs 24 h p.i. with H. pylori PMSS1 ± 25 mM putrescine added 60 min prior to infection. 
*P<0.05 vs. Odcfl/fl + PMSS1; @P<0.05, @@@P<0.001 vs. Odcfl/fl + PMSS1 + putrescine; 
§P<0.05, §§P<0.01 vs. Odc∆mye + PMSS1 by one-way ANOVA with Newman-Keuls post-test. n 
= 4 biological replicates. Data displayed as mean ± S.E.M. 
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Appendix C, Figure 15. Odc deletion in macrophages alters acetylation and di/tri-
methylation of histone 3, lysine 9 during C. rodentium infection. (a) Representative 
western blot of H3K9ac and levels in BMmacs 6 h p.i. with C. rodentium. n = 3 biological 
replicates. (b) Representative western blot of H3K9me2/3 levels in BMmacs 24 h p.i. with C. 
rodentium. n = 3 biological replicates.   
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Appendix C, Figure 16. Putrescine add-back returns the H3K9ac and H3K9me2/3 levels 
in Odc∆mye BMmacs to those in Odcfl/fl BMmacs. (a) Representative western blot of H3K9ac 
and H3K9me2/3 levels in BMmacs 24 h p.i. with H. pylori PMSS1 ± 25 mM putrescine, 10 mM 
spermidine, or 10 mM spermine added 60 min prior to infection. n = 3 biological replicates. 
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Appendix C, Figure 17. Gene expression of unchanged markers of general 
transcriptional levels following ChIP with anti-H3K9ac and anti-H3K9me3 antibodies in 
Odc-deficient BMmacs. (a) Expression of Gapdh and Iap was assessed by RT-PCR in 
BMmacs from Odcfl/fl and Odc∆mye mice 24 h p.i. with H. pylori PMSS1 with subsequent ChIP 
with the denoted antibodies. n = 3 biological replicates. (b) Expression of Myod1 was assessed 
by RT-PCR in BMmacs from Odcfl/fl and Odc∆mye mice 24 h p.i. with H. pylori PMSS1 with 
subsequent ChIP with the denoted antibodies. Data displayed as mean ± S.E.M. 
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Appendix C, Figure 18. Gene expression of unchanged pro-inflammatory markers 
following ChIP with anti-H3K9ac and anti-H3K9me3 antibodies in Odc-deficient 
BMmacs. (a) Expression of Il1b, Il6, Tnfa, and Nos2 promoter sequences was assessed by 
RT-PCR in BMmacs from Odcfl/fl and Odc∆mye mice 24 h p.i. with H. pylori PMSS1, followed by 
subsequent ChIP with the denoted antibodies. n = 3 biological replicates. Data displayed as 
mean ± S.E.M. 
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Appendix C, Figure 19. Alterations in histone modifications and chromatin structure in 
ODC-deficient macrophages does not alter M2 macrophage activation during H. pylori 
infection. (a) M2 markers, Arg1, Chil3, and Retnla, Il10, and Tgfb were assessed at the 
mRNA level by RT-PCR in BMmacs 24 h p.i. with H. pylori PMSS1 ± 5 µM BIX 01924 added 
60 min prior to infection. *P<0.05, **P<0.01, by one-way ANOVA with Kruskal-Wallis post-test, 
followed by Mann-Whitney U test. n = 5 mice per genotype. (b) M2 markers, Arg1, Chil3, and 
Retnla, Il10, and Tgfb were assessed at the mRNA level by RT-PCR in BMmacs 24 h p.i. with 
H. pylori PMSS1 ± 10 µM anacardic acid added 60 min prior to infection. ***P<0.001 by one-
way ANOVA with Kruskal-Wallis post-test, followed by Mann-Whitney U test. n = 5 mice per 
genotype. Data displayed as mean ± S.E.M. 
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Analyte 
Concentration of Analyte (pg/mg protein); Mean ± S.E.M. 
Odcfl/fl Odc∆mye LysMcre/cre 
Uninfected H. pylori 
SS1 
Uninfected H. pylori 
SS1 
Uninfected H. pylori 
SS1 
CSF2 3.70 ± 0.77 5.30 ± 0.53 3.42 ± 0.24 6.77 ± 0.86* 2.61 ± 0.56 4.09 ± 0.64 
CSF3 0.79 ± 0.35 0.95 ± 0.20 0.30 ± 0.04 0.44 ± 0.11 0.38 ± 0.10 0.29 ± 0.07 
IFN-γ 0.84 ± 0.11 1.33 ± 0.21 0.86 ± 0.20 2.02 ± 0.47*** 0.67 ± 0.13 0.53 ± 0.07 
IL-1α 24.01 ± 2.41 
24.30 ± 
4.01 
31.80 ± 
3.52 
32.00 ± 
2.97 
31.01 ± 
5.44 
28.17 ± 
2.44 
IL-2 1.08 ± 0.08 0.65 ± 0.09 0.90 ± 0.20 0.53 ± 0.07 1.19 ± 0.26 0.74 ± 0.14 
IL-4 0.22 ± 0.03 0.20 ± 0.03 0.18 ± 0.03 0.18 ± 0.04 0.20 ± 0.06 0.21 ± 0.05 
IL-5 0.84 ± 0.24 0.70 ± 0.08 0.40 ± 0.04 0.56 ± 0.12 0.40 ± 0.07 0.58 ± 0.17 
IL-6 1.30 ± 0.40 1.07 ± 0.12 1.23 ± 0.27 1.76 ± 0.64 2.15 ± 1.27 0.93 ± 0.10 
IL-7 0.68 ± 0.14 1.31 ± 0.33 0.69 ± 0.06 0.96 ± 0.11 0.46 ± 0.09 0.60 ± 0.08 
IL-9 10.84 ± 2.01 8.91 ± 1.40 
10.73 ± 
3.35 7.46 ± 1.63 
10.81 ± 
3.25 5.49 ± 1.28 
IL-10 0.24 ± 0.09 0.26 ± 0.05 0.14 ± 0.02 0.24 ± 0.08 0.12 ± 0.01 0.10 ± 0.03 
IL-12B 1.96 ± 0.54 1.01 ± 0.15 1.13 ± 0.28 0.49 ± 0.15 0.62 ± 0.53 0.69 ± 0.21 
IL-12 0.56 ± 0.10 0.48 ± 0.09 0.47 ± 0.09 0.78 ± 0.22 0.46 ± 0.09 0.29 ± 0.04 
IL-13 0.06 ± 0.04 0.57 ± 0.29 0.04 ± 0.02 0.99 ± 0.40 0.54 ± 0.52 0.37 ± 0.18 
IL-15 0.51 ± 0.19 2.13 ± 0.41 1.59 ± 0.40 1.77 ± 0.29 1.11 ± 0.36 0.87 ± 0.10 
 
Appendix C, Table 1. Luminex analytes that did not demonstrate significant differences 
in gastric tissues from uninfected and infected Odcfl/fl, Odc∆mye, and LysMcre/cre mice. A 
total of 25 distinct analytes were assessed in gastric tissue from uninfected and infected mice 
from each of the three genotypes. Listed are the analytes that were not significantly induced by 
infection, or demonstrated few or no significant differences between genotypes. Note that IL-1β 
is not shown, as this analyte was measured by ELISA. n = 4 uninfected and 8-9 H. pylori SS1 
infected mice per genotype. *P<0.05 and ***P< 0.001 versus LysMcre/cre + H. pylori SS1. 
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Antibody Dilution Application Source (Location) 
Rabbit polyclonal anti-NOS2 1:5,000 WB EMD Millipore (Darmstadt, 
Germany) 
Cat. no. ABN26 
Mouse monoclonal anti-IL-1β 1:1,000 WB Cell Signaling Technology 
(Danvers, MA) 
Cat. no. 12242 
Rabbit polyclonal anti-ODC 1:5,000 
1:2,000 
1:2,000 
WB 
IF 
IHC-P 
Lisa Shantz (Penn State College of 
Medicine) 
David Feith (University of Virginia)  
Mouse monoclonal anti-
H3K9me2/3 
1:1,000 WB Cell Signaling Technology 
(Danvers, MA) 
Cat. no. 5327 
Rabbit polyclonal anti-
H3K9ac 
1:1,000 
1:200 
WB 
IF 
Cell Signaling Technology 
(Danvers, MA) 
Cat. no. 9649 
Rabbit polyclonal anti-
H3K4me1 
1:1,000 WB Cell Signaling Technology 
(Danvers, MA) 
Cat. no. 9723 
Mouse monoclonal anti-β-
actin 
1:10,000 WB Sigma-Aldrich (St. Louis, MO) 
Cat. no. A1978 
Goat anti-mouse IgG, HRP 
labeled 
1:30,000 WB Sigma-Aldrich (St. Louis, MO) 
Cat. no. 115-035-003 
Goat anti-rabbit IgG, HRP 
labeled 
1:3,000 WB Sigma-Aldrich (St. Louis, MO) 
Cat. no. 111-035-003 
Rabbit polyclonal anti-CD68 1:200 IF Boster Biological Technology 
(Pleasanton, CA) 
Cat. no. PA1518 
Goat anti-rabbit IgG, 
Alexa488 
1:400 IF ThermoFisher Scientific (Waltham, 
MA) 
Cat. no. A11078 
Goat anti-rabbit IgG, 
Alexa555 
1:500 IF ThermoFisher Scientific (Waltham, 
MA) 
Cat. no. A21429 
 
Appendix C, Table 2. List of all antibodies used for this study, including the dilution, 
application and company from which the antibodies were purchased. WB = western blotting, IF 
= immunofluorescence. IHC-P = immunoperoxidase.  	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Species Target Sequence 
Mouse β-actin F: CCAGAGCAAGAGAGGTATCC R: CTGTGGTGGTGAAGCTGTAG 
Mouse Nos2 F: CACCTTGGAGTTCACCCAGT R: ACCACTCGTACTTGGGATGC 
Mouse Tnfa F: CTGTGAAGGGAATGGGTGTT R: GGTCACTGTCCCAGCATCTT 
Mouse Il1b F: ACCTGCTGGTGTGTGACGTTCC R: GGGTCCGACAGCACGAGGCT 
Mouse Il6 F: AGTTGCCTTCTTGGGACTGA R: TCCACGATTTCCCAGAGAAC 
Mouse Il12a F: AAATGAAGCTCTGCATCCTGC R: TCACCCTGTTGATGGTCACG 
Mouse Il12b F: GAAAGACCCTGACCATCACT R: CCTTCTCTGCAGACAGAGAC 
Mouse Il23a F: CCAGCAGCTCTCTCGGAATC R: TCATAGTCCCGCTGGTGC 
Mouse Arg1 F: AAGAAAAGGCCGATTCACCT R: CACCTCCTCTGCTGTCTTCC 
Mouse Chil3 F: ACTTTGATGGCCTCAACCTG R: AATGATTCCTGCTCCTGTGG 
Mouse Retnla F: GGGATGACTGCTACTGGGTG R: TCAACGAGTAAGCACAGGCA 
Mouse Il10 F: CCAAGCCTTATCGGAAATGA R: TCACTCTTCACCTGCTCCAC 
Mouse Tgfb1 F: TCCTTGCCTGCGGAAGTG R: GGAGAGCATTGAGCAGTTCGA 
Mouse Tnfsf14 F: CTGCATCAACGTCTTGGAGA R: GATACGTCAAGCCCCTCAAG 
Mouse  Odc F: CCTTGTGAGGAGCTGGTGATA R: GGTCCAGAATGTCCTTAGCAGT 
Mouse Nlrp3 F: ATGCTGGCTTCGACATCTCCT R: GTTTCTGGAGGTTGCAGAGC 
Mouse Casp1 F: AGATGCCCACTGCTGATAGG R: TTGGCACGATTCTCAGCATA 
Mouse Nos2 (Promoter) 
F: ATGGCCTTGCATGAGGATAC 
R: CACCAAGGTGGCTGAGAAGT 
Mouse Il1b (Promoter) F: CCCCTAAGAATTCCCATCAAGC R: GAGCTGTGAAATTTTCCCTTGG 
Mouse Tnfa (Promoter) F: CCCCAGATTGCCACAGAATC R: CCAGTGAGTAAAGGGACAG 
Mouse Il6 (Promoter) F: CCCACCCTCCAACAAAGATT  R: GCTCCAGAGCAGAATGAGCTA  
Human IL1B F: TGAACTGCACGCTCCGG R: GAACACCACTTGTTGCTC 
Human TNFA F: ATGAGCACTGAAAGCATGATCC R: GAGGGCTGATTAGAGAGAGGTC 
203
Human IL6 F: GTAGCCGCCCCACACAGA R: CATGTCTCCTTTCTCAGGGCTG 
Human IL12A F: CAAAACCTGCTGAGGGCCGTCA R: GGAGGCCAGGCAACTCCCATTAG 
Human IL12B F: CCAAGAACTTGCAGCTGAAG R: TGGGTCTATTCCGTTGTGTC 
Human IL10 F: GCCTAACATGCTTCGAGATC R: TGATGTCTGGGTCTTGGTTC 
 
Appendix C, Table 3. List of primers used for RT-PCR. (Promoter) = primers utilized for ChIP-
PCR. 	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  APPENDIX D 
 
The original publication (listed below) is included as a PDF, as it relates to macrophage activation and 
function during H. pylori infection. 
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Casero, R.A. Jr., Piazuelo, M.B., and Wilson, K.T. Arginase 2 deletion leads to enhanced M1 
macrophage activation and upregulated polyamine metabolism in response to Helicobacter pylori 
infection. (2016) Amino Acids.  48(10): 2375-2388. PMID: 27074721 
 
 
 
 
 
 
 
205
1 3
DOI 10.1007/s00726-016-2231-2
Amino Acids (2016) 48:2375–2388
ORIGINAL ARTICLE
Arginase 2 deletion leads to enhanced M1 macrophage 
activation and upregulated polyamine metabolism in response 
to Helicobacter pylori infection
Dana M. Hardbower1,2 · Mohammad Asim2 · Tracy Murray‑Stewart3 · 
Robert A. Casero Jr.3 · Thomas Verriere2 · Nuruddeen D. Lewis2 · 
Rupesh Chaturvedi2,4 · M. Blanca Piazuelo2 · Keith T. Wilson1,2,5,6,7 
Received: 28 January 2016 / Accepted: 5 April 2016 / Published online: 13 April 2016 
© Springer-Verlag Wien 2016
gastric tissues and splenic T-cells from Arg2−/−, but not 
Nos2−/− or Arg2−/−;Nos2−/− mice. Gastric tissues from 
infected Arg2−/− mice demonstrated increased expression 
of arginase 1, ornithine decarboxylase, adenosylmethionine 
decarboxylase 1, spermidine/spermine N1-acetyltransferase 
1, and spermine oxidase, along with increased spermine 
levels. These data indicate that ARG2 deletion results in 
compensatory upregulation of gastric polyamine synthe-
sis and catabolism during H. pylori infection, which may 
contribute to increased gastric inflammation and associ-
ated decreased bacterial load. Overall, the finding of this 
study is that ARG2 contributes to the immune evasion of H. 
pylori by restricting M1 macrophage activation and poly-
amine metabolism.
Keywords Helicobacter pylori · Immune evasion · 
Polyamines · Macrophage activation
Abbreviations
AMD1  Adenosylmethionine decarboxylase 1
ARG1  Arginase 1; arginase, type I
ARG2  Arginase 2; arginase, type II
Abstract We reported that arginase 2 (ARG2) dele-
tion results in increased gastritis and decreased bacte-
rial burden during Helicobacter pylori infection in mice. 
Our studies implicated a potential role for inducible nitric 
oxide (NO) synthase (NOS2), as Arg2−/− mice exhibited 
increased NOS2 levels in gastric macrophages, and NO 
can kill H. pylori. We now bred Arg2−/− to Nos2−/− mice, 
and infected them with H. pylori. Compared to wild-type 
mice, both Arg2−/− and Arg2−/−;Nos2−/− mice exhib-
ited increased gastritis and decreased colonization, the 
latter indicating that the effect of ARG2 deletion on bac-
terial burden was not mediated by NO. While Arg2−/− 
mice demonstrated enhanced M1 macrophage activation, 
Nos2−/− and Arg2−/−;Nos2−/− mice did not demonstrate 
these changes, but exhibited increased CXCL1 and CXCL2 
responses. There was an increased expression of the Th1/
Th17 cytokines, interferon gamma and interleukin 17, in 
Handling Editor: E. Agostinelli.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00726-016-2231-2) contains supplementary 
material, which is available to authorized users.
 * Keith T. Wilson 
 keith.wilson@vanderbilt.edu
1 Department of Pathology, Microbiology and Immunology, 
Vanderbilt University Medical Center, Vanderbilt University 
School of Medicine, 2215 Garland Avenue, 1030C Medical 
Research Building IV, Nashville, TN 37232, USA
2 Division of Gastroenterology, Hepatology and Nutrition, 
Department of Medicine, Vanderbilt University Medical 
Center, Nashville, TN, USA
3 The Sydney Kimmel Comprehensive Cancer Center, Johns 
Hopkins University School of Medicine, Baltimore, MD, 
USA
4 School of Biotechnology, Jawaharlal Nehru University,  
New Delhi, India
5 Department of Cancer Biology, Vanderbilt University 
Medical Center, Nashville, TN, USA
6 Center for Mucosal Inflammation and Cancer, Vanderbilt 
University Medical Center, Nashville, TN, USA
7 Veterans Affairs Tennessee Valley Healthcare System, 
Nashville, TN, USA
206
2376 D. M. Hardbower et al.
1 3
CCL  C–C chemokine ligand
CD  Cluster of differentiation
CHIA1  Chitinase, acidic 1
CXCL  C–X–C chemokine ligand
FPL  French-pressed lysate
IFN-γ  Interferon gamma
IL  Interleukin
M-CSF  Macrophage colony stimulating factor
MOI  Multiplicity of infection
NO  Nitric oxide
NOS2  Nitric oxide synthase 2; inducible nitric oxide 
synthase
ODC  Ornithine decarboxylase
PMSS1  Pre-mouse Sydney Strain 1
RT-PCR  Real-time polymerase chain reaction
RETNLA  Resistin like molecule alpha
SAT1  Spermidine/spermine N1-acetyltransferase 1
SMOX  Spermine oxidase
SS1  Sydney Strain 1
TGF  Transforming growth factor
Th  T helper
TNF  Tumor necrosis factor
TNFSF14  Tumor necrosis factor superfamily member 14
Introduction
Helicobacter pylori is a Gram-negative, microaerophilic 
bacterium that selectively colonizes the gastric mucosa of 
humans (Cover and Blaser 2009; Hardbower et al. 2014; 
Sibony and Jones 2012). It is estimated that more than 
50 % of the human population is infected with H. pylori, 
leading to chronic gastritis and peptic ulcer disease (Cover 
and Blaser 2009; Sibony and Jones 2012). Importantly, 
H. pylori is the greatest risk factor for the development of 
gastric adenocarcinoma, the third leading cause of cancer 
deaths worldwide (Bonequi et al. 2013; Hardbower et al. 
2013, 2014; Nomura et al. 1991; Parsonnet et al. 1991; 
Peek and Blaser 2002; Ferlay et al. 2015). The global prev-
alence of infection and the high degree of gastric cancer 
mortality clearly indicate that H. pylori is a significant pub-
lic health issue.
H. pylori infection induces both innate and adaptive 
immune responses, but these responses are inadequate to 
clear the infection and result in pro-carcinogenic, chronic 
inflammation (Hardbower et al. 2013, 2014; Peek et al. 
2010; Robinson et al. 2007; Wilson and Crabtree 2007). 
Macrophages represent a dynamic subset of innate immune 
cells and serve to coordinate the immune response to H. 
pylori (Murray and Wynn 2011; Peek et al. 2010; Robinson 
et al. 2007; Wilson and Crabtree 2007). Macrophage acti-
vation is a critical component in the response to bacterial 
pathogens (Benoit et al. 2008). There are three classes of 
activated macrophages—M1, M2, and Mreg (Martinez and 
Gordon 2014; Mosser 2003; Mosser and Edwards 2008). 
M1 macrophages are highly pro-inflammatory: express-
ing high levels of inducible nitric oxide synthase (NOS2), 
interleukin (IL)-1β, and tumor necrosis factor (TNF)-α; 
they are aimed at the clearance of pathogens (Benoit et al. 
2008; Martinez and Gordon 2014; Mosser 2003; Mosser 
and Edwards 2008; Murray and Wynn 2011; Strauss-Ayali 
et al. 2007). Alternatively activated M2 macrophages are 
specialized for wound healing and responses to parasites, 
with enhanced expression of arginase 1 (ARG1), chitinase 
1 (CHIA1) and resistin-like molecule alpha (RETNLA) 
(Anderson and Mosser 2002; Martinez and Gordon 2014; 
Mosser and Edwards 2008). M2 macrophages are also 
referred to as tumor-associated macrophages, given their 
pro-angiogenic and pro-tumorigenic properties (Ostuni 
et al. 2015; Pander et al. 2011). Regulatory macrophages, 
Mreg, are anti-inflammatory and secrete high levels of 
IL-10 and transforming growth factor (TGF)-β (Fleming 
and Mosser 2011; Mosser and Edwards 2008; Murray and 
Wynn 2011). H. pylori infection most commonly results in 
M1 and Mreg macrophage activation (Gobert et al. 2014).
H. pylori has developed effective mechanisms to thwart 
the macrophage response, which appears to be centraliz-
ing around the roles of NOS2 and arginase 2 (ARG2) in 
macrophage function. Infection with a bacterial pathogen, 
including H. pylori, leads to induction of NOS2 and pro-
duction of nitric oxide (NO), a potent anti-microbial mole-
cule, from l-arginine (l-Arg) (Shapiro and Hotchkiss 1996; 
Wilson et al. 1996; Gobert et al. 2002b). H. pylori dimin-
ishes the efficacy of the NO response via production of the 
bacterial arginase, RocF, leading to depletion of l-Arg that 
is available to the host (Gobert et al. 2001, 2011; Chatur-
vedi et al. 2007). Additionally, H. pylori infection leads 
to induction of ARG2, which also utilizes l-Arg as a sub-
strate (Lewis et al. 2010, 2011). Induction of ARG2 further 
reduces l-Arg availability to NOS2, and also leads to mac-
rophage apoptosis (Gobert et al. 2002a; Gogoi et al. 2015; 
Lewis et al. 2010, 2011). By modulating l-Arg levels, the 
efficacy of both NOS2 and ARG2, and macrophage viabil-
ity, H. pylori effectively hinders the macrophage response, 
allowing for the establishment of a pro-tolerogenic envi-
ronment in which to survive over the lifetime of the host 
(Chaturvedi et al. 2010, 2012; Wilson and Crabtree 2007). 
The purpose of the current study was to determine the role 
of NO or other mechanisms in the altered immunity to H. 
pylori attributable to ARG2.
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Results
The role of ARG2 in H. pylori immunopathogenesis  
is not NOS2‑dependent
We have previously reported that Arg2−/− mice had sig-
nificantly increased H. pylori-induced gastritis, with a con-
comitant decrease in bacterial burden (Lewis et al. 2011). 
We determined that ARG2 attenuated NOS2 translation, 
and thus, we hypothesized that the augmented gastritis in 
the Arg2−/− mice was due to enhanced NOS2 translation 
and NO production (Lewis et al. 2010, 2011). To deter-
mine if the ARG2 phenotype was dependent on NOS2, 
we crossed Nos2−/− mice and Arg2−/− mice, creating 
Arg2−/−;Nos2−/− mice. ARG2 and NOS2 are both highly 
inducible in macrophages during H. pylori infection (Gob-
ert et al. 2002a; Shapiro and Hotchkiss 1996; Wilson et al. 
1996). Thus, we took advantage of this fact and utilized 
macrophages to confirm Arg2 and Nos2 knockout in bone 
marrow-derived macrophages (BMmacs) infected ex vivo 
with H. pylori (Supp. Fig. 1a, b), as differences in ARG2 
and NOS2 levels would be most apparent in macrophages. 
Wild type (WT), Arg2−/−, Nos2−/− and Arg2−/−;Nos2−/− 
mice were infected with H. pylori SS1 for 4 months, after 
which the mice were killed and their stomachs isolated for 
analysis. Consistent with our previous studies (Lewis et al. 
2011), Arg2−/− mice had significantly increased gastri-
tis versus WT mice (Fig. 1a). Arg2−/−;Nos2−/− mice also 
had significantly increased gastritis when compared to 
WT mice (Fig. 1a). Nos2−/− mice had similar gastritis as 
WT mice (Fig. 1a). The representative images of the gas-
tritis further demonstrate the increased inflammation in 
Arg2−/− and Arg2−/−;Nos2−/− mice, as compared to WT 
and Nos2−/− mice (Fig. 1b). Consistent with the increase in 
gastritis, Arg2−/− and Arg2−/−;Nos2−/− mice both showed 
significantly decreased bacterial burden when compared to 
WT mice (Fig. 1c). These data, especially the finding that 
Arg2−/−;Nos2−/− mice did not lose the reduced coloniza-
tion of Arg2−/− mice, indicate that the role of ARG2 in H. 
pylori pathogenesis is not dependent on NOS2, but rather 
some other aspect of the immune response to the pathogen. 
Additionally, Nos2−/− mice exhibited a modest decrease in 
colonization compared to WT mice (Fig. 1c), further sug-
gesting that NOS2-derived NO is not the primary effector 
that controls colonization in this infection model.
ARG2 reduces pro‑inflammatory cytokine expression 
and immune cell‑derived chemokine production 
in response to H. pylori
To begin to address how ARG2 alters the immune 
response to H. pylori, we performed Luminex analy-
sis on gastric tissues from WT, Arg2−/−, Nos2−/− and 
Arg2−/−;Nos2−/− mice after chronic infection to assess 
differences in cytokine and chemokine levels in tissues. 
We found that Arg2−/− and Arg2−/−;Nos2−/− mice had 
significantly increased protein levels of C–C chemokine 
ligand (CCL) 3 (MIP-1α), CCL4 (MIP-1β), and CCL5 
(RANTES), as compared to WT and Nos2−/− mice 
(Fig. 2a). CCL3, CCL4, and CCL5 are typically produced 
by immune cells, such as macrophages, in response to path-
ogens (Algood et al. 2004). These data indicate that ARG2 
regulates the innate immune response to H. pylori. Specifi-
cally, ARG2 deletion may affect M1 macrophage activation, 
as M1 macrophages are pro-inflammatory drivers of the 
innate immune response to many pathogens (Benoit et al. 
2008; Martinez and Gordon 2014; Mosser and Edwards 
2008; Murray and Wynn 2011). Thus, we assessed mRNA 
expression levels of the M1 macrophage markers, Nos2, Il-
1β, and Tnf-α (Mosser and Edwards 2008) in gastric tissues 
from WT, Arg2−/−, Nos2−/−, and Arg2−/−;Nos2−/− mice. 
Nos2−/− and Arg2−/−;Nos2−/− mice did not express Nos2, 
further confirming knockout of the gene (Fig. 2b). Arg2−/− 
mice had significantly enhanced mRNA levels of the M1 
markers, compared to the other three genotypes (Fig. 2b). 
Markers of M2 and Mreg macrophage activation were also 
assessed in these gastric tissues. M2 markers, Chia1 (also 
known as Ym1) and Retnla (also known as Fizz1/Relm-α) 
(Anderson and Mosser 2002; Mosser and Edwards 2008), 
were not induced by H. pylori infection (data not shown). 
Moreover, Mreg markers, Il-10 and Tgf-β (Anderson and 
Mosser 2002; Mosser and Edwards 2008; Murray and 
Wynn 2011), were not significantly altered between the 
four genotypes (data not shown), indicating that the effect 
of ARG2 knockout is specifically on M1 activation.
Interestingly, as shown in Fig. 3, NOS2 knockout, in 
both Nos2−/− and Arg2−/−;Nos2−/− mice, resulted in sig-
nificantly increased levels of the chemokines, C–X–C 
chemokine ligand (CXCL) 1 (KC) and CXCL2 (MIP2), 
which have been shown to be primarily produced by epi-
thelial cells (Schleimer et al. 2007). These data indicate that 
the effects of the Nos2 deletion may be more significant in 
epithelial cell function than in immune cell function.
ARG2 diminishes Th1/Th17 T‑cell differentiation 
in response to chronic H. pylori infection
A second essential component to H. pylori-driven gastri-
tis is the adaptive T-cell response (Robinson et al. 2007). 
To evaluate the T helper (Th) cell response to H. pylori 
infection, gastric tissues from WT, Arg2−/−, Nos2−/−, and 
Arg2−/−;Nos2−/− mice were assessed for gene expression of 
Th1-, Th17-, Th2-, and Treg-specific markers. The mRNA 
levels of Th1 marker, Ifn-γ, and Th17 marker, Il-17, were 
significantly increased in Arg2−/− mice, when compared 
to WT mice (Fig. 4a). This correlates with the significantly 
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increased histologic gastritis observed in these mice 
(Fig. 1a). However, WT, Nos2−/−, and Arg2−/−;Nos2−/− 
mice demonstrated similar levels of Ifn-γ and Il-17a expres-
sion in gastric tissues, and each had significantly lower 
expression than in Arg2−/− mice (Fig. 4a). These data sug-
gest that the increase in the Th1/Th17 response to H. pylori 
in Arg2−/− mice is dependent on NOS2, as Arg2−/−;Nos2−/− 
mice demonstrated the same Th1/Th17 phenotype as 
Nos2−/− mice. mRNA expression of Th2 marker, Il-4, and 
expression of Treg marker, Foxp3, were also measured in 
gastric tissues from these mice and no significant differ-
ences were found between genotypes (data not shown).
To confirm the enhanced Th1/Th17 findings in Arg2−/− 
mice, splenocytes were isolated from H. pylori-infected 
WT and Arg2−/− mice, and cultured in the presence of 
CD3 and CD28 to promote T-cell proliferation. The splenic 
T-cells were then treated with H. pylori SS1 French-
pressed lysate (FPL) to allow H. pylori-specific T-cells to 
proliferate, and levels of secreted IFN-γ and IL-17 were 
assessed. Consistent with the mRNA findings in gastric tis-
sue, Arg2−/− mice had significantly increased IFN-γ and 
IL-17 secretion from splenic T-cells (Fig. 4b). Additionally, 
the Th1 population within the H. pylori-stimulated splenic 
T-cells was assessed by flow cytometry for CD4, a T helper 
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Fig. 1  Effect of Arg2 and/or Nos2 knockout on H. pylori patho-
genesis after chronic infection. WT, Arg2−/−, Nos2−/−, and 
Arg2−/−;Nos2−/− mice were infected with H. pylori Sydney Strain 1 
(SS1) for 4 months. Mice were killed and their stomachs were iso-
lated for analysis. a Histologic gastritis was assessed in a blinded 
manner according to the Sydney System by a gastrointestinal pathol-
ogist. n = 9–10 uninfected and 16–20 H. pylori SS1-infected mice 
per genotype. Statistical significance was determined by one-way 
ANOVA with Kruskal–Wallis test, followed by Mann–Whitney U 
test. b Representative images of hematoxylin and eosin-stained tis-
sues, from H. pylori-infected mice of each genotype. Scale bars 
100 μM. c H. pylori colonization was assessed by serial dilution and 
culture. n = 16–20 H. pylori SS1-infected mice per genotype. Sta-
tistical significance was determined by one-way ANOVA with New-
manKeuls post-test. In a and c, *p < 0.05, **p < 0.01, ***p < 0.001
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cell marker, and intracellular IFN-γ. Again, Arg2−/− mice 
had a significantly increased CD4+/IFN-γ+ Th1 popu-
lation, as compared to H. pylori-stimulated WT splenic 
T-cells (Fig. 4c).
ARG2 mediates M1 macrophage activation 
and function, but not M2 or Mreg activation, 
in response to H. pylori
As previously reported, ARG2 and NOS2 are highly induc-
ible in macrophages during H. pylori infection (Gobert 
et al. 2002a, b; Lewis et al. 2010). Bone marrow-derived 
macrophages (BMmacs) were isolated from WT, Arg2−/−, 
Nos2−/− and Arg2−/−;Nos2−/− mice to specifically evalu-
ate the affect of ARG2 and NOS2 knockout on macrophage 
activation and function. BMmacs from each of the four 
genotypes in this study were co-cultured with H. pylori 
for 24 h, followed by assessment of M1, M2, and Mreg 
activation markers by real-time polymerase chain reaction 
(RT-PCR). Gene expression levels of Nos2, Il-1β, and Tnf-
α were utilized as representative M1 markers, Chia1 and 
Retnla as M2 markers, and Il-10, Tgf-β, and Tnfsf14 as 
Mreg markers. As expected, Nos2−/− and Arg2−/−;Nos2−/− 
BMmacs did not expresses Nos2 (Fig. 5a). Arg2−/− 
BMmacs demonstrated enhanced M1 activation, as evi-
denced by significantly increased Nos2, Il-1β, and Tnf-α, 
as compared to WT and Nos2−/− BMmacs (Fig. 5a). 
Interestingly, Arg2−/−;Nos2−/− BMmacs demonstrated 
increased Il-1β expression to a similar level as Arg2−/− 
BMmacs, while Tnf-α expression remained similar to WT 
and Nos2−/− BMmacs, rather than increasing as in Arg2−/− 
BMmacs (Fig. 5a). The effects of ARG2 and NOS2 on 
b
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Fig. 2  Loss of ARG2 leads to enhanced pro-inflammatory innate 
immune responses to H. pylori. a Protein was isolated from gas-
tric tissues from WT, Arg2−/−, Nos2−/−, and Arg2−/−;Nos2−/− mice 
4 months post-inoculation (p.i.). with H. pylori SS1. Protein levels 
of the immune cell-derived chemokines, CCL3 (MIP-1α), CCL4 
(MIP-1β), and CCL5 (RANTES) were assessed by Luminex assay. 
n = 4–5 uninfected and 8–10 H. pylori SS1-infected mice per geno-
type. Statistical significance was determined by one-way ANOVA 
with Kruskal–Wallis test, followed by Mann–Whitney U test. b RNA 
was isolated from gastric tissues from WT, Arg2−/−, Nos2−/−, and 
Arg2−/−;Nos2−/− mice 4 months p.i. with H. pylori SS1. The pro-
inflammatory markers, Nos2, Il-1β, and Tnf-α, were assessed by RT-
PCR. n = 4 uninfected and 7–8 H. pylori SS1-infected mice per gen-
otype. Statistical significance was determined by one-way ANOVA 
with Kruskal–Wallis test, followed by Mann–Whitney U test. In a 
and b, *p < 0.05, **p < 0.01, ***p < 0.001
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macrophage activation were also studied in BMmacs from 
each genotype, utilizing IFN-γ/LPS activation as a classi-
cal M1 stimulus. Under these conditions, both Arg2−/− and 
Arg2−/−;Nos2−/− BMmacs had enhanced M1 activation, 
when compared with WT and Nos2−/− BMmacs (Supp. 
Fig. 2a). Arg2−/−;Nos2−/− BMmacs had the highest expres-
sion of Il-1β, even when compared to Arg2−/− BMmacs 
(Supp. Fig. 2a).
M2 and Mreg markers were also assessed in BMmacs 
from all four genotypes. Consistent with the gastric tissue 
mRNA data, H. pylori infection did not induce expression 
of Arg1, Chia1, or Retnla in BMmacs, from any of the gen-
otypes (data not shown). As H. pylori did not induce an M2 
response, BMmacs from each of the four genotypes were 
stimulated with IL-4, the canonical M2 stimulus. Stimula-
tion with IL-4 induced an M2 response in these mice, but 
there were no significant differences between the genotypes 
(Supp. Fig. 2b). Moreover, H. pylori infection had a very 
modest effect on Mreg activation between the four geno-
types. Arg2−/− BMmacs had significantly increased Il-10 
expression, when compared to each of the other genotypes 
(data not shown). Additionally, there was no difference in 
Tgf-β or Tnfsf14 expression between each of the genotypes 
(data not shown).
To confirm the effect of ARG2 on M1 macrophage acti-
vation in vivo, splenic macrophages were isolated from 
chronically infected WT and Arg2−/− mice, and stimulated 
with H. pylori SS1 FPL. As expected, splenic macrophages 
from Arg2−/− mice had significantly increased levels of 
secreted IL-1β and TNF-α (Fig. 5b). Moreover, Arg2−/− 
BMmacs produced significantly increased levels of NO, 
in response to H. pylori infection ex vivo (Fig. 5c). Taken 
together, these data demonstrate that ARG2 can modulate 
M1 macrophage responses to H. pylori and other stimuli, 
but ARG2 does not have a role in regulating M2 and Mreg 
activation.
ARG2 deletion results in a compensatory upregulation 
in polyamine metabolism in response to H. pylori
ARG1 and ARG2 are redundant enzymes responsible for 
the conversion of l-Arg to l-ornithine, which is the sub-
strate for ornithine decarboxylase (ODC) (Chaturvedi et al. 
2010, 2012). ARG1 is essential for life, and can be induced 
by certain stimuli; ARG2 is also inducible under conditions 
of stress, such as bacterial infections (Chaturvedi et al. 
2012; Gobert et al. 2002a; Gogoi et al. 2015; Lewis et al. 
2010, 2011). Arg2−/− and Arg2−/−;Nos2−/− mice are lack-
ing this inducible form of the enzyme, potentially altering 
both the response to pathogens and polyamine metabolism. 
We hypothesized that the loss of Arg2 could lead to an 
upregulation of Arg1 expression, and an increase in gene 
expression related to polyamine metabolism. We assessed a 
panel of genes involved in polyamine metabolism, includ-
ing Arg1, which generates substrates for polyamine metab-
olism, polyamine synthetic enzymes, Odc and adenosylme-
thionine decarboxylase 1 (Amd1), and polyamine catabolic 
enzymes, spermidine/spermine N1-acetyltransferase 1 
(Sat1) and spermine oxidase (Smox). Expression of each 
of these genes was examined in chronically infected gas-
tric tissues from WT, Nos2−/−, and Arg2−/−;Nos2−/− mice 
by RT-PCR. Arg2−/− mice had significantly increased Arg1 
and Sat1 levels compared to each of the other genotypes 
(Fig. 6a). Both Arg2−/− and Arg2−/−;Nos2−/− mice had sig-
nificantly enhanced Odc, Amd1, and Smox expression, as 
compared to WT and Nos2−/− mice (Fig. 6a). Thus, ARG2 
knockout enhanced the expression of polyamine metabo-
lism genes, while NOS2 deletion had no effect on expres-
sion of these genes.
Additionally, Arg1 and Odc gene expression 
was increased in BMmacs from both Arg2−/− and 
Arg2−/−;Nos2−/− mice (Fig. 6b). However, Amd1, Sat1, 
and Smox were not significantly induced by H. pylori infec-
tion in BMmacs, nor were differences between the geno-
types detected (data not shown). These data suggest that 
ARG2 in macrophages has a role in polyamine synthesis, 
but not in polyamine catabolism.
Furthermore, the levels of putrescine, spermi-
dine, and spermine were measured in gastric tissues 
by high-performance liquid chromatography. Arg2−/− 
and Arg2−/−;Nos2−/− mice demonstrated significantly 
increased spermine levels (Fig. 7a), and higher spermi-
dine and total polyamine levels as compared to WT and 
Nos2−/− mice, although the latter differences did not reach 
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Fig. 3  Loss of NOS2 leads to enhanced epithelial cell-derived 
chemokine production. Protein was isolated from gastric tissues from 
WT, Arg2−/−, Nos2−/−, and Arg2−/−;Nos2−/− mice 4 months p.i. 
with H. pylori SS1. Levels of the epithelial cell-derived chemokines, 
CXCL1 (KC) and CXCL2 (MIP-2), were assessed by Luminex assay. 
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with Kruskal–Wallis test, followed by Mann–Whitney U test. 
*p < 0.05, **p < 0.01, ***p < 0.001
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significance (Fig. 7a, b). Further, the significant decrease in 
putrescine (Fig. 7a) in the Arg2−/− and Arg2−/−;Nos2−/− 
mice suggests an increased conversion to spermidine 
and spermine. These data indicate that the loss of ARG2 
drives enhanced polyamine metabolism in Arg2−/− and 
Arg2−/−;Nos2−/− mice. Taken together, these data indicate 
that the loss of ARG2 enhances polyamine metabolism.
Discussion
In this study, we show that ARG2 deletion leads to 
increased gastritis following chronic H. pylori infec-
tion. This is similar to previously published data from our 
laboratory (Lewis et al. 2011), which implied that effects 
of ARG2 deletion were mediated by enhanced NOS2 
expression and NO production (Lewis et al. 2010, 2011). 
However, the present study demonstrated that the role 
of ARG2 in H. pylori infection is more complex. ARG2 
knockout leads to enhanced overall M1 macrophage acti-
vation, and upregulated polyamine metabolism. There 
appeared to be a partial role for NOS2 in regulation of M1 
activation, as some changes observed in Arg2−/− mice were 
observed in Arg2−/−;Nos2−/− mice, and others were not.
Our previous studies led us to hypothesize that deletion 
of both ARG2 and NOS2 in Arg2−/−;Nos2−/− mice would 
restore WT colonization levels, such that reduced coloni-
zation in Arg2−/− mice would be lost when the Nos2 gene 
was also deleted. However, Arg2−/−;Nos2−/− mice demon-
strated similar colonization and gastritis levels as Arg2−/− 
mice, indicating that the role of ARG2 is NOS2-independ-
ent. While Nos2−/− mice demonstrated a similar level of 
gastritis as WT mice, colonization was decreased, and sta-
tistically similar to the Arg2−/− and Arg2−/−;Nos2−/− mice. 
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tric tissues from WT, Arg2−/−, Nos2−/−, and Arg2−/−;Nos2−/− mice 
4 months p.i. Expression of the Th1 marker, Ifn-γ, and the Th17 
marker, Il-17a, was assessed by RT-PCR. n = 4 uninfected and 8 H. 
pylori SS1-infected mice per genotype. Statistical significance was 
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CD28. The splenic T-cells were then stimulated with H. pylori SS1 
French-pressed lysate (FPL) for 24 h. Protein levels of secreted IFN-γ 
(Th1) and IL-17 (Th17) were assessed by Luminex assay on the 
splenic T-cell supernatants. n = 5 mice per genotype. Statistical sig-
nificance was determined by Student’s t test. c Splenic T-cells were 
generated as in b. The CD4+IFN-γ+ population of Th1 cells was 
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This may be explained by an increased production of epi-
thelial-derived chemokines, which activate inflammatory 
cells, in Nos2−/− and Arg2−/−;Nos2−/− mice, indicating 
that NOS2 has an important role in modulating responses 
in epithelial cells. This is unexpected given that the major 
source of NOS2 during infection has been reported to be 
macrophages and neutrophils (Goto et al. 1999; Man-
nick et al. 1996; Sakaguchi et al. 1999; Lewis et al. 2011). 
Future studies are required to determine the role of NOS2 
in epithelial cells during H. pylori infection.
We focused on the role that ARG2 plays in innate and 
adaptive immune response to H. pylori infection. Consist-
ent with the increase in gastritis, ARG2 knockout led to 
increased M1 macrophage activation in tissues and mac-
rophages. Il-1β expression was increased in Arg2−/− and 
Arg2−/−;Nos2−/− BMmacs with either H. pylori infection 
or the classical M1 stimuli, IFN-γ and LPS. These findings 
were limited to mice carrying the ARG2 deletion and not 
found in WT or Nos2−/− mice, indicating that these find-
ings are NOS2/NO-independent. The overall increase in 
Il-1β gene expression, despite the stimulus, could indicate 
that ARG2 plays a role in inflammasome function within 
macrophages, as pro-IL-1β cleavage into mature IL-1β is 
the primary pro-inflammatory function of the inflammas-
ome (Latz et al. 2013). This may contribute to the enhanced 
inflammation observed in Arg2−/−;Nos2−/− mice after 
chronic H. pylori infection.
ARG2 does not appear to play a global role in mac-
rophage activation. While loss of ARG2 enhanced M1 
macrophage activation, M2 macrophage activation was not 
affected by ARG2. Our laboratory reported that H. pylori 
does not induce a significant M2 response (Gobert et al. 
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Fig. 5  Arg2 knockout leads to super-induction of M1 macrophage 
activation in response to H. pylori. a Bone marrow-derived mac-
rophages (BMmacs) were isolated from WT, Arg2−/−, Nos2−/−, and 
Arg2−/−;Nos2−/− mice and stimulated with H. pylori Pre-Mouse Syd-
ney Strain 1 (PMSS1) ex vivo for 24 h. Markers of M1 macrophage 
activation, Nos2, Il-1β, and Tnf-α, were assessed by RT-PCR. n = 5 
biological replicates per genotype. Statistical significance was deter-
mined by one-way ANOVA with NewmanKeuls post-test. b Splenic 
macrophages were isolated from WT and Arg2−/− mice 4 months p.i. 
and stimulated ex vivo with SS1 FPL. Protein levels of secreted IL-1β 
and TNF-α, M1 macrophage effector proteins, were assessed by 
Luminex assay on the splenic macrophage supernatants. n = 5 mice 
per genotype. Statistical significance was determined by Student’s 
t test. c BMmacs were isolated as in a. Levels of the oxidized NO 
metabolite, NO2
−, was assessed by the Griess reaction. n = 5 biologi-
cal replicates per genotype. Statistical significance was determined 
by one-way ANOVA with NewmanKeuls post-test. In a–c, *p < 0.05, 
**p < 0.01, ***p < 0.001
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2014). However, we now show that IL-4 stimulation pro-
duced an M2 response in BMmacs, but there were no dif-
ferences between the genotypes. Moreover, ARG2 knock-
out did not have a profound effect on Mreg macrophage 
activation. There was a modest increase in Il-10 expression 
in Arg2−/− mice that was not found in Arg2−/−;Nos2−/− 
mice. The lack of Il-10 expression in Arg2−/−;Nos2−/− 
BMmacs may partially explain why histologic gastritis 
in Arg2−/−;Nos2−/− mice is statistically similar to that in 
Arg2−/− mice; lack of an anti-inflammatory response may 
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Fig. 6  Loss of ARG2 leads to a compensatory upregulation in poly-
amine metabolic enzyme expression in response to H. pylori. a RNA 
was isolated from gastric tissues from WT, Arg2−/−, Nos2−/−, and 
Arg2−/−;Nos2−/− mice 4 months p.i. mRNA levels of Arg1, Odc, 
Amd1, Sat1, and Smox were assessed by RT-PCR. n = 3–4 uninfected 
and 7–8 H. pylori SS1-infected mice per genotype. Statistical sig-
nificance was determined by one-way ANOVA with Kruskal–Wallis 
test, followed by Mann–Whitney U test. b RNA was isolated from 
BMmacs from WT, Arg2−/−, Nos2−/−, and Arg2−/−;Nos2−/− mice 
24 h (Arg1) and 6 h (Odc) p.i. mRNA levels of Arg1 and Odc were 
assessed by RT-PCR. n = 3–5 biological replicates per genotype. Sta-
tistical significance was determined by one-way ANOVA with New-
manKeuls post-test. In a and b, *p < 0.05, **p < 0.01, ***p < 0.001
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allow for pro-inflammatory M1 macrophage response to 
go unchecked. Together, these data reinforce that the role 
of ARG2 is specifically important in M1 macrophage 
activation. The T-cell phenotypes herein provide partial 
support for our initial hypothesis that effects of ARG2 
deletion were dependent on NOS2. There is a signifi-
cant Th1/Th17 response in Arg2−/− mice, that is ablated 
in Arg2−/−;Nos2−/− mice. These data indicate that either 
expression of Th1/Th17 markers and/or that recruitment 
and differentiation of Th1/Th17 cells is directly dependent 
on NOS2.
Our most novel finding was the dramatic effect of ARG2 
deletion on the polyamine pathway. Both Arg2−/− and 
Arg2−/−;Nos2−/− mice demonstrated upregulated expres-
sion of various polyamine metabolism enzymes, as well 
as significantly increased spermine levels within gastric 
tissue. These data suggest that ARG2 has an important 
role in regulation of polyamine synthesis and catabolism, 
which would have broad effects on polyamine flux within 
tissues. Arg1 and Odc expression was similarly increased 
in primary macrophages as well, indicating an impor-
tant role for ARG2 in polyamine synthesis within mac-
rophages. Our laboratory has demonstrated that polyam-
ines and the enzymes involved in their metabolism are 
important in macrophage function, specifically in response 
to H. pylori infection (Barry et al. 2011; Chaturvedi et al. 
2004, 2007, 2010, 2012, 2014; Gobert et al. 2002a, b, 
2001, 2011; Lewis et al. 2010, 2011). The current study 
specifically highlights the importance of ARG2 as a regu-
lator of polyamine metabolism in gastric tissues and in 
macrophage function and thus, the immune response to 
chronic H. pylori infection. Potential explanations for how 
upregulation of polyamine metabolism within Arg2−/− and 
Arg2−/−;Nos2−/− mice could contribute to increased gas-
tritis in a NOS2-independent manner, include alterations 
in macrophage viability allowing for enhanced function 
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Fig. 7  Loss of ARG2 increases polyamine levels in response to 
H. pylori. a Levels of putrescine, spermidine, and spermine were 
assessed by high-performance liquid chromatography in gastric tis-
sues 4 months p.i. from WT, Arg2−/−, Nos2−/−, and Arg2−/−;Nos2−/− 
mice. n = 3 uninfected and 7–8 H. pylori SS1-infected mice per gen-
otype. Statistical significance was determined by one-way ANOVA 
with Kruskal–Wallis test, followed by Mann–Whitney U test. 
*p < 0.05, **p < 0.01. b Total polyamine levels were calculated from 
the sum of putrescine, spermidine, and spermine in a
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(Gobert et al. 2002a; Chaturvedi et al. 2004) or direct alter-
ation of macrophage phenotypes (Van den Bossche et al. 
2012).
Polyamine metabolism has been implicated in the regu-
lation of immune responses to various pathogens, in addi-
tion to H. pylori (Bansal and Ochoa 2003; Bronte and 
Zanovello 2005; Chaturvedi et al. 2010). We have now 
identified ARG2 as a critical player in polyamine metabo-
lism in response to a major human pathogen. Future studies 
investigating the role of ARG2 in polyamine metabolism 
during other bacterial infections, particularly in the gas-
trointestinal system, could provide additional insights into 
their immunopathogenesis. ARG2 could potentially serve 
as a target for intervention in mucosal infections, allowing 
for an enhanced immune response to prevent bacterial sur-
vival within the host.
Methods
Materials
All chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) unless otherwise stated. All reagents 
used for cell culture were from Invitrogen (Carlsbad, CA, 
USA). RNA extraction reagents were from Qiagen (Valen-
cia, CA, USA), and reagents utilized for cDNA synthesis 
and RT-PCR were from Bio-Rad (Hercules, CA, USA). 
Recombinant macrophage colony stimulating factor 
(M-CSF) was purchased from Peprotech (Rocky Hill, NJ, 
USA). Protease Inhibitor Cocktail, Set III and Phosphatase 
Inhibitor Cocktail, Set I were purchased from Calbiochem 
(Darmstadt, Germany). BCA protein assay was from Pierce 
Biotechnology (Rockford, IL, USA).
Bacteria, cells, cell culture conditions and infections
Helicobacter pylori strains PMSS1 and SS1 were grown as 
previously described (Chaturvedi et al. 2010; Lewis et al. 
2011). French-pressed lysates were prepared as described 
(Asim et al. 2010).
Bone marrow-derived macrophages (BMmacs) were 
isolated from all mouse genotypes utilized in this study. 
BMmacs were differentiated as previously described 
(Weischenfeldt and Porse 2008), but with the following 
exceptions: red blood cells were lysed with ammonium-
chloride-potassium (ACK) lysing buffer for 3–5 min, and 
recombinant murine M-CSF was utilized at a concentration 
of 20 ng/mL over the course of 7 days.
All co-culture experiments were performed in an antibi-
otic-free Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10 % fetal bovine serum (FBS), 
2 mM l-glutamine, 25 mM HEPES, and 10 mM sodium 
pyruvate. BMmacs were infected at a multiplicity of infec-
tion (MOI) of 100, for all H. pylori experiments in vitro.
Animal studies
WT and Arg2−/− mice were utilized as previously 
described (Lewis et al. 2011). Nos2−/− mice were ini-
tially purchased from Jackson Laboratories (Farmington, 
CT, USA) and then bred in-house for all animal experi-
ments. Arg2−/−;Nos2−/− mice were generated by crossing 
the Arg2−/− and Nos2−/− mice. See Supplemental Table 1 
for primers used for genotyping. Male mice between the 
ages of 6–12 weeks at the time of infection were used 
for all studies, regardless of genotype, and mice were not 
moved from the cages into which they were weaned. Male 
mice were selected based on previous data indicating that 
female mice were protected from H. pylori-induced his-
tologic gastritis (Sheh et al. 2011). Sample sizes were 
based on previous studies from our laboratory (Chatur-
vedi et al. 2010; Gobert et al. 2014; Lewis et al. 2011). All 
mice were randomly selected for control and experimental 
groups.
Mice were orogastrically infected with 5 × 108 CFUs of 
H. pylori SS1, every other day for a total of three inocu-
lations. Mice were killed 4 months post-inoculation and 
their stomachs divided longitudinally into four sections 
for additional studies. Colonization was assessed by serial 
dilution and culture. Histologic gastritis was assessed by a 
gastrointestinal pathologist (M.B.P.), using the Sydney Sys-
tem (Gobert et al. 2014). All scoring was performed in a 
blinded manner.
Real‑time polymerase chain reaction
RNA was isolated from tissue and BMmacs using the RNe-
asy kit. cDNA was prepared using the iScript cDNA syn-
thesis kit with 1 μg of RNA. RT-PCR was performed as 
described (Gobert et al. 2014). See Supplemental Table 1 
for all primers utilized in this study.
Western blot analysis
Tissue and BMmacs were lysed in CellLytic MT Reagent 
supplemented with Protease Inhibitor Cocktail (Set III) and 
Phosphatase Inhibitor Cocktail (Set I). Protein concentra-
tion was determined by BCA protein assay. The following 
antibodies were utilized in this study: Rabbit polyclonal 
anti-NOS2 (1:5000; EMD Millipore), Rabbit polyclonal 
anti-ARG2 (1:1000; Santa Cruz Biotechnology), Mouse 
monoclonal anti-β-actin (1:10,000; Sigma-Aldrich), Goat 
anti-mouse IgG, HRP labeled (1:30,000; Sigma-Aldrich), 
and Goat anti-rabbit IgG, HRP labeled (1:3000–1:6000; 
Sigma-Aldrich).
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Luminex assay
A 25-plex assay (EMD Millipore, Cat. MCYTOMAG-
70K-PMX, Billerica, MA, USA) was performed on gas-
tric tissues from control and H. pylori SS1-infected mice 
from all genotypes. A 25-plex assay was also performed on 
supernatants from splenic T-cell cultures. Protein isolation, 
quantification and Luminex assay were performed as previ-
ously described (Coburn et al. 2013).
Measurement of nitric oxide
The concentration of nitrite (NO2
−), the oxidized metabo-
lite of NO, was assessed by the Griess reaction as previ-
ously described (Chaturvedi et al. 2010).
Flow cytometry
Flow cytometry was performed as previously described 
(Lewis et al. 2011). The following antibodies were uti-
lized in this study: Anti-mouse CD4-PerCp-Cy5.5 (1:200; 
Biolegend), and Anti-mouse IFN-γ-FITC (1:100; BD 
Biosciences).
Measurement of polyamines
Polyamines were measured from gastric tissue lysates by 
high-performance liquid chromatography as previously 
described (Chaturvedi et al. 2010).
Splenocyte isolation
Splenocytes were isolated from the spleens of control and 
infected WT and Arg2−/− mice. Red blood cells were lysed 
with ACK for 3–5 min. Splenocytes utilized for T-cell stud-
ies were plated in 96-well plates coated with anti-CD3 anti-
body and stimulated with anti-CD28 for 24 h. Cells were 
then stimulated with H. pylori SS1 French-pressed lysate 
for 4 days. Luminex assay and flow cytometry were then 
performed. Splenocytes utilized for macrophage studies 
were plated in 96-well plates without anti-CD3. Adherent 
cells were then stimulated with H. pylori French-pressed 
lysate for 24 h.
Statistical analysis
All data shown in this study represent the mean. The n 
for each experiment is listed in the figure legends. Where 
data were normally distributed, Student’s t test was used 
to determine significance in studies with only two groups, 
and one-way ANOVA with a NewmanKeuls post-test 
was used to determine significance in studies with mul-
tiple groups. Where data were not normally distributed, 
one-way ANOVA with a Kruskal–Wallis test, followed by 
a Mann–Whitney U test was performed. All statistical tests 
for each experiment are listed in the figure legends. All sta-
tistical analyses were performed using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA, USA). A p value of 
<0.05 was considered to be significant.
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